

=> d his

(FILE 'HOME' ENTERED AT 14:55:04 ON 10 FEB 1999)  
SET COST OFF

FILE 'REGISTRY' ENTERED AT 14:55:16 ON 10 FEB 1999  
E BOSWELLIC ACID/CN  
E BOSWELL/CN

FILE 'HCAPLUS' ENTERED AT 14:55:41 ON 10 FEB 1999

L1 60 S BOSWELLIC ACID  
E AMMON H/AU  
L2 195 S E3,E5,E14  
E SAFAYHI H/AU  
L3 35 S E3,E4  
L4 20 S L1 AND L2,L3

FILE 'REGISTRY' ENTERED AT 15:00:02 ON 10 FEB 1999

L5 2 S 631-69-6 OR 471-66-9  
L6 1 S 67416-61-9  
L7 1 S 5968-70-7  
L8 1 S 17019-92-0  
L9 1 S 89913-60-0

FILE 'HCAPLUS' ENTERED AT 15:01:28 ON 10 FEB 1999

SET SMARTSELECT ON  
L10 SEL L4 1- RN : 36 TERMS  
SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 15:01:31 ON 10 FEB 1999

L11 36 S L10  
L12 17 S L11 AND C6-C6-C6-C6-C6/ES  
L13 11 S L12 NOT L5-L9  
L14 19 S L11 NOT L5-L9,L12,L13  
E PLASMIN/CN  
L15 1 S E3  
E LEUKOCYTIC ELASTASE/CN  
E LEUKOCYTE ELASTASE/CN  
E ELASTASE/CN  
L16 1 S E3  
E ELASTASE, LEU/CN  
E BOSWEL  
L17 12 S E10  
L18 7 S L17 NOT L5-L9,L12,L13  
L19 24 S L5-L9,L12,L13,L17

FILE 'HCAPLUS' ENTERED AT 15:05:34 ON 10 FEB 1999

L20 2659 S L19  
L21 2682 S L1 OR L20  
L22 21 S L2,L3 AND L21  
L23 21 S L4,L22  
L24 8435 S L16 OR ELASTASE  
L25 8742 S L15 OR PLASMIN OR FIBRINOLYSIN OR THROMBOLYSIN  
L26 8 S L21 AND L24  
L27 2 S L21 AND L25  
L28 9 S L26,L27  
L29 3 S L5 AND L28  
L30 14 S (?ARTHRIT? OR ?RHEUMAT? OR ?BRONCH? OR ?FIBROS? OR ?EMPHYSEM?  
L31 6 S (?TUMOR? OR ?TUMOUR? OR ?CANCER? OR ?CARCIN? OR ?NEOPLAS? OR

L32 4 S (?RESPIRAT? OR PULMON? OR LUNG OR KIDNEY) AND (L1 OR L5)  
L33 2 S L30-L32 AND L24,L25  
L34 3 S L29,L33  
L35 23 S L26-L33 NOT L34  
L36 7 S L5 AND L35  
L37 428 S BOSWELL? OR SALAI OR OLIBANUM OR DAMARA OR D ORIENTALIS OR FR  
L38 2 S L27 AND L24,L25  
L39 18 S L6  
L40 2 S L39 AND L24,L25  
L41 11 S L34,L36,L38,L40  
L42 429 S L37 OR L5 OR L39  
L43 17 S L42 AND (?ARTHRIT? OR ?RHEUMAT? OR ?BRONCH? OR FIBROS? OR ?EM  
L44 15 S L42 AND (?NEPHRIT? OR ?TUMOR? OT ?TUMOUR? OR ?CANCER? OR ?CAR  
L45 7 S L42 AND (?MALIGN? OR ?RESPIRAT? OR PULMON? OR LUNG OR KIDNEY)  
L46 33 S L43-L45  
L47 25 S L46 NOT L41  
L48 22 S L47 AND (1 OR 15 OR 63)/SC,SX  
L49 21 S L48 NOT 7/SC  
L50 3 S L47 NOT L48  
L51 2 S L50 NOT 8/SC  
L52 34 S L49,L51,L41  
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 15:28:56 ON 10 FEB 1999

L53 7 S E1-E7

=> fil reg

FILE 'REGISTRY' ENTERED AT 15:29:13 ON 10 FEB 1999

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 1999 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 6 FEB 99 HIGHEST RN 219473-81-1

DICTIONARY FILE UPDATES: 9 FEB 99 HIGHEST RN 219473-81-1

TSCA INFORMATION NOW CURRENT THROUGH JUNE 29, 1998

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

=> d ide can tot 153

L53 ANSWER 1 OF 7 REGISTRY COPYRIGHT 1999 ACS

RN 67416-61-9 REGISTRY

CN Urs-12-en-23-oic acid, 3-(acetyloxy)-11-oxo-, (3.alpha.,4.beta.)- (9CI)  
(CA INDEX NAME)

OTHER NAMES:

CN Acetyl-11-oxo-.beta.-boswellic acid

CN AKBA


FS STEREOSEARCH

DR 187945-03-5

MF C32 H48 O5

LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAPLUS, TOXLIT, USPATFULL  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



18 REFERENCES IN FILE CA (1967 TO DATE)  
18 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:298120  
REFERENCE 2: 129:72038  
REFERENCE 3: 127:302851  
REFERENCE 4: 126:338554  
REFERENCE 5: 126:203738  
REFERENCE 6: 126:195256  
REFERENCE 7: 125:211471  
REFERENCE 8: 125:184523  
REFERENCE 9: 124:331705  
REFERENCE 10: 124:277960

L53 ANSWER 2 OF 7 REGISTRY COPYRIGHT 1999 ACS

RN 9004-06-2 REGISTRY

CN Elastase (9CI) (CA INDEX NAME)

OTHER NAMES:

CN E.C. 3.4.21.11

CN E.C. 3.4.21.36

CN E.C. 3.4.21.37

CN E.C. 3.4.24.65

CN E.C. 3.4.4.7

CN Elaszym

CN Macrophage metalloelastase

CN Matrix metalloproteinase-12

CN MMP-12

CN Pancreatopeptidase E

CN Peptidase, pancreato-, E

DR 9001-21-2, 139074-64-9

MF Unspecified

CI COM, MAN

LC STN Files: AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA, CABA, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMLIST, CBNB, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MRCK\*, NAPRALERT, NIOSHTIC, PHAR, PROMT, RTECS\*, TOXLINE, TOXLIT, USAN, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

5670 REFERENCES IN FILE CA (1967 TO DATE)

219 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

5685 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:86058

REFERENCE 2: 130:81894

REFERENCE 3: 130:81830

REFERENCE 4: 130:79498

REFERENCE 5: 130:79346

REFERENCE 6: 130:77971

REFERENCE 7: 130:77102

REFERENCE 8: 130:76330

REFERENCE 9: 130:75744

REFERENCE 10: 130:66781

L53 ANSWER 3 OF 7 REGISTRY COPYRIGHT 1999 ACS

RN 9001-90-5 REGISTRY

CN Plasmin (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Actase

CN E.C. 3.4.21.7

CN E.C. 3.4.4.14

CN Fibrinase

CN Fibrinolysin

CN Serum tryptase

CN Thrombolysin

DR 9065-96-7

MF Unspecified

CI COM, MAN

LC STN Files: AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA, CABA, CAPLUS, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK\*, NAPRALERT, PROMT, TOXLINE, TOXLIT, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

4398 REFERENCES IN FILE CA (1967 TO DATE)

377 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

4404 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:79190  
 REFERENCE 2: 130:78443  
 REFERENCE 3: 130:75992  
 REFERENCE 4: 130:64715  
 REFERENCE 5: 130:64380  
 REFERENCE 6: 130:64240  
 REFERENCE 7: 130:63250  
 REFERENCE 8: 130:52411  
 REFERENCE 9: 130:50868  
 REFERENCE 10: 130:49530

L53 ANSWER 4 OF 7 REGISTRY COPYRIGHT 1999 ACS

RN 631-69-6 REGISTRY

CN Urs-12-en-23-oic acid, 3-hydroxy-, (3.alpha.,4.beta.)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN .beta.-Boswellic acid (6CI)

CN Urs-12-en-24-oic acid, 3.alpha.-hydroxy- (8CI)

FS STEREOSEARCH


MF C30 H48 O3

CI COM

LC STN Files: ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, DDFU, DRUGU, EMBASE, MEDLINE, MRCK\*, NAPRALERT, TOXLINE, TOXLIT, USPATFULL

(\*File contains numerically searchable property data)

Absolute stereochemistry.



29 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

29 REFERENCES IN FILE CAPLUS (1967 TO DATE)

## 5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:7330  
REFERENCE 2: 129:298120  
REFERENCE 3: 129:100026  
REFERENCE 4: 129:72038  
REFERENCE 5: 128:101578  
REFERENCE 6: 127:272136  
REFERENCE 7: 126:338554  
REFERENCE 8: 126:203738  
REFERENCE 9: 126:195256  
REFERENCE 10: 125:185261

L53 ANSWER 5 OF 7 REGISTRY COPYRIGHT 1999 ACS

RN 471-66-9 REGISTRY

CN Olean-12-en-23-oic acid, 3-hydroxy-, (3.alpha.,4.beta.)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN .alpha.-Boswellic acid (6CI)


CN Olean-12-en-24-oic acid, 3.alpha.-hydroxy- (8CI)

FS STEREOSEARCH

MF C30 H48 O3

LC STN Files: AGRICOLA, BEILSTEIN\*, BIOSIS, CA, CAOLD, CAPLUS, DDFU, DRUGU, NAPRALERT, TOXLIT  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



8 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
8 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 128:101578  
REFERENCE 2: 126:203738  
REFERENCE 3: 121:18104  
REFERENCE 4: 119:152084  
REFERENCE 5: 119:125204  
REFERENCE 6: 117:40043  
REFERENCE 7: 100:188743  
REFERENCE 8: 89:117519

L53 ANSWER 6 OF 7 REGISTRY COPYRIGHT 1999 ACS

RN 471-53-4 REGISTRY

CN Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3.beta.,20.beta.)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Olean-12-en-30-oic acid, 3.beta.-hydroxy-11-oxo- (8CI)

CN Uralenic acid (7CI)

OTHER NAMES:

CN .alpha.-Glycyrrhetic acid

CN 18.beta.-Glycyrrhetic acid

CN 18.beta.-Glycyrrhetic acid

CN Biosone

CN Enoxolone

CN Glycyrrhetic acid

CN Glycyrrhetin

CN Glycyrrhetic acid

CN GM 1658

CN Subglycyrrhelinic acid

FS STEREOSEARCH

DR 8055-71-8, 15301-63-0, 107420-91-7, 202522-39-2

MF C30 H46 O4

CI COM


LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, NAPRALERT, NIOSHTIC, PROMT, RTECS\*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



803 REFERENCES IN FILE CA (1967 TO DATE)  
 64 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 807 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


REFERENCE 1: 130:75703  
 REFERENCE 2: 130:66624  
 REFERENCE 3: 130:60702  
 REFERENCE 4: 130:46279  
 REFERENCE 5: 130:43387  
 REFERENCE 6: 130:43318  
 REFERENCE 7: 130:38590  
 REFERENCE 8: 130:33192  
 REFERENCE 9: 130:7496  
 REFERENCE 10: 130:7409

L53 ANSWER 7 OF 7 REGISTRY COPYRIGHT 1999 ACS  
 RN 77-52-1 REGISTRY  
 CN Urs-12-en-28-oic acid, 3-hydroxy-, (3.beta.)- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Urs-12-en-28-oic acid, 3.beta.-hydroxy- (8CI)  
 OTHER NAMES:  
 CN (+)-Ursolic acid  
 CN .beta.-Ursolic acid  
 CN Bungeolic acid  
 CN Malol  
 CN Prunol  
 CN Ursolic acid  
 CN Urson  
 FS STEREOSEARCH  
 DR 209545-05-1  
 MF C30 H48 O3



CI COM  
 LC STN Files: ADISINSIGHT, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS,  
 BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS,  
 CHEMINFORMRX, CHEMLIST, CSCHEM, DETHERM\*, DDFU, DRUGU, EMBASE, HODOC\*,  
 IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, NAPRALERT, PROMT, SPECINFO,  
 TOXLINE, TOXLIT, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



1087 REFERENCES IN FILE CA (1967 TO DATE)  
 13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 1090 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 18 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:78688  
 REFERENCE 2: 130:75713  
 REFERENCE 3: 130:49823  
 REFERENCE 4: 130:49797  
 REFERENCE 5: 130:49792  
 REFERENCE 6: 130:47411  
 REFERENCE 7: 130:47294  
 REFERENCE 8: 130:47152  
 REFERENCE 9: 130:38539  
 REFERENCE 10: 130:29193

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 15:29:25 ON 10 FEB 1999

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 1999 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 10 Feb 1999 VOL 130 ISS 7  
FILE LAST UPDATED: 10 Feb 1999 (19990210/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d bib abs hitrn tot 152

L52 ANSWER 1 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1998:756322 HCAPLUS  
DN 130:7330  
TI Effect of Boswellia serrata gum resin in patients with **bronchial** asthma. Results of a double-blind, placebo-controlled, 6-week clinical study  
AU Gupta, I.; Gupta, V.; Parihar, A.; Gupta, S.; Luedtke, R.; Safayhi, H.; Ammon, H. P. T.  
CS Dep. Medicine, Govt. Medical College, Jammu Tawi, India  
SO Eur. J. Med. Res. (1998), 3(11), 511-514  
CODEN: EJMRFL; ISSN: 0949-2321  
PB I. Holzapfel Publishers  
DT Journal  
LA English  
AB B. serrata gum resin (Salai guggal in Ayurvedic medicine) was examd. in a double-blind, placebo-controlled study. **Bronchial** asthma patients were treated with 300 mg 3.times. /day for 6 wk. Improvement occurred in 70% (disappearance of symptoms, dyspnoea, rhonchi, redn. of attack no., increase in forced expiratory vol. in 1 s, forced vital capacity, and peak expiratory flow rate, decrease in eosinophilic count and erythrocyte sedimentation).  
IT 631-69-6, .beta.-Boswellic acid  
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(B. serrata gum resin (Salai guggal) in **bronchial** asthma)

L52 ANSWER 2 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1998:633203 HCAPLUS  
DN 130:46928  
TI Retinoids in the management of central nervous system (CNS) tumors  
AU Westarp, M. E.  
CS Department of Neurology, Ulm University, Bad Orb, Germany  
SO Adv. Organ Biol. (1997), 3(Retinoids: Their Physiological Function and Therapeutic Potential), 231-260  
CODEN: AOBIFW  
PB JAI Press Inc.  
DT Journal; General Review  
LA English

AB A review with many refs. We have analyzed and investigated with clin. means the potential use of retinoids in primary CNS (brain) tumors. Established to be effective in ectodermal skin disorders, retinoids also effectively alter the growth of neuro-epithelial tissue, i.e. cells of neuro-ectodermal origin. 13-Cis-Retinoic acid and inhibitor of RA catabolism, liarozole, can both be given orally and as addnl., adjuvant medication to std. treatment protocols. Particularly in conjunction with liarozole to avoid decreasing plasma and tissue concns., 13cRA seems to be safe and promising in the therapy of intracranial tumors. The combined medication did not lead to increased intracranial pressure, was well tolerated, and may be able to induce tumor cell differentiation, slow de-differentiation and improve anti-tumoral responses. Retinoids are compatible with all other treatment modalities, including radiotherapy, anti-edematous **Boswellia** acids and intra-tumoral approaches such as herpes-simplex thymidine kinase/ganciclovir insertion, and may prove useful even in lower-grade astrocytoma or other neuro-epithelial, e.g. spinal, **neoplasia**.

L52 ANSWER 3 OF 34 HCAPLUS COPYRIGHT 1999 ACS

AN 1998:315240 HCAPLUS

DN 129:72038

TI Inhibitory activity of **boswellic acids** from **Boswellia** serrata against human leukemia HL-60 cells in culture

AU Shao, Yu; Ho, Chi-Tang; Chin, Chee-Kok; Badmaev, Vladimir; Ma, Wei; Huang, Mou-Tuan

CS Department Plant Science, Cook College, State University New Jersey, New Brunswick, NJ, 08903, USA

SO Planta Med. (1998), 64(4), 328-331

CODEN: PLMEAA; ISSN: 0032-0943

PB Georg Thieme Verlag

DT Journal

LA English

AB Four major triterpene acids including **.beta.-boswellic acid**, **3-O-acetyl-.beta.-boswellic acid**, **11-keto-O-boswellic acid**, and **3-O-acetyl-11-keto-.beta.-boswellic acid** were isolated from the gum resin of **Boswellia serrata** and examd. for their in vitro **antitumor** activity. They inhibited the synthesis of DNA, RNA, and protein in human leukemia HL-60 cells dependent with IC50 values from 0.6- 7.1 .mu.M. Among them, **3-O-acetyl-11-keto-.beta.-boswellic acid** induced the most pronounced inhibitory effects on DNA, RNA, and protein synthesis with IC50 values of 0.6, 0.5, and 4.1 .mu.M, resp. The effect of **3-O-acetyl-11-keto-.beta.-boswellic acid** on DNA synthesis was irreversible. **3-O-acetyl-11-keto-.beta.-boswellic acid** inhibited the cellular growth of HL-60 cells, but did not affect cell viability.

IT 631-69-6, **.beta.-Boswellic acid**

RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(**antitumor** activity of **boswellic acids** from **Boswellia**)

L52 ANSWER 4 OF 34 HCAPLUS COPYRIGHT 1999 ACS

AN 1997:631612 HCAPLUS

DN 127:272136

TI Pharmacological aspects of incense and **boswellic acids**

AU Safayhi, Hasan; Ammon, Hermann P. T.

CS Pharmazeutisches Institut, Universitat Tübingen, Tuebingen, D-72076,

- Germany  
SO Pharm. Ztg. (1997), 142(39), 3277-3280, 3282, 3284-3286  
CODEN: PHZIAP; ISSN: 0031-7136  
PB Govi-Verlag Pharmazeutischer Verlag  
DT Journal; General Review  
LA German  
AB A review with 40 refs. is given on pharmacol. effects of incense, its exts., and **boswellic acids** isolated from it. The best known effect is the antiinflammatory action due to inhibition of leukotriene biosynthesis by a hitherto unique mechanism. Other enzymes, such as leukocyte **elastase**, topoisomerase I, and serin proteases, are inhibited in vitro at 10- to 20-fold higher **boswellic acid** concns. as it is necessary for lipoxxygenase inhibition. Clin. studies on applications of incense exts. in the treatment of articular **rheumatism**, colitis ulcerosa, and **tumor**-induced brain edema are also reviewed and toxicol. aspects are discussed.
- IT 631-69-6, .beta.-**Boswellic acid**  
RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)  
(pharmacol. aspects of incense and **boswellic acids**)
- L52 ANSWER 5 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1997:270851 HCAPLUS  
DN 126:338554  
TI Inhibition by **boswellic acids** of human leukocyte **elastase**  
AU Safayhi, Hasan; Rall, Beatrice; Sailer, Eckart-Roderich; Ammon, Hermann P. T.  
CS Institute Pharmaceutical Sciences, Univ. Tuebingen, Tuebingen, D-72076, Germany  
SO J. Pharmacol. Exp. Ther. (1997), 281(1), 460-463  
CODEN: JPETAB; ISSN: 0022-3565  
PB Williams & Wilkins  
DT Journal  
LA English  
AB Frankincense exts. and **boswellic acids**, biol. active pentacyclic triterpenes of frankincense, block leukotriene biosynthesis and exert potent anti-inflammatory effects. Screening for addnl. effects of **boswellic acids** on further proinflammatory pathways, the authors obsd. that acetyl-11-keto-.beta.-**boswellic acid**, an established direct, nonredox and noncompetitive 5-lipoxxygenase inhibitor, decreased the activity of human leukocyte **elastase** (HLE) in vitro with an IC50 value of about 15 .mu.M. Among the pentacyclic triterpenes tested in concns. .ltoreq.20 .mu.M, the authors also obsd. substantial inhibition by .beta.-**boswellic acid**, amyrrin and ursolic acid, but not by 18.beta.-glycyrrhetinic acid. The data show that the dual inhibition of 5-lipoxxygenase and HLE is unique to **boswellic acids**: other pentacyclic triterpenes with HLE inhibitory activities (e.g., ursolic acid and amyrrin) do not inhibit 5-lipoxxygenase, and leukotriene biosynthesis inhibitors from different chem. classes (e.g., NDGA, MK-886 and ZM-230,487) do not impair HLE activity. Because leukotriene formation and HLE release are increased simultaneously by neutrophil stimulation in a variety of inflammation- and hypersensitivity-based human diseases, the reported blockade of two proinflammatory enzymes by **boswellic acids** might be the rationale for the putative antiphlogistic activity of acetyl-11-keto-.beta.-**boswellic acid** and derivs.

IT 67416-61-9  
 RL: BAC (Biological activity or effector, except adverse); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhibition by **boswellic acids** of human leukocyte  
**elastase** in relation to anti-inflammatory activity)  
 IT 77-52-1, Ursolic acid 471-53-4, 18.beta.-Glycyrrhetic  
 acid 631-69-6, .beta.-**Boswellic acid**  
 9004-06-2, **Elastase**  
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
 (inhibition by **boswellic acids** of human leukocyte  
**elastase** in relation to anti-inflammatory activity)

L52 ANSWER 6 OF 34 HCAPLUS COPYRIGHT 1999 ACS

AN 1997:215775 HCAPLUS

DN 126:203738

TI Inhibition of leukocyte **elastase** and **plasmin** activity  
 by **boswellic acid**

IN Ammon, Hermann P. T.; Safayhi, Hasan

PA Ammon, Hermann P. T., Germany

SO Ger. Offen., 12 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19531067	A1	19970227	DE 95-19531067	19950823
	WO 9707796	A1	19970306	WO 96-EP3705	19960822
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 854709	A1	19980729	EP 96-929309	19960822
	R: AT, BE, CH, DE, DK, ES, FR, GB, LI, LU, NL, SE, PT, IE, FI				
PRAI	DE 95-19531067		19950823		
	WO 96-EP3705		19960822		
AB	Human and veterinary <b>respiratory</b> diseases assocd. with elevated leukocyte <b>elastase</b> and <b>plasmin</b> activity are treated by administration of <b>boswellic acid</b> or its salts or derivs. These diseases include <b>pulmonary emphysema</b> , acute <b>respiratory</b> distress syndrome, shock lung, cystic <b>fibrosis</b> , and chronic <b>bronchitis</b> , as well as <b>glomerulonephritis</b> , <b>rheumatoid arthritis</b> , and certain <b>tumors</b> and <b>metastases</b> . Thus, acetyl-11-keto-.beta.- <b>boswellic acid</b> inhibited human leukocyte <b>elastase</b> and human <b>plasmin</b> in vitro with IC50 .apprx.17 .mu.M and 4-6 .mu.M, resp. Tablets were prepd. contg. <b>boswellic acid</b> 15-30, Mg stearate 0.65, and lactose 80 mg.				

IT 471-66-9, .alpha.-**Boswellic acid**  
 471-66-9D, .alpha.-**Boswellic acid**, derivs.  
 631-69-6, .beta.-**Boswellic acid**  
 631-69-6D, .beta.-**Boswellic acid**, derivs.  
 67416-61-9  
 RL: BAC (Biological activity or effector, except adverse); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhibition of leukocyte **elastase** and **plasmin**  
 activity by **boswellic acid**)  
 IT 9001-90-5, **Plasmin** 9004-06-2, **Elastase**  
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
 (inhibition of leukocyte **elastase** and **plasmin**

activity by **boswellic acid**)

L52 ANSWER 7 OF 34 HCAPLUS COPYRIGHT 1999 ACS

AN 1997:207552 HCAPLUS

DN 126:195256

TI **Boswellic acid** compositions and preparation thereof

IN Taneja, Subhash Chandra; Sethi, Vijay Kumar; Dhar, Kanaya Lal; Kapil, Randhir Singh

PA Council of Scientific and Industrial Research, India

SO Eur. Pat. Appl., 15 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 755940	A1	19970129	EP 95-305242	19950727
	R: AT, BE, CH, DE, DK, FR, GB, IT, LI, SE				
	US 5629351	A	19970513	US 95-421500	19950413
PRAI	EP 95-305242		19950727		

AB A novel fraction exhibiting anti-inflammatory, **antiarthritic**, and antiulcerogenic activities is isolated from the gum resin of *Boswellia serrata*. A process for isolating the fraction and individual **boswellic acids** therefrom is also disclosed. In a dose range of 25-200 mg/kg orally, the fraction displayed 25.71-47.54% inhibitory action in carrageenan, histamine, and dextran-induced edema in rats and mice.

IT **631-69-6P**

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)

(**boswellic acids** of *Boswellia serrata* gum as anti-inflammatory and antiulcer agents)

L52 ANSWER 8 OF 34 HCAPLUS COPYRIGHT 1999 ACS

AN 1996:491734 HCAPLUS

DN 125:185262

TI Anti-inflammatory actions of **boswellic acids**

AU Singh, G. B.; Singh, Surjeet; Bani, Sarang

CS Regional Research Laboratory, Department Pharmacology, Jammu Tawi, 180 001, India

SO Phytomedicine (1996), 3(1), 81-85

CODEN: PYTOEY; ISSN: 0944-7113

DT Journal

LA English

AB **Boswellic acids** (BA) demonstrated dose-related anti-inflammatory activity (AIA) in acute tests of carrageenan-, histamine- and dextran-induced edema in rats and mice. It elicited inhibitory action on vascular permeability in mice induced by acetic acid. Marked AIA was obsd. in chronic models of adjuvant-induced **polyarthritis** and formaldehyde **arthritis** in rats and bovine serum albumin-induced **arthritis** in rabbits. It produced significant protective effects in sodium urate gouty **arthritis** in dogs. BA reduced exudate vol. and inhibited leukocyte migration in carrageenan-induced pleurisy in rats. It did not affect the parturition period in pregnant rats or castor oil-induced diarrhea in rats. It failed to exhibit any analgesic or ulcerogenic effects. BA elicited antipyretic activity in rats and rabbits. LD50 of BA was greater than 2 g/kg in rats and mice when

administered orally or i.p.

L52 ANSWER 9 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
 AN 1996:435242 HCAPLUS  
 DN 125:67823  
 TI **Boswellic acid** for treatment of brain tumors  
 IN Simmet, Thomas; Ammon, Hermann P. T.  
 PA Germany  
 SO Ger. Offen., 6 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4445728	A1	19960627	DE 94-4445728	19941221
	WO 9619212	A1	19960627	WO 95-EP5073	19951221
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 871437	A1	19981021	EP 95-942720	19951221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	JP 10511647	T2	19981110	JP 95-519521	19951221
PRAI	DE 94-4445728		19941221		
	WO 95-EP5073		19951221		
AB	.beta.- <b>Boswellic acid</b> , its salts and derivs., and plant prepn. from <i>Boswellia serrata</i> contg. them are useful in medications for treatment of brain tumors. Thus, tablets were prepd. by wet granulation from a mixt. contg. .beta.- <b>boswellic acid</b> 15-30, lactose 150.0, starch 30.0, gelatinized corn starch 15.0, and Mg stearate 1.5 mg/tablet.				
IT	631-69-6, .beta.- <b>Boswellic acid</b> 631-69-6D, .beta.- <b>Boswellic acid</b> , derivs. RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (b <b>oswellic acid</b> for treatment of brain tumors)				

L52 ANSWER 10 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
 AN 1995:544100 HCAPLUS  
 DN 122:298750  
 TI Recent progress in the study of **anticancer** drugs originating from plants and traditional medicines in China  
 AU Han, Rui  
 CS Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, 100050, Peop. Rep. China  
 SO Chin. Med. Sci. J. (1994), 9(1), 61-9  
 CODEN: CMSJEP  
 DT Journal; General Review  
 LA English  
 AB Drugs of plant origin have received much attention due to their enormous potential for the prevention and treatment of **cancer**. Recent progress in the study of **anticancer** drugs originating from plants and traditional medicines in China is reviewed with 28 refs., with particular emphasis on taxol, daidzein, acetyl **boswellic acid**, curcumin and ginsenoside Rh2.

L52 ANSWER 11 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
 AN 1995:400379 HCAPLUS  
 DN 122:177890

- TI Cytotoxic constituents of *Bursera permollis*  
AU Wickramaratne, D. B. M.; Mar, W.; Chai, H.; Castillo, J. J.; Farnsworth,  
N. R.; Soejarto, D. D.; Cordell, G. A.; Pezzuto, J. M.; Kinghorn, A. D.  
CS Coll. Pharmacy, Univ. Illinois, Chicago, IL, 60612, USA  
SO Planta Med. (1995), 61(1), 80-1  
CODEN: PLMEAA; ISSN: 0032-0943  
DT Journal  
LA English  
AB Four cytotoxic lignans were isolated from the stem bark of *Bursera permollis* (**Burseraceae**), namely, deoxypodophyllotoxin, .beta.-peltatin Me ether, picro-.beta.-peltatin Me ether, and dehydro-.beta.-peltatin Me ether. Also isolated was the inactive lignan, nemerosin. Deoxypodophyllotoxin and .beta.-peltatin Me ether were potentially cytotoxic when evaluated against a panel of human **cancer** cell lines.
- L52 ANSWER 12 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1994:645519 HCAPLUS  
DN 121:245519  
TI Effect of **boswellic** acids on complement in adjuvant- and carrageenan-induced inflammation  
AU Kapil, A.  
CS Pharmacology Division, Regional Research Laboratory, Jammu Tawi, 180 001, India  
SO Inflammopharmacology (1994), 2(4), 361-7  
CODEN: IAOAES; ISSN: 0925-4692  
DT Journal  
LA English  
AB The in-vivo effects of non-steroidal anti-inflammatory agents on the host immune system are still poorly understood. However, through inhibition of complement, **boswellic** acids (BA) exhibit adjuvant-induced and carrageenan-induced anti-inflammatory properties. The present work was aimed at evaluating the influence of BA on complement-related inflammation in the exptl. models of inflammation. In adjuvant-induced **arthritis** and carrageenan-induced paw edema in rats, BA were found to possess significant anti-inflammatory and complement-inhibitory activities. The i.p. injection of BA (100 mg/kg twice a day), before and after FCA challenge and thereafter repeated for several days, significantly reduced foot pad thickness of exptl. animal models and simultaneously also reduced complement activity. It also showed marked redn. in complement levels and inflammatory effects on carrageenan-induced paw edema in rats when injected i.p. (100 mg/kg twice a day).
- L52 ANSWER 13 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1994:524803 HCAPLUS  
DN 121:124803  
TI Application of papaya latex-induced rat paw inflammation: model for evaluation of slowly acting **antiarthritic** drugs  
AU Gupta, O. P.; Sharma, N.; Chand, D.  
CS Dep. Pharmacol., Reg. Res. Lab., Jammu-Tawi, India  
SO J. Pharmacol. Toxicol. Methods (1994), 31(2), 95-8  
CODEN: JPTMEZ; ISSN: 1056-8719  
DT Journal  
LA English  
AB Papaya latex-induced rat paw inflammation model for evaluating antiinflammatory activity has been developed and reported earlier. A no. of drugs viz. aspirin, indomethacin, piroxicam, ibuprofen, prednisolone, levamisole, chloroquine, and **boswellic** acids showed antiinflammatory activity in this model. As the last three drugs showing



the activity belonged to the group of slowly acting **antiarthritic** drugs, this present study was undertaken to study in detail the sensitivity of this model for slowly acting, clin. effective, **antiarthritic** drug viz. chloroquine, levamisole, penicillamine, aurothioglucose, cyclophosphamide, and **boswellic** acids. These drugs are known to show no appreciable activity in the known models of inflammation and **arthritis**. All these drugs tested in three graded doses showed dose-related significant antiinflammatory activity in this model, whereas those drugs in the carrageenan model tested in similar doses showed insignificantly activity. Aspirin employed as a ref. std. showed significant activity in both the models. Thus the slowly acting **antiarthritic** drugs will be identified as those displaying significant activity in the papaya latex model and insignificant activity in the carrageenan model and to be aspirin-like by their significant activity in both the above models of inflammation.

L52 ANSWER 14 OF 34 HCAPLUS COPYRIGHT 1999 ACS

AN 1994:200438 HCAPLUS

DN 120:200438

TI Controlled-release transdermal pharmaceuticals containing cyrogels

IN Wood, Louis L.; Calton, Gary J.

PA SRCHEM Inc., USA

SO U.S., 15 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5260066	A	19931109	US 92-821627	19920116
	US 5288503	A	19940222	US 92-899369	19920616
PRAI	US 92-821627		19920116		

AB A controlled-release transdermal pharmaceutical contg. therapeutic agents in a poly(vinyl alc.) (I) cyrogel is disclosed. A slurry of 11.0 mg ciprofloxacin.HCl (II) and 200 mg 10% I was warmed to 50-60.degree. to obtain a clear homogeneous soln. The soln. was then placed in a mold and subjected to 6 freeze-thaw cycles to give a white opaque elastomeric cryogel having 15mm diam. and 0.5mm thickness. The release of II from the gel in 0.9% NaCl was 74% in th 1st 4 hs and it was const. in the subsequent 5-24 hs.

IT 471-53-4, Glycyrrhetic acid 9001-90-5,

**Fibrinolysin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(controlled-release transdermal pharmaceuticals contg. cryogels and)

L52 ANSWER 15 OF 34 HCAPLUS COPYRIGHT 1999 ACS

AN 1993:552084 HCAPLUS

DN 119:552084

TI **Boswellic acid** as inflammation inhibitor.

IN Amnon, Hermann P. T.; Safayhi, Hasan; Singh, G. B.

PA Germany

SO Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 552657	A1	19930728	EP 93-100398	19930113

- R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE  
DE 4201903 A1 19930729 DE 92-4201903 19920124  
PRAI DE 92-4201903 19920124
- AB **Boswellic acid** (I) or I-contg. plant preps. are inhibitors of inflammation caused by enhanced leukotriene formation, such as ulcerative colitis and Crohn's disease. The mechanism of I action involves inhibition of 5-lipoxygenase.
- IT **471-66-9, .alpha.-Boswellic acid**  
**631-69-6, .beta.-Boswellic acid**  
RL: BIOL (Biological study)  
(antiinflammatory agent, 5-lipoxygenase inhibition in relation to)
- L52 ANSWER 16 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1993:183037 HCAPLUS  
DN 118:183037  
TI Antiinflammatory activity of resins from some species of the plant family **Burseraceae**  
AU Duwiejua, M.; Zeitlin, I. J.; Waterman, P. G.; Chapman, J.; Mhango, G. J.; Provan, G. J.  
CS Dep. Physiol. Pharmacol., Univ. Strathclyde, Glasgow, G1 1XW, UK  
SO Planta Med. (1993), 59(1), 12-16  
CODEN: PLMEAA; ISSN: 0032-0943  
DT Journal  
LA English  
AB The antiinflammatory activities of exts. from the resins of four species of the plant family **Burseraceae**, **Boswellia dalzielii**, **B. carteri** (gum **olibanum**), **Commiphora mukul**, and **C. incisa**, were studied. The aq. exts. of the resins of **B. dalzielii**, **C. incisa**, and **C. mukul** significantly inhibited both the maximal edema response and the total edema response during 6 h of carrageenan-induced rat paw edema. The octanordammarane triterpenes, mansumbinone and mansumbionic acid, isolated from the resin of **C. incisa**, were sepd. and tested. Administered prophylactically, mansumbinone proved to be more than 20 times less potent than indomethacin and prednisolone in inhibiting carrageenan-induced rat paw edema. However, the molar potency of mansumbionic acid was within one order of magnitude of those of indomethacin and prednisolone. The antiinflammatory action of the acid on the carrageenan-induced edema was dose-related between 1.3 .times. 10<sup>-5</sup> and 2.5 .times. 10<sup>-4</sup> mol kg<sup>-1</sup> when given before the inflammatory stimulus. The acid was able to reverse an established carrageenan-induced inflammatory response when administered 2 h after induction. Daily administration of mansumbionic acid at a single dose level (1.5 .times. 10<sup>-4</sup> mol kg<sup>-1</sup>) significantly reduced joint swelling in adjuvant **arthritis** in rats. The results indicated that this compd. is worthy of further investigation as an antiinflammatory drug.
- L52 ANSWER 17 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1993:160662 HCAPLUS  
DN 118:160662  
TI Combination induction of cell differentiation of HL-60 cells by daidzein (S86019) and BC-4 or ARA-c  
AU Jing, Y. K.; Han, R.  
CS Inst. Mater. Med., Chin. Acad. Med. Sci., Beijing, 100050, Peop. Rep. China  
SO Yaoxue Xuebao (1993), 28(1), 11-16  
CODEN: YHHPAL; ISSN: 0513-4870  
DT Journal  
LA Chinese  
AB The cell differentiation of HL-60 cells induced by single treatment of low

concns. of daidzein (S86019), BC-4 (active principle of *Boswellia carterii*) or Ara-C was not impressive. However, when daidzein and BC-4 were used in combination 80% of HL-60 cells exhibited NBT redn. and 82% of the cells showed phagocytosis after four days exposure. When HL-60 cells were exposed to combination of daidzein and Ara-c, 70% of the cells exhibited NBT redn. and phagocytosis. Flow cytometry indicated that the majority of the cells were blocked at G1 phase when treated with daidzein-BC-4 or daidzein-Ara-C.

o

L52 ANSWER 18 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1993:144 HCAPLUS  
DN 118:144  
TI A sensitive and relevant model for evaluating anti-inflammatory activity - papaya latex-induced rat paw inflammation  
AU Gupta, O. P.; Sharma, N.; Chand, D.  
CS Dep. Pharmacol., Reg. Res. Lab., Jammu-Tawi, India  
SO J. Pharmacol. Toxicol. Methods (1992), 28(1), 15-19  
CODEN: JPTMEZ; ISSN: 1056-8719  
DT Journal  
LA English  
AB A new model employing latex of papaya as an inflammagen has been developed for testing anti-inflammatory activity. The latex (exudate) was harvested from the unripe papaya fruit, which had been dried under vacuum. The latex was then suspended in 0.05 M sodium acetate buffer. This suspension when injected in rat hind paw produced concn.-dependent inflammation. At a concn. of 0.25%, 0.1 mL was found to be ideal for evaluating anti-inflammatory activity of test drugs. This concn. produced 70%-100% inflammation lasting for about 5 h with a max. effect at 3 h. The test drugs employed were prednisolone, aspirin, indomethacin, phenylbutazone, ibuprofen, piroxicam, chloroquine, levamisole, and a mixt. of **boswellic** acids. For comparison, these drugs were also tested against carrageenan-induced inflammation. All the test drugs-steroidal, aspirin, and non-aspirin-like-showed anti-inflammatory activity against latex-induced inflammation. The activity of chloroquine, levamisole, and **boswellic** acids was significantly more against latex as compared with that of the carrageenan model. The inflammation caused by latex may be attributed to both its hydrolytic enzymes-papain and chymopapain-and glutathione, the activator of these enzymes. These enzymes seem to act like lysosomal enzymes that are released in inflammatory disease processes which mediate inflammation by stimulating the synthesis of prostaglandins. The papaya latex-induced inflammation model appears to be a sensitive, broad-based, and relevant one likely to prove useful for discovering new and effective drugs against inflammation and **rheumatoid arthritis**.

L52 ANSWER 19 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1992:584502 HCAPLUS  
DN 117:184502  
TI Anticomplementary activity of **boswellic** acids. An inhibitor of C3-convertase of the classical complement pathway  
AU Kapil, Aruna; Moza, Nalini  
CS Pharmacol. Div., Reg. Res. Lab., Jammu Tawi, 180 001, India  
SO Int. J. Immunopharmacol. (1992), 14(7), 1139-43  
CODEN: IJIMDS; ISSN: 0192-0561  
DT Journal  
LA English  
AB **Boswellic** acids (BA), anti-inflammatory and anti-**arthritic** principle/s of *Boswellia serrata*, were found to possess anticomplementary activity. They inhibit the in vitro

immuno-hemolysis of antibody-coated sheep erythrocytes by pooled guinea-pig serum. The reduced immuno-hemolysis was found to be due to inhibition of C3-convertase of the classical complement pathway. The threshold concn. for inhibiting C3-convertase was found to be 100 .mu.g. However, higher concns. of BA showed const. inhibitory effects on immuno-hemolysis. BA also exhibited weak inhibitory effects on individual components of the complement system. In vivo administration of BA also showed the inhibitory effect on guinea-pig serum.

L52 ANSWER 20 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1991:409081 HCAPLUS  
DN 115:9081  
TI Synthesis, anti-inflammatory and anti-arthritic activity of  
newer .beta.-boswellic acid derivatives  
AU Rangari, Vinod; Gupta, V. N.; Atal, C. K.  
CS Reg. Res. Lab., Jammu Tawi, 180 001, India  
SO Indian J. Pharm. Sci. (1990), 52(3), 158-60  
CODEN: IJSIDW; ISSN: 0250-474X  
DT Journal  
LA English  
GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB 3-Oxo-.beta.-boswellic acid Me ester was derivatized  
using different arom. aldehydes yielding corresponding arylidene derivs. I  
[R = H, 3-OH, 3-NO<sub>2</sub>, 4-OMe, 4-Me<sub>2</sub>N, 4-NO<sub>2</sub>, 3,4-(MeO)<sub>2</sub>]. Cyclization of I  
with hydrazine hydrate gave pyrazoline derivs. II. The compds. were  
characterized spectrally. The pyrazoline derivs. were screened for  
anti-inflammatory and anti-arthritic activity.  
IT 631-69-6P, .beta.-Boswellic acid  
RL: PREP (Preparation); RCT (Reactant)  
(isolation and esterification of)


L52 ANSWER 21 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1990:545330 HCAPLUS  
DN 113:145330  
TI Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell  
differentiation inducers  
IN Lee, Yue Wei; Fang, Qicheng; Wang, Zhenguo; Li, Dehua; Cook, C. Edgar  
PA Research Triangle Institute, USA  
SO PCT Int. Appl., 54 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9001937	A1	19900308	WO 89-US3581	19890824
	W: AU, DK, JP, KR, NO				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	CA 1330944	A1	19940726	CA 89-608654	19890817
	AU 8943033	A1	19900323	AU 89-43033	19890824
	AU 630374	B2	19921029		
	CN 1043131	A	19900620	CN 89-107605	19890824
	EP 431076	A1	19910612	EP 89-910793	19890824


EP 431076	B1	19931013		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 04500209	T2	19920116	JP 89-510077	19890824
JP 2828295	B2	19981125		
AT 95699	E	19931015	AT 89-910793	19890824
US 5064823	A	19911112	US 90-517176	19900501
NO 9100696	A	19910221	NO 91-696	19910221
DK 9100313	A	19910222	DK 91-313	19910222
PRAI US 88-235903		19880824		
EP 89-910793		19890824		
WO 89-US3581		19890824		
OS	MARPAT 113:145330			
GI				




I



II



III



IV

AB Pentacyclic triterpenoids I, II, III, and IV (R1 = COOR4, H, C1-4 alkyl, CONH2, CONHR5, etc.; R4, R5 = (di)(tri)(mono)saccharide; R2, R3 = H, OR4, NH2, R5, NHR5, etc.; R6, R7 = R2, R3) are inhibitors of topoisomerases I and II. They can be used to treat various **cancers** and for inducing cellular differentiation. Thus, a 1:1 mixt. of .alpha.-**boswellic acid** acetate and .beta.-**boswellic acid** acetate (purified from oleogum resin) at 100 mg/kg increased av. survival time of leukemic mice to 22.9 days, vs. 15.7 days for untreated controls.

IT 631-69-6

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(neoplasm inhibitor)

- L52 ANSWER 22 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1990:30360 HCAPLUS  
DN 112:30360  
TI Studies on the metabolism of glycosaminoglycans under the influence of new herbal anti-inflammatory agents  
AU Reddy, G. Kesava; Chandrakasan, Gowri; Dhar, S. C.  
CS Dep. Biochem., Cent. Leather Res. Inst., Madras, 600 020, India  
SO Biochem. Pharmacol. (1989), 38(20), 3527-34  
CODEN: BCPA6; ISSN: 0006-2952  
DT Journal  
LA English  
AB The in vivo effect of a herbal-based, nonsteroidal anti-inflammatory product, **salai guggal**, prepd. from the gum resin exudate of **Boswellia serrata** and its active principle "**boswellic acids**" on glycosaminoglycan metab. was studied in rats. The biosynthesis of sulfated glycosaminoglycans was evaluated by the uptake of [<sup>35</sup>S]sulfate, and the content of glycosaminoglycans was measured in specimens of skin, liver, **kidney** and spleen. Data obtained with the **boswellic acids** and **salai guggal** were compared with those with ketoprofen. A redn. in glycosaminoglycan biosynthesis was obsd. in rats treated with all of the drugs. Glycosaminoglycan content was decreased in the ketoprofen-treated group, whereas that of the **boswellic acid**- or **salai guggal**-treated groups remained unaltered. The catabolism of glycosaminoglycans was followed by estg. the activities of lysosomal glycohydrolases, namely .beta.-glucuronidase, .beta.-N-acetylglucosaminidase, cathepsin B1, cathepsin B2 and cathepsin D, in tissues and by estg. the urinary excretion of hexosamine and uronic acid. The degrdn. of glycosaminoglycans was reduced markedly in all drug-treated animals as compared to controls. The potential of **boswellic acids** and **salai guggal** is discussed in the light of changes in the metab. of glycosaminoglycans.
- L52 ANSWER 23 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1990:30350 HCAPLUS  
DN 112:30350  
TI Anti-**arthritic** activity of **boswellic acids** in bovine serum albumin (BSA)-induced **arthritis**  
AU Sharma, M. L.; Bani, S.; Singh, G. B.  
CS Reg. Res. Lab., CSIR, Jammu Tawi, 180 001, India  
SO Int. J. Immunopharmacol. (1989), 11(6), 647-52  
CODEN: IJIMDS; ISSN: 0192-0561  
DT Journal  
LA English  
AB The effect of **boswellic acids** on bovine serum albumin (BSA)-induced **arthritis** in rabbits was studied. Oral administration of **boswellic acids** (25, 50, and 100 mg/kg/day) reduced the population of leukocytes in a BSA-injected knee and changed the electrophoretic pattern of the synovial fluid proteins. The local injection of **boswellic acids** (5, 10, and 20 mg) into the knee 15 min prior to BSA challenge also reduced the infiltration of leukocytes into the knee joint, reduced the infiltration of leukocytes into the pleural cavity, and inhibited the migration of PMN in vitro. The leukocyte-inhibitory activity of **boswellic acids** was not due to their cytotoxic effect. The **boswellic acids** did not show any detergent or surfactant properties.
- L52 ANSWER 24 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1988:16003 HCAPLUS  
DN 108:16003


- TI Effect of a new nonsteroidal anti-inflammatory agent on lysosomal stability in adjuvant induced **arthritis**
- AU Reddy, G. Kesava; Dhar, S. C.
- CS Dep. Biochem., Cent. Leather Res. Inst., Madras, India
- SO Ital. J. Biochem. (1987), 36(4), 205-17
- CODEN: IJBIAC; ISSN: 0021-2938
- DT Journal
- LA English
- AB Effects of the new natural anti-inflammatory agent **salai-guggal** (I) and its active principle, **boswellic acid** (II), on stability of lysosomes in liver, **kidneys**, and spleen were studied in rats with adjuvant **arthritis**. The rats were given orally 100 mg I or II/kg 2 wks. after the induction, and their lysosomes were isolated 5 wks. later. Activity of .beta.-glucuronidase (III) was used as an indicator of lysosomal stability. **Arthritis** increased the total tissue III in liver and **kidney**. The rates of III release from lysosomes and the ratios of sol.-to-lysosomal III activity were increased due to **arthritis**, but decreased after treatment with I or II in all 3 tissues. I was more effective than II. I and II have apparently a protective effect on lysosomal integrity which is an important factor in the pathogenesis of **arthritic syndrome**.
- L52 ANSWER 25 OF 34 HCAPLUS COPYRIGHT 1999 ACS
- AN 1987:568449 HCAPLUS
- DN 107:168449
- TI Urinary excretion of connective tissue metabolites under the influence of a new non-steroidal anti-inflammatory agent in adjuvant induced **arthritis**
- AU Reddy, G. Kesava; Dhar, S. C.; Singh, G. B.
- CS Dep. Biochem., Cent. Leather Res. Inst., Madras, 600 020, India
- SO Agents Actions (1987), 22(1-2), 99-105
- CODEN: AGACBH; ISSN: 0065-4299
- DT Journal
- LA English
- AB The therapeutic effect on **boswellic acids** and **salai guaggal** in adjuvant-induced **arthritic** rats in relation to urinary excretion of connective tissue metabolites (viz. hydroxyproline, hexosamine and uronic acid) was investigated. Compared to controls, the **arthritic** animals showed an increase in the excretion of these metabolites in urine. The elevated levels of urinary hydroxyproline (free, total, nondialyzable and dialyzable), hexosamine and uronic acid in the **arthritic** animals were slightly decreased in the acute phase and significantly decreased in the chronic phase of the disease following administration of **boswellic acids** or **salai guggal**.
- L52 ANSWER 26 OF 34 HCAPLUS COPYRIGHT 1999 ACS
- AN 1987:131398 HCAPLUS
- DN 106:131398
- TI Biochemical investigations of a new nonsteroidal anti-inflammatory agent in adjuvant induced **arthritis** in relation to serum glycohydrolases and glycoproteins
- AU Reddy, G. Kesava; Dhar, S. C.; Singh, G. B.
- CS Cent. Leather Res. Inst., Madras, 600 020, India
- SO Leather Sci. (Madras) (1986), 33(7), 192-9
- CODEN: LESCA9; ISSN: 0023-9771
- DT Journal
- LA English
- AB **Salai guggal** (oleoresins from **Boswellia serrata**) and its triterpene acids were anti-inflammatory in rats with adjuvant-induced

**arthritis.** The drugs also decreased the levels of glycohydrolases and glycoproteins, which were higher in the **arthritic** animals compared to those in control animals.

- L52 ANSWER 27 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1986:418039 HCAPLUS  
DN 105:18039  
TI Pharmacology of an extract of **salai guggal** ex-**Boswellia serrata**, a new nonsteroidal anti-inflammatory agent  
AU Singh, G. B.; Atal, C. K.  
CS Pharmacol. Dep., Reg. Res. Lab., Jammu-Tawi, 180 001, India  
SO Agents Actions (1986), 18(3-4), 407-12  
CODEN: AGACBH; ISSN: 0065-4299  
DT Journal  
LA English  
AB Pharmacol. evaluation of alc. ext. of **salai guggal** (AESG) has been carried out in exptl. animals. AESG displayed marked anti-inflammatory activity in carrageenan induced edema in rats and mice and dextran edema in rats. It was equally effective in adrenalectomized rats. In formaldehyde and adjuvant **arthritis**, AESG produced prominent anti-**arthritic** activity but no significant effect was obsd. in cotton pellet-induced granuloma test. It inhibited inflammation induced increase in serum transaminase levels and leukocyte counts but lacked any analgesic or antipyretic effects. The gestation period or parturition time in pregnant rats or onset time of castor oil-induced diarrhea was unaffected by AESG and no significant effect was seen on cardiovascular, **respiratory** and central nervous system functions. No ulcerogenic effects were found in the rat stomach. The oral and i.p. LD50 was greater than 2 g/kg in mice and rats.
- L52 ANSWER 28 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1985:534646 HCAPLUS  
DN 103:134646  
TI Antitumor activities of several phytopolysaccharides  
AU Moon, Chang Kiu; Park, Kwang Sik; Lee, Soo Hwan; Yoon, Yeo Pyo  
CS Coll. Pharm., Seoul Natl. Univ., Seoul, 151, S. Korea  
SO Arch. Pharmacol. Res. (1985), 8(1), 42-4  
CODEN: APHRDQ; ISSN: 0253-6269  
DT Journal  
LA English  
AB Polysaccharides isolated from 12 pharmaceutical plants (used against tumors in oriental herb medicine) were examd. for antitumor activities. In mice implanted with sarcoma 180 cells, polysaccharides from *Forsythia corea*, *Curcuma zedoaria*, *Albizia julibrissin*, *Prunus persica*, *Foeniculum vulgare* and *Daphne pseudogenkwa* showed inhibition rates of 88.0%, 61.1%, 73.0%, 72.8%, 55.1% and 71.7%, resp. Significant, prolongation of life span was obsd. only with *F. corea* (18.1%). The other 6 polysaccharides from **Olibanum**, *Lonicera japonica*, *Rheum coreanum*, *Scirpus maritimus*, *Gleditchia officinalis* and *Brassica juncea* showed negligible inhibition rates.
- L52 ANSWER 29 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1977:478324 HCAPLUS  
DN 87:78324  
TI Cytotoxic agents from *Bursera klugii* (**Burseraceae**). I: isolation of sapelins A and B  
AU Jolad, S. D.; Wiedhopf, R. M.; Cole, J. R.  
CS Coll. Pharm., Univ. Arizona, Tucson, Ariz., USA  
SO J. Pharm. Sci. (1977), 66(6), 889-90



CODEN: JPMSAE  
 DT Journal  
 LA English  
 GI



AB A crude chloroform-sol. fraction of the ethanol ext. of the leaves of *B. klugii* showed activity against 2 test systems, the P-388 lymphocytic leukemia (3PS) and the human epidermoid carcinoma of the nasopharynx (9KB). The PS activity was due to 2 constituents, sapelin A (I) [26790-93-2] and sapelin B (II) [26790-94-3].

L52 ANSWER 30 OF 34 HCAPLUS COPYRIGHT 1999 ACS

AN 1977:465330 HCAPLUS

DN 87:65330

TI Cytotoxic agents from *Bursera morelensis* (**Burseraceae**):

deoxypodophyllotoxin and a new lignan, 5'-desmethoxydeoxypodophyllotoxin

AU Jolad, S. D.; Wiedhopf, R. M.; Cole, J. R.

CS Coll. Pharm., Univ. Arizona, Tucson, Ariz., USA

SO J. Pharm. Sci. (1977), 66(6), 892-3

CODEN: JPMSAE

DT Journal

LA English

GI For diagram(s), see printed CA Issue.

AB The isolation and identification of deoxypodophyllotoxin (I) and a new lignan named morelensin (II, 5'-desmethoxydeoxypodophyllotoxin) from the dried exudate of *B. morelensis* were reported. I showed high activity in the KB and PS test systems; II, although highly active against the KB test system, demonstrated only marginal activity against the PS test system.

L52 ANSWER 31 OF 34 HCAPLUS COPYRIGHT 1999 ACS

AN 1973:47709 HCAPLUS

DN 78:47709

TI Antitumor activity of *Bursera schlechtendalii* (**Burseraceae**).

Isolation and structure determination of two new lignans

AU McDoniel, P. B.; Cole, J. R.

CS Coll. Pharm., Univ. Arizona, Tucson, Ariz., USA

SO J. Pharm. Sci. (1972), 61(12), 1992-4

CODEN: JPMSAE

DT Journal

LA English

GI For diagram(s), see printed CA Issue.

AB *B. schlechtendalii* (**Burseraceae**) has shown antitumor activity

against the 9KB (adenocarcinoma of nasal pharynx) test system. Two new lignans isolated from the biol. active plant fraction were identified as (-)-trans-2-(3,4,5-trimethoxybenzyl)-3(3,4-methylenedioxybenzyl) butyrolactone (I) and (-)-trans-2-(3,4-dimethoxybenzyl)-3-- (3,4-methylenedioxybenzyl)butyrolactone (II). In addn., the triterpene .alpha.-amyrin was isolated from the active fraction.

- L52 ANSWER 32 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1971:431255 HCAPLUS  
DN 75:31255  
TI Isolation and characterization of potential antitumor agents from *Bursera schlechtendalii* Family **Burseraceae**  
AU McDoniel, Phillip B.  
CS Univ. Arizona, Tucson, Ariz., USA  
SO (1970) 72 pp. Avail.: Univ. Microfilms, Ann Arbor, Mich., Order No. 70-18,178  
From: Diss. Abstr. Int. B 1970, 31(4), 1853-4  
DT Dissertation  
LA English  
AB Unavailable
- L52 ANSWER 33 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1970:454418 HCAPLUS  
DN 73:54418  
TI Plant antitumor agents. I  
AU Mukerji, S.; Banerjee, A. K.; Mitra, B. N.  
CS Indian Inst. Exptl. Med., Calcutta, India  
SO Indian J. Pharm. (1970), 32(2), 48-9  
CODEN: IJPAAO  
DT Journal  
LA English  
AB Phytochem. and pharmacol. properties of exts. of the barks, root, and stem of *Saraca indica* and ***Boswellia serrata***, *Xanthium strumarium*, and *Geranium bourbon*, resp., were examd. on Ehrlich ascites **carcinoma** and S-180 tumors transplanted in Swiss and A strain inbred mice. The aq. exts. of *S. indica* bark increased the life span of mice with Ehrlich ascites **carcinoma** by 24% and in the case of S-180 decreased tumor wt. by 24%. The MeOH and aq. root exts. (contg. a glycoside, m. 242.degree.) of *X. strumarium* increased the life span with Ehrlich ascites **carcinoma** by 14% and 39.8%, resp.; the MeOH ext. reduced tumor wt. by 13% in S-180. At least 4, 6, and 32 unidentified compds. were isolated or detected by thin layer chromatog. in exts. from *S. indica*, *B. serrata*, and *G. bourbon*, resp.
- L52 ANSWER 34 OF 34 HCAPLUS COPYRIGHT 1999 ACS  
AN 1969:491187 HCAPLUS  
DN 71:91187  
TI Antitumor agents from *Bursera fagaroides* (**Burseraceae**)  
(.beta.-peltatin A-methyl ether and 5'demethoxy-.beta.-peltatin A-methyl ether)  
AU Bianchi, Ennio; Sheth, K.; Cole, Jack Robert  
CS Coll. of Pharm., Univ. of Arizona, Tucson, Ariz., USA  
SO Tetrahedron Lett. (1969), (32), 2759-62  
CODEN: TELEAY  
DT Journal  
LA English  
GI For diagram(s), see printed CA Issue.  
AB The CHCl3 ext. of the Mexican plant *Bursera fagaroides* chromatographed

successively over Al<sub>2</sub>O<sub>3</sub> and silica gel G gave .beta.-peltatin A-methyl ether (I) and a new compd. 5'-demethoxy-.beta.-peltatin A-methyl ether (II), with biol. activity in the Walker carcinoma 256 (intramuscular) tumor system at levels of 10% test-control at 12.5 mg./kg. and 20% test-control at 100 mg./kg., resp. I, C<sub>23</sub>H<sub>24</sub>O<sub>8</sub>, m/e 428 (M<sup>+</sup>) showed satisfactory m.p. and spectroscopic data. I treated with NaOAc gave the known .beta.-peltatin B-methyl ether. II, C<sub>22</sub>H<sub>22</sub>O<sub>7</sub>, m/e 398 (M<sup>+</sup>), m. 142-3.degree. (MeOH, Me<sub>2</sub>CO), m. 167.0-7.5 and 182.0-2.5.degree., after keeping 24 hrs. at 100.degree. in high vacuum, exhibited N.M.R. signals indicating the presence of 3 OMe groups and a methylenedioxy group. The mass fragmentation of II confirmed the assigned location of the OMe groups. The A-type isomer (trans 2/3, cis 3/4) II, [.alpha.]<sub>D</sub><sup>24</sup> -146.degree., was converted by alkali treatment to a B-type isomer (cis 2/3, trans 3/4), [.alpha.]<sub>D</sub><sup>24</sup> 23.degree..

=> fil biosis

FILE 'BIOSIS' ENTERED AT 15:34:00 ON 10 FEB 1999  
COPYRIGHT (C) 1999 BIOSIS(R)

FILE COVERS 1969 TO DATE.  
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNS) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 3 February 1999 (19990203/ED)

The BIOSIS file has been reloaded. Enter HELP RLOAD and HELP REINDEXING for details.

=> d his 154-

(FILE 'REGISTRY' ENTERED AT 15:29:13 ON 10 FEB 1999)

FILE 'HCAPLUS' ENTERED AT 15:29:25 ON 10 FEB 1999

FILE 'BIOSIS' ENTERED AT 15:30:00 ON 10 FEB 1999

```
L54      1040 S L19 OR BOSWEL?
L55      0 S L54 AND L15
L56      3 S L54 AND L16
L57      4 S L54 AND ELASTASE
L58      1 S L54 AND (PLASMIN OR FIBRINOLYSIN OR THROMBOLYSIN)
L59      5 S L56-L58
          E AMMON H/AU
L60      228 S E3,E6,E7,E12,E13
          E SAFAYHI H/AU
L61      46 S E3-E5
L62      21 S L54 AND L60-L61
L63      12 S L62 AND (00520/CC OR CONFERENCE/DT OR ABSTRACT OR POSTER OR M
L64      17 S L59,L63
```

FILE 'BIOSIS' ENTERED AT 15:34:00 ON 10 FEB 1999

=> d all tot 164

```
L64  ANSWER 1 OF 17  BIOSIS  COPYRIGHT 1999 BIOSIS
AN   1998:293506  BIOSIS
DN   PREV199800293506
TI   Identification of a genuine triterpene from the gum of Boswellia
      serrata with 5-lipoxygenase activity stabilizing properties.
AU   Boden, S. E.; Sailer, E.-R.; Taneja, S. C.; Ammon, H. P. T.;
```

**Safayhi, H.**  
 CS Dep. Pharmacology, Inst. Pharmaceutical Sciences, Univ. Tuebingen, Auf der  
 Morgenstelle 8, D-72076 Tuebingen Germany  
 SO Naunyn-Schmiedeberg's Archives of Pharmacology, (1998) Vol. 357, No. 4  
 SUPPL, pp. R40.  
 Meeting Info.: 39th Spring Meeting of the German Society for Experimental  
 and Clinical Pharmacology and Toxicology Mainz, Germany March 17-19, 1998  
 German Society for Experimental and Clinical Pharmacology and Toxicology  
 . ISSN: 0028-1298.  
 DT **Conference**  
 LA English  
 CC Pharmacology - Drug Metabolism; Metabolic Stimulators \*22003  
 Cytology and Cytochemistry - Animal \*02506  
 Biochemical Studies - General \*10060  
 Biochemical Studies - Lipids \*10066  
 Enzymes - Physiological Studies \*10808  
 Immunology and Immunochemistry - General; Methods \*34502  
 Pharmacognosy and Pharmaceutical Botany \*54000  
**General Biology - Symposia, Transactions and Proceedings of**  
**Conferences, Congresses, Review Annuals \*00520**  
 BC Burseraceae 25695  
 Muridae 86375  
 IT Major Concepts  
     Pharmacognosy (Pharmacology)  
 IT Parts, Structures, & Systems of Organisms  
     neutrophil: immune system  
 IT Chemicals & Biochemicals  
     leukotriene; 3-oxo-tirucall-8,24-dien-21-oic acid: metabolic agent,  
     natural product, triterpene; 5-lipoxygenase: stabilization  
 IT Miscellaneous Descriptors  
     **Meeting Abstract**  
 ORGN Super Taxa  
     Burseraceae: Dicotyledones, Angiospermae, Spermatophyta, Plantae;  
     Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia  
 ORGN Organism Name  
     rat (Muridae); **Boswellia-serrata** (Burseraceae)  
 ORGN Organism Superterms  
     Angiosperms; Animals; Chordates; Dicots; Mammals; Nonhuman Mammals;  
     Nonhuman Vertebrates; Plants; Rodents; Spermatophytes; Vascular Plants;  
     Vertebrates  
 RN 80619-02-9 (5-LIPOXYGENASE)  
 L64 ANSWER 2 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
 AN 1998:293392 BIOSIS  
 DN PREV199800293392  
 TI Inhibition of human topoisomerase type I and II by **boswellic**  
 acids.  
 AU Syrovets, T. (1); Buechele, B. (1); **Safayhi, H.**; **Ammon, H.**  
 P. T.; Simmet, T. (1)  
 CS (1) Inst. Pharmacology Toxicology and Natural Products, Univ. Ulm, 89081  
 Ulm Germany  
 SO Naunyn-Schmiedeberg's Archives of Pharmacology, (1998) Vol. 357, No. 4  
 SUPPL, pp. R11.  
 Meeting Info.: 39th Spring Meeting of the German Society for Experimental  
 and Clinical Pharmacology and Toxicology Mainz, Germany March 17-19, 1998  
 German Society for Experimental and Clinical Pharmacology and Toxicology  
 . ISSN: 0028-1298.  
 DT **Conference**  
 LA English

CC Pharmacology - General \*22002  
Genetics and Cytogenetics - General \*03502  
Biochemical Studies - General \*10060  
Biochemical Studies - Nucleic Acids, Purines and Pyrimidines \*10062  
Enzymes - Physiological Studies \*10808  
**General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals \*00520**

BC Hominidae 86215

IT Major Concepts  
Enzymology (Biochemistry and Molecular Biophysics); Pharmacology

IT Chemicals & Biochemicals  
acetyl-**boswellic** acid: antineoplastic agent, enzyme inhibitor  
agent; acetyl-11-keto-beta-**boswellic** acid: antineoplastic  
agent, enzyme inhibitor agent; **boswellic** acid: enzyme  
inhibitor agent; topoisomerase type I; topoisomerase type II; DNA:  
enzyme substrate

IT Miscellaneous Descriptors  
**Meeting Abstract**

ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name  
human (Hominidae)

ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates

RN 80449-01-0 (TOPOISOMERASE)  
**67416-61-9 (ACETYL-11-KETO-BETA-BOSWELLIC ACID)**

L64 ANSWER 3 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS

AN 1997:231659 BIOSIS

DN PREV199799530862

TI Analysis of pentacyclic triterpene-mediated antiproliferative effects on  
malignant melanoma cells.

AU Bogenrieder, T. (1); Glaessl, A.; Bosserhoff, A.-K.; Sailer, E.-R.;  
Landthaler, M.; **Ammon, H. P. T.**; Stolz, W.

CS (1) Univ. Regensburg, Regensburg 93042 Germany

SO Proceedings of the American Association for Cancer Research Annual  
Meeting, (1997) Vol. 38, No. 0, pp. 216-217.  
Meeting Info.: Eighty-eighth Annual Meeting of the American Association  
for Cancer Research San Diego, California, USA April 12-16, 1997  
ISSN: 0197-016X.

DT **Conference; Abstract**

LA English

CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals 00520**  
Cytology and Cytochemistry - Human \*02508  
Pathology, General and Miscellaneous - Therapy \*12512  
Pharmacology - General \*22002  
Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy \*24008  
Developmental Biology - Embryology - Morphogenesis, General \*25508  
In Vitro Studies, Cellular and Subcellular \*32600  
Pharmacognosy and Pharmaceutical Botany \*54000

BC Burseraceae 25695  
Hominidae \*86215

IT Major Concepts  
Cell Biology; Development; Oncology (Human Medicine, Medical Sciences);  
Pathology; Pharmacognosy (Pharmacology); Pharmacology

IT Chemicals & Biochemicals  
**BETULINIC ACID**

IT Miscellaneous Descriptors

ACETYL-11-KETO-BETA-BOSWELLIC ACID; ANALYSIS;  
ANTINEOPLASTIC-DRUG; ANTIPROLIFERATIVE EFFECTS; BETULINIC ACID; GROWTH  
INHIBITION; MELANOMA; NEOPLASTIC DISEASE; PENTACYCLIC TRITERPENE;  
PHARMACOGNOSY; SK-MEL CELL LINE; TUMOR BIOLOGY

## ORGN Super Taxa

Burseraceae: Dicotyledones, Angiospermae, Spermatophyta, Plantae;  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

## ORGN Organism Name

**Boswellia serrata** (Burseraceae); HL-60 (Hominidae): cell line

## ORGN Organism Superterms

angiosperms; animals; chordates; dicots; humans; mammals; plants;  
primates; spermatophytes; vascular plants; vertebrates

RN 472-15-1 (BETULINIC ACID)

L64 ANSWER 4 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS

AN 1997:231493 BIOSIS

DN PREV199799530696

TI Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL60 and  
CCRF-CEM cells and inhibits topoisomerase I.

AU Hoernlein, R. F. (1); Orlikowsky, T.; Zehrer, C.; Niethammer, D.; Sailer,  
E. R.; Dannecker, G. E.; Ammon, H. P. T.

CS (1) Inst. Pharmaceutical Sci., Auf der Morgenstelle 8, 72076 Tuebingen  
Germany

SO Proceedings of the American Association for Cancer Research Annual  
Meeting, (1997) Vol. 38, No. 0, pp. 192.

Meeting Info.: Eighty-eighth Annual Meeting of the American Association  
for Cancer Research San Diego, California, USA April 12-16, 1997

ISSN: 0197-016X.

DT Conference; Abstract

LA English

CC General Biology - Symposia, Transactions and Proceedings of

Conferences, Congresses, Review Annuals 00520

Cytology and Cytochemistry - Animal \*02506

Cytology and Cytochemistry - Human \*02508

Biochemical Studies - General \*10060

Biophysics - General Biophysical Studies \*10502

Enzymes - General and Comparative Studies; Coenzymes \*10802

Blood, Blood-Forming Organs and Body Fluids - General; Methods \*15001

Neoplasms and Neoplastic Agents - General \*24002

Developmental Biology - Embryology - General and Descriptive \*25502

BC Bovidae 85715

Hominidae \*86215

IT Major Concepts

Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport  
and Circulation); Cell Biology; Development; Enzymology (Biochemistry  
and Molecular Biophysics); Oncology (Human Medicine, Medical Sciences)

IT Chemicals & Biochemicals

TOPOISOMERASE; 5-LIPOXYGENASE; ALPHA-AMYRIN; CD95

IT Miscellaneous Descriptors

ACETYL-11-KETO-BETA-BOSWELLIC ACID; ALPHA-AMYRIN; APOPTOSIS;  
BLOOD AND LYMPHATICS; CD95 RECEPTOR; CYTOLOGICAL METHOD; ENDOCRINE  
SYSTEM; ENZYME INHIBITOR; ENZYMOLOGY; FLOW CYTOMETRY; HUMAN LEUKEMIA  
CELLS; IMMUNE SYSTEM; INHIBITION; THYMUS; TOPOISOMERASE-I; TUMOR  
BIOLOGY; 5-LIPOXYGENASE INHIBITOR

## ORGN Super Taxa

Bovidae: Artiodactyla, Mammalia, Vertebrata, Chordata, Animalia;  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

## ORGN Organism Name

calf (Bovidae); CCRF-CEM (Hominidae): cell line; HL60 (Hominidae): cell

line

ORGN Organism Superterms

animals; artiodactyls; chordates; humans; mammals; nonhuman mammals;  
nonhuman vertebrates; primates; vertebratesRN 80449-01-0 (TOPOISOMERASE)  
80619-02-9 (5-LIPOXYGENASE)  
**638-95-9** (ALPHA-AMYRIN)  
81271-93-4 (CD95)

L64 ANSWER 5 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS

AN 1997:216445 BIOSIS

DN PREV199799522949

TI Inhibition by **boswellic** acids of human leukocyte  
**elastase**.AU Safayhi, Hasan (1); Rall, Beatrice; Sailer, Eckart-Roderich; Ammon,  
Hermann P. T.CS (1) Inst. Pharm. Sci., Univ. Tuebingen, Auf der Morgenstelle 8, D-72076  
Tuebingen GermanySO Journal of Pharmacology and Experimental Therapeutics, (1997) Vol. 281,  
No. 1, pp. 460-463.  
ISSN: 0022-3565.

DT Article

LA English

AB Frankincense extracts and **boswellic** acids, biologically active  
pentacyclic triterpenes of frankincense, block leukotriene biosynthesis  
and exert potent anti-inflammatory effects. Screening for additional  
effects of **boswellic** acids on further proinflammatory pathways,  
we observed that acetyl-11-keto-beta-**boswellic** acid, an  
established direct, nonredox and noncompetitive 5-lipoxygenase inhibitor,  
decreased the activity of human leukocyte **elastase** (HLE) in  
vitro with an IC-50 value of about 15  $\mu$ M. Among the pentacyclic  
triterpenes tested in concentrations up to 20  $\mu$ M, we also observed  
substantial inhibition by beta-**boswellic** acid, amylin and  
ursolic acid, but not by 18-beta-glycyrrhetic acid. The data show that  
the dual inhibition of 5-lipoxygenase and HLE is unique to  
**boswellic** acids: other pentacyclic triterpenes with HLE inhibitory  
activities (e.g., ursolic acid and amylin) do not inhibit 5-lipoxygenase,  
and leukotriene biosynthesis inhibitors from different chemical classes  
(e.g., NDGA, MK-886 and ZM-230,487) do not impair HLE activity. Because  
leukotriene formation and HLE release are increased simultaneously by  
neutrophil stimulation in a variety of inflammation- and  
hypersensitivity-based human diseases, the reported blockade of two  
proinflammatory enzymes by **boswellic** acids might be the  
rationale for the putative antiphlogistic activity of acetyl-11-keto-beta-  
**boswellic** acid and derivatives.

CC Biochemical Studies - General 10060

Biochemical Studies - Proteins, Peptides and Amino Acids 10064

Enzymes - Physiological Studies \*10808

Pathology, General and Miscellaneous - Inflammation and Inflammatory  
Disease \*12508Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and  
Reticuloendothelial System \*15008

Pharmacology - Immunological Processes and Allergy \*22018

BC Hominidae 86215

Muridae \*86375

IT Major Concepts

Blood and Lymphatics (Transport and Circulation); Enzymology

(Biochemistry and Molecular Biophysics); Pathology; Pharmacology

IT Chemicals &amp; Biochemicals

**ELASTASE**

IT Miscellaneous Descriptors  
ANIMAL MODEL; **BOSWELLIC ACIDS**; HUMAN LEUKOCYTE  
**ELASTASE**; INFLAMMATION; INHIBITION; PHARMACOLOGY

ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae:  
Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name  
human (Hominidae); rat (Muridae)

ORGN Organism Superterms  
animals; chordates; humans; mammals; nonhuman mammals; nonhuman  
vertebrates; primates; rodents; vertebrates

RN 9004-06-2 (**ELASTASE**)

L64 ANSWER 6 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
AN 1997:104103 BIOSIS  
DN PREV199799403306  
TI Synthesis of a radio-iodinated photoaffinity analogue of the direct,  
non-redox, non-competitive 5-lipoxygenase inhibitor acetyl-11-keto-beta-  
**boswellic acid**.  
AU Sailer, E. R.; Hoernlein, R. H.; Schneider, N.; Ammon, H. P. T.;  
**Safayhi, H.**  
CS Inst. Pharmaceutical Sci., Univ. Tuebingen, Auf der Morgenstelle 8,  
D-72076 Tuebingen Germany  
SO European Journal of Pharmaceutical Sciences, (1996) Vol. 4, No. SUPPL.,  
pp. S113.  
Meeting Info.: Third European Congress of Pharmaceutical Sciences  
Edinburgh, Scotland, UK September 15-17, 1996  
ISSN: 0928-0987.

DT **Conference; Abstract; Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals 00520**  
Radiation - Radiation and Isotope Techniques \*06504  
Biochemical Methods - General \*10050  
Biochemical Studies - General \*10060  
Biophysics - Molecular Properties and Macromolecules \*10506  
Pharmacology - General \*22002

IT Major Concepts  
Biochemistry and Molecular Biophysics; Methods and Techniques;  
Pharmacology; Radiology (Medical Sciences)

IT Chemicals & Biochemicals  
5-LIPOXYGENASE

IT Miscellaneous Descriptors  
CHEMICAL SYNTHESIS; CHEMISTRY; NON-COMPETITIVE INHIBITOR; NON-REDOX  
INHIBITOR; PHARMACOLOGY; RADIO-IODINATED ACETYL-11-KETO-BETA-  
**BOSWELLIC ACID PHOTOAFFINITY ANALOGUE**; STRUCTURE-ACTIVITY  
RELATIONSHIP; SYNTHESIS; 5-LIPOXYGENASE INHIBITOR

RN 80619-02-9 (5-LIPOXYGENASE)

L64 ANSWER 7 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
AN 1997:104009 BIOSIS  
DN PREV199799403212  
TI The pentacyclic triterpene selective binding site of 5-lipoxygenase.  
AU **Safayhi, H.**; Hoemiein, R. H.; Ammon, H. P. T.; Sailer,  
E. R.  
CS Dep. Pharmacol., Inst. Pharmaceutical Sci., Univ. Tuebingen, D-72076  
Tubingen Germany  
SO European Journal of Pharmaceutical Sciences, (1996) Vol. 4, No. SUPPL.,



pp. S79.  
Meeting Info.: Third European Congress of Pharmaceutical Sciences  
Edinburgh, Scotland, UK September 15-17, 1996  
ISSN: 0928-0987.

DT **Conference; Abstract**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals 00520**  
Biochemical Studies - General \*10060  
Enzymes - General and Comparative Studies; Coenzymes \*10802  
Pharmacology - General \*22002

IT Major Concepts  
Biochemistry and Molecular Biophysics; Enzymology (Biochemistry and  
Molecular Biophysics); Pharmacology

IT Chemicals & Biochemicals  
5-LIPOXYGENASE

IT Miscellaneous Descriptors  
BIOSYNTHESIS; **BOSWELLIC ACID**; ENZYMOLOGY; LEUKOTRIENE;  
PENTACYCLIC TRITERPENE SELECTIVE EFFECTOR SITE; PHARMACOLOGY;  
5-LIPOXYGENASE

RN 80619-02-9 (5-LIPOXYGENASE)

L64 ANSWER 8 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
AN 1997:103969 BIOSIS  
DN PREV199799403172  
TI Structure-activity-relationships of 5-lipoxygenase-inhibition by  
**boswellic** acids.  
AU Sailer, E. R.; Hoernlein, R. H.; **Ammon, H. P. T.; Safayhi,**  
H.  
CS Inst. Pharmaceutical Sci., Univ. Tuebingen, Auf der Morgenstelle 8,  
D-72076 Tuebingen Germany  
SO European Journal of Pharmaceutical Sciences, (1996) Vol. 4, No. SUPPL.,  
pp. S54.  
Meeting Info.: Third European Congress of Pharmaceutical Sciences  
Edinburgh, Scotland, UK September 15-17, 1996  
ISSN: 0928-0987.

DT **Conference; Abstract**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals 00520**  
Biophysics - Molecular Properties and Macromolecules \*10506  
Enzymes - Chemical and Physical \*10806  
Pharmacology - Drug Metabolism; Metabolic Stimulators \*22003

BC Muridae \*86375

IT Major Concepts  
Biochemistry and Molecular Biophysics; Enzymology (Biochemistry and  
Molecular Biophysics); Pharmacology

IT Chemicals & Biochemicals  
5-LIPOXYGENASE; **URSOLIC ACID**

IT Miscellaneous Descriptors  
**ACETYL-11-KETO-BETA-BOSWELLIC ACID**; AMYRIN; DRUG RECEPTORS;  
EFFECTOR SITE BINDING; ENZYMOLOGY; PENTACYCLIC TRITERPENES;  
PHARMACOLOGY; STRUCTURE-ACTIVITY RELATIONSHIP; **URSOLIC ACID**;  
**11-KETO-BETA-BOSWELLIC ACID METHYL ESTER**; 5-LIPOXYGENASE

ORGN Super Taxa  
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name  
rat (Muridae)

ORGN Organism Superterms

animals; chordates; mammals; nonhuman mammals; nonhuman vertebrates;  
rodents; vertebrates

RN 80619-02-9 (5-LIPOXYGENASE)  
77-52-1 (URSOLIC ACID)

L64 ANSWER 9 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
AN 1996:304390 BIOSIS  
DN PREV199699026746  
TI Structure-activity-relationships of 5-lipoxygenase-inhibition by  
**boswellic** acids.  
AU Sailer, E. R.; Hoernlein, R. F.; Ammon, H. P. T.; Safayhi,  
H.  
CS Pharmazeutisches Inst., Univ. Tuebingen, Auf der Morgenstelle 8, D-72076  
Tuebingen Germany  
SO Naunyn-Schmiedeberg's Archives of Pharmacology, (1996) Vol. 353, No. 4  
SUPPL., pp. R43.  
Meeting Info.: 37th Spring Meeting of the German Society for Experimental  
and Clinical Pharmacology and Toxicology Mainz, Germany March 12-14, 1996  
ISSN: 0028-1298.

DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of**  
**Conferences, Congresses, Review Annuals 00520**  
Cytology and Cytochemistry - Animal 02506  
Biochemical Studies - General \*10060  
Biophysics - General Biophysical Techniques 10504  
Enzymes - Physiological Studies \*10808

BC Muridae \*86375  
IT Major Concepts  
Biochemistry and Molecular Biophysics; Enzymology (Biochemistry and  
Molecular Biophysics)

IT Miscellaneous Descriptors  
ACETYL-11-KETO-BETA-**BOSWELLIC** ACID; **MEETING**  
**ABSTRACT**

ORGN Super Taxa  
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name  
rat (Muridae)

ORGN Organism Superterms  
animals; chordates; mammals; nonhuman mammals; nonhuman vertebrates;  
rodents; vertebrates

L64 ANSWER 10 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
AN 1996:65756 BIOSIS  
DN PREV199698637891  
TI Anti-**elastase** and anti-hyaluronidase activities of saponins and  
sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus  
aculeatus: Factors contributing to their efficacy in the treatment of  
venous insufficiency.  
AU Facino, Roberto Maffei (1); Carini, Marina; Stefani, Rita; Saibene,  
Giancarlo Aldini And Luisella  
CS (1) Istituto Chimico Farmaceutico Tossicologico, Fac. Pharm., Univ. Milan,  
Viale Abruzzi 42, I-20131 Milan Italy  
SO Archiv der Pharmazie (Weinheim), (1995) Vol. 328, No. 10, pp. 720-724.  
ISSN: 0365-6233.

DT Article  
LA English  
AB Triterpene and steroid saponins and sapogenins of medicinal plants  
(Aesculus hippocastanum L., Hedera helix L., Ruscus aculeatus L.) are

claimed to be effective for the treatment/prevention of venous insufficiency. In this work we evaluated the inhibitory effects of these plant constituents on the activity of **elastase** and hyaluronidase, the enzyme systems involved in the turnover of the main components of the perivascular amorphous substance. The results evidence that for *Hedera helix* L., the saponinins only non-competitively inhibit hyaluronidase activity in a dose-dependent fashion, showing comparable IC-50 values (hederagenin IC-50 = 280.4  $\mu$ M; oleanolic acid IC-50 = 300.2  $\mu$ M): both the saponins hederacoside C and  $\alpha$ -hederin are very weak inhibitors. The same behaviour is observed for serine protease porcine pancreatic **elastase**: the glycosides are devoid of inhibitory action, while genins are potent competitive inhibitors (oleanolic acid IC-50 = 5.1  $\mu$ M; hederagenin IC-50 = 40.6  $\mu$ M). Constituents from *Aesculus hippocastanum* L. show inhibitory effects only on hyaluronidase, and this activity is mainly linked to the saponin escin (IC-50 = 149.9  $\mu$ M), less to its genin escinol (IC-50 = 1.65 mM). By contrast, ruscogenins from *Ruscus aculeatus* L., ineffective on hyaluronidase activity, exhibit remarkable anti-**elastase** activity (IC-50 = 119.9  $\mu$ M; competitive inhibition). The mechanism of **elastase** inhibition by triterpene and steroid aglycones, with a nitroanilide derivative as substrate, is discussed.

- CC Biochemical Studies - Sterols and Steroids \*10067  
 Enzymes - Chemical and Physical \*10806  
 Pharmacology - Cardiovascular System \*22010  
 Plant Physiology, Biochemistry and Biophysics - Chemical Constituents \*51522  
 Pharmacognosy and Pharmaceutical Botany \*54000
- BC Liliaceae \*25345
- IT Major Concepts  
 Biochemistry and Molecular Biophysics; Enzymology (Biochemistry and Molecular Biophysics); Pharmacognosy (Pharmacology); Pharmacology
- IT Chemicals & Biochemicals  
 ANTI-**ELASTASE**; HYALURONIDASE; ESCINOL; ESCIN; HEDERAGENIN;  
 OLEANOLIC ACID; HEDERACOSIDE C; ALPHA-HEDERIN; GLYCYRRHETIC ACID;  
 RUSCOGENIN
- IT Miscellaneous Descriptors  
 ALPHA-HEDERIN; CARDIOVASCULAR AGENT; ENZYME INHIBITOR; ESCIN; ESCINOL;  
 GLYCYRRHETIC ACID; HEDERACOSIDE C; HEDERAGENIN; NATURAL PRODUCT;  
 OLEANOLIC ACID; RUSCOGENIN; STRUCTURE-ACTIVITY RELATIONSHIP
- ORGN Super Taxa  
 Araliaceae: Dicotyledones, Angiospermae, Spermatophyta, Plantae;  
 Hippocastanaceae: Dicotyledones, Angiospermae, Spermatophyta, Plantae;  
 Liliaceae: Monocotyledones, Angiospermae, Spermatophyta, Plantae
- ORGN Organism Name  
 Aesculus hippocastanum (Hippocastanaceae); Hedera helix (Araliaceae);  
 Ruscus aculeatus (Liliaceae)
- ORGN Organism Superterms  
 angiosperms; dicots; monocots; plants; spermatophytes; vascular plants
- RN 9012-20-8 (ANTI-**ELASTASE**)  
 9001-54-1Q (HYALURONIDASE)  
 37259-53-3Q (HYALURONIDASE)  
 37288-34-9Q (HYALURONIDASE)  
 37326-33-3Q (HYALURONIDASE)  
 127120-27-8 (ESCINOL)  
 6805-41-0 (ESCIN)  
 465-99-6 (HEDERAGENIN)  
 508-02-1 (OLEANOLIC ACID)  
 14216-03-6 (HEDERACOSIDE C)  
 27013-91-8 (ALPHA-HEDERIN)

471-53-4 (GLYCYRRHETIC ACID)  
472-11-7 (RUSCOGENIN)

L64 ANSWER 11 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
AN 1995:90304 BIOSIS  
DN PREV199598104604  
TI Structure requirements for 5-LO inhibition by **boswellic** acids.  
AU **Safayhi, H.**; Sailer, E.-R.; Rall, B.; **Ammon, H. P. T.**  
CS Dep. Pharmacol., Inst. Pharm. Sci., Univ. Tuebingen, 72076 Tuebingen  
Germany  
SO European Journal of Pharmaceutical Sciences, (1994) Vol. 2, No. 1-2, pp.  
101.  
Meeting Info.: Second European Congress of Pharmaceutical Sciences Berlin,  
Germany September 29-October 1, 1994  
ISSN: 0928-0987.  
DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of**  
**Conferences, Congresses, Review Annuals 00520**  
Cytology and Cytochemistry - Animal 02506  
Cytology and Cytochemistry - Human 02508  
Biochemical Studies - General 10060  
Biochemical Studies - Proteins, Peptides and Amino Acids 10064  
Enzymes - Chemical and Physical \*10806  
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and  
Reticuloendothelial System \*15008  
Pharmacology - Drug Metabolism; Metabolic Stimulators \*22003  
Pharmacology - Immunological Processes and Allergy \*22018  
Plant Physiology, Biochemistry and Biophysics - Chemical Constituents  
\*51522  
Pharmacognosy and Pharmaceutical Botany \*54000  
BC Burseraceae 25695  
Hominidae 86215  
Muridae \*86375  
IT Major Concepts  
Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport  
and Circulation); Enzymology (Biochemistry and Molecular Biophysics);  
Pharmacognosy (Pharmacology); Pharmacology  
IT Chemicals & Biochemicals  
5-LIPOXYGENASE  
IT Miscellaneous Descriptors  
**MEETING ABSTRACT; NEUTROPHIL; 5-LIPOXYGENASE**  
ORGN Super Taxa  
Burseraceae: Dicotyledones, Angiospermae, Spermatophyta, Plantae;  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae:  
Rodentia, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
human (Hominidae); rat (Muridae); Burseraceae (Burseraceae)  
ORGN Organism Superterms  
angiosperms; animals; chordates; dicots; humans; mammals; nonhuman  
mammals; nonhuman vertebrates; plants; primates; rodents;  
spermatophytes; vascular plants; vertebrates  
RN 80619-02-9 (5-LIPOXYGENASE)  
  
L64 ANSWER 12 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
AN 1995:49568 BIOSIS  
DN PREV199598063868  
TI Potent inhibitors of prostaglandine and/or leukotriene synthesis from  
turmeric acid and salai guggal.

AU **Ammon, H. P. T.; Safayhi, H.; Mack, T.; Sabieraj, J.**  
CS Dep. Pharmacol., Inst. Pharm. Sci., Eberhard-Karls-Univ., D-W-7400  
Tuebingen Germany  
SO Mukherjee, B. [Editor]. (1993) pp. 110-124. Traditional medicine.  
Publisher: International Science Publisher Lebanon, New Hampshire, USA.  
Meeting Info.: International Seminar on Traditional Medicine: A Challenge  
of the Twenty-first Century Calcutta, India November 7-9, 1992  
ISBN: 1-881570-32-0.  
DT Book; **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of**  
**Conferences, Congresses, Review Annuals 00520**  
Biochemical Studies - Proteins, Peptides and Amino Acids 10064  
Biochemical Studies - Lipids 10066  
Enzymes - Physiological Studies \*10808  
Pathology, General and Miscellaneous - Inflammation and Inflammatory  
Disease \*12508  
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies \*15004  
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and  
Reticuloendothelial System \*15008  
Endocrine System - General \*17002  
Pharmacology - General \*22002  
Plant Physiology, Biochemistry and Biophysics - Chemical Constituents  
\*51522  
Pharmacognosy and Pharmaceutical Botany \*54000  
BC Zingiberaceae 25470  
Burseraceae \*25695  
IT Major Concepts  
Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport  
and Circulation); Endocrine System (Chemical Coordination and  
Homeostasis); Enzymology (Biochemistry and Molecular Biophysics);  
Pathology; Pharmacognosy (Pharmacology); Pharmacology  
IT Chemicals & Biochemicals  
TURMERIC; 5-LIPOXYGENASE; 12-LIPOXYGENASE  
IT Miscellaneous Descriptors  
ANTIINFLAMMATORIES; BOOK CHAPTER; HERBAL MEDICINE; **MEETING**  
PAPER; NEUTROPHILS; PROSTAGLANDIN; 12-LIPOXYGENASE; 5-LIPOXYGENASE  
ORGN Super Taxa  
Burseraceae: Dicotyledones, Angiospermae, Spermatophyta, Plantae;  
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia;  
Zingiberaceae: Monocotyledones, Angiospermae, Spermatophyta, Plantae  
ORGN Organism Name  
rat (Muridae); **Boswellia serrata** (Burseraceae); *Curcuma longa*  
(Zingiberaceae)  
ORGN Organism Superterms  
angiosperms; animals; chordates; dicots; mammals; monocots; nonhuman  
mammals; nonhuman vertebrates; plants; rodents; spermatophytes;  
vascular plants; vertebrates  
RN 458-37-7 (TURMERIC)  
80619-02-9 (5-LIPOXYGENASE)  
82391-43-3 (12-LIPOXYGENASE)  
L64 ANSWER 13 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
AN 1993:378385 BIOSIS  
DN PREV199345049810  
TI Mechanism of antiinflammatory actions of curcumine and **boswellic**  
acids.  
AU **Ammon, H. P. T. (1); Safayhi, H.; Mack, T.; Sabieraj,**  
J.

CS (1) Dep. Pharmacol., Inst. Pharmaceutical Sci., Eberhard-Karls Univ.,  
D-W-7400 Tuebingen Germany

SO Journal of Ethnopharmacology, (1993) Vol. 38, No. 2-3, pp. 113-119.  
Meeting Info.: Second International Congress on Ethnopharmacology Uppsala,  
Sweden July 2-4, 1992  
ISSN: 0378-8741.

DT Article

LA English

CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals 00520**  
Cytology and Cytochemistry - Human \*02508  
Biochemical Studies - General 10060  
Biochemical Studies - Proteins, Peptides and Amino Acids 10064  
Biochemical Studies - Lipids 10066  
Enzymes - Physiological Studies \*10808  
Pathology, General and Miscellaneous - Inflammation and Inflammatory  
Disease \*12508  
Metabolism - Lipids \*13006  
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies \*15004  
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and  
Reticuloendothelial System \*15008  
Endocrine System - General \*17002  
Pharmacology - Immunological Processes and Allergy \*22018  
Plant Physiology, Biochemistry and Biophysics - Chemical Constituents  
\*51522  
Pharmacognosy and Pharmaceutical Botany \*54000

BC Zingiberaceae 25470  
Burseraceae 25695  
Muridae \*86375

IT Major Concepts  
Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport  
and Circulation); Cell Biology; Endocrine System (Chemical Coordination  
and Homeostasis); Enzymology (Biochemistry and Molecular Biophysics);  
Metabolism; Pathology; Pharmacognosy (Pharmacology); Pharmacology

IT Chemicals & Biochemicals  
5-LIPOXYGENASE; CYCLOOXYGENASE

IT Miscellaneous Descriptors  
ANTIINFLAMMATORY-DRUG; ANTIOXIDANT ACTIVITY; CYCLOOXYGENASE;  
LEUKOTRIENE SYNTHESIS; NEUTROPHIL; PHARMACODYNAMICS; PLATELET;  
5=LIPOXYGENASE

ORGN Super Taxa  
Burseraceae: Dicotyledones, Angiospermae, Spermatophyta, Plantae;  
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia;  
Zingiberaceae: Monocotyledones, Angiospermae, Spermatophyta, Plantae

ORGN Organism Name  
rat (Muridae); **Boswellia serrata** (Burseraceae); *Curcuma longa*  
(Zingiberaceae)

ORGN Organism Superterms  
angiosperms; animals; chordates; dicots; mammals; monocots; nonhuman  
mammals; nonhuman vertebrates; plants; rodents; spermatophytes;  
vascular plants; vertebrates

RN 80619-02-9 (5-LIPOXYGENASE)  
39391-18-9 (CYCLOOXYGENASE)

L64 ANSWER 14 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS

AN 1991:404826 BIOSIS

DN BA92:71791

TI INHIBITION OF HUMAN LEUKOCYTE ELASTASE BY URSOLIC ACID EVIDENCE  
FOR A BINDING SITE FOR PENTACYCLIC TRITERPENES.

AU YING Q-L; RINEHART A R; SIMON S R; CHERONIS J C  
CS DEP. PATHOL., STATE UNIV. NEW YORK AT STONY BROOK, STONY BROOK, N.Y.  
11794.  
SO BIOCHEM J, (1991) 277 (2), 521-526.  
CODEN: BIJOAK. ISSN: 0306-3275.  
FS BA; OLD  
LA English  
AB Several pentacyclic triterpenoid metabolites of plant origin are inhibitors of hydrolysis of both synthetic peptide substrates and elastin by human leukocyte **elastase** (HLE). Ursolic acid, the most potent of these compounds, has an inhibition constant of 4-6 .mu.M for hydrolysis of peptide substrates in phosphate-buffered saline. With tripeptide and tetrapeptide substrates, the inhibition is purely competitive, whereas with a shorter dipeptide substrate the inhibition is non-competitive, suggesting that ursolic acid interacts with subsite S3 of the extended substrate-binding domain in HLE, but not with subsites S1 and S2. The carboxy group at position 28 in the pentacyclic-ring system of the triterpenes contributes to binding to HLE, since replacement of this group with a hydroxy group, as in uvaol, the alcohol analogue of ursolic acid, reduces the potency of inhibition. The inhibitory potency of ursolic acid is also reduced by addition of 1 M-NaCl, further supporting a postulated electrostatic interaction between the negative charge on the triterpene and a positively charged residue on the enzyme, which we assign to the side chain of Arg-217, located in the vicinity of subsites S4 and S5 in HLE. These observations are consistent with a binding site for ursolic acid which extends from S3 towards S4 and S5 on the enzyme. Other triterpenes, including oleanolic acid, erythrodiol, hederagenin and 18.beta.-glycyrrhetic acid, can also interact with this binding site. On the basis of these results we conclude that the extended substrate-binding domain of HLE can accommodate a variety of hydrophobic ligands, including not only such molecules as fatty acids [Ashe & Zimmerman (1977) Biochem. Biophys. Res. Commun. 75, 194-199; Cook & Ternai (1988) Biol. Chem. Hoppe-Seyler 369, 629-637], but also polycyclic molecules such as the pentacyclic triterpenoids.

CC Cytology and Cytochemistry - Human \*02508  
Biochemical Studies - Proteins, Peptides and Amino Acids 10064  
Biochemical Studies - Lipids \*10066  
Biophysics - Molecular Properties and Macromolecules \*10506  
Enzymes - Chemical and Physical \*10806  
Enzymes - Physiological Studies \*10808  
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies 15004  
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System \*15008  
Plant Physiology, Biochemistry and Biophysics - Chemical Constituents \*51522

BC Hominidae 86215  
IT Miscellaneous Descriptors  
EC 3.4.21.37 SUBSTRATE-BINDING DOMAIN HYDROPHOBIC LIGAND  
RN 77-52-1 (URSOLIC ACID)  
9004-06-2 (ELASTASE)

L64 ANSWER 15 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
AN 1991:353879 BIOSIS  
DN BR41:38394  
TI URSOLIC ACID AND ITS TRITERPENOID ANALOGS ARE NATURAL SLOWLY BINDING INHIBITORS OF **PLASMIN**.  
AU YING Q-L; SIMON S R  
CS DEP. PATHOL., STATE UNIV. N.Y., STONY BROOK, N.Y. 11794-8691, USA.  
SO SYMPOSIUM ON PROTEOLYSIS IN REGULATION AND DISEASE HELD AT THE 20TH ANNUAL

MEETING OF THE KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY,  
KEYSTONE, COLORADO, USA, APRIL 8-14, 1991. J CELL BIOCHEM SUPPL. (1991) 0  
(15 PART G), 127.  
CODEN: JCBSD7.

DT Conference  
FS BR; OLD  
LA English  
CC General Biology - Symposia, Transactions and Proceedings of Conferences,  
Congresses, Review Annuals 00520  
Biochemical Studies - Proteins, Peptides and Amino Acids 10064  
Biochemical Studies - Lipids \*10066  
Biochemical Studies - Carbohydrates 10068  
Biophysics - Molecular Properties and Macromolecules \*10506  
Enzymes - Chemical and Physical \*10806  
Metabolism - Carbohydrates \*13004  
Blood, Blood-Forming Organs and Body Fluids - Blood and Lymph Studies  
\*15002  
Plant Physiology, Biochemistry and Biophysics - Chemical Constituents  
\*51522

BC Angiospermae 25200  
Hominidae 86215  
IT Miscellaneous Descriptors  
ABSTRACT HUMAN FRUIT AMIDOLYSIS  
RN 77-52-1 (URSOLIC ACID)

L64 ANSWER 16 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
AN 1991:174270 BIOSIS  
DN BR40:82730  
TI INHIBITION OF LEUKOTRIENE GENERATION BY A GUM RESIN EXUDATE OF  
**BOSWELLIA-SERRATA** IN RAT PERITONEAL LEUKOCYTES.  
AU MACK T; AMMON H P T; SAFAYHI H  
CS PHARMAZEUTISCHES INST., LEHRSTUHL PHARMAKOL., UNIV. TUEBINGEN, D-7400  
TUEBINGEN, W. GER.  
SO MEETING ON BIOLOGY AND CHEMISTRY OF ACTIVE NATURAL SUBSTANCES HELD AT THE  
INTERNATIONAL JOINT SYMPOSIUM OF THE SOCIETY FOR MEDICINAL PLANT RESEARCH,  
AMERICAN SOCIETY OF PHARMACOGNOSY, ASSOCIATION FRANCAISE POUR  
L'ENSEIGNEMENT ET LA RECHERCHE EN PHARMACOGNOSIE (FRENCH ASSOCIATION FOR  
EDUCATION AND RESEARCH IN PHARMACOGNOSY), AND THE PHYTOCHEMICAL SOCIETY OF  
EUROPE, BONN, GERMANY, JULY 17-22, 1990. PLANTA MED. (1990) 56 (6), 662.  
CODEN: PLMEAA. ISSN: 0032-0943.

DT **Conference**  
FS BR; OLD  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals 00520**  
Cytology and Cytochemistry - Animal 02506  
Biochemical Studies - General \*10060  
Chordate Body Regions - Abdomen 11314  
Pathology, General and Miscellaneous - Inflammation and Inflammatory  
Disease \*12508  
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies 15004  
Coelomic Membranes; Mesenteries and Related Structures 18200  
Pharmacology - General \*22002  
Plant Physiology, Biochemistry and Biophysics - Chemical Constituents  
\*51522  
Pharmacognosy and Pharmaceutical Botany \*54000

BC Burseraceae 25695  
Muridae 86375  
IT Miscellaneous Descriptors



## MEDICINAL PLANT ANTIINFLAMMATORY-DRUG

L64 ANSWER 17 OF 17 BIOSIS COPYRIGHT 1999 BIOSIS  
 AN 1990:367153 BIOSIS  
 DN BR39:51629  
 TI INHIBITION OF SERINE PROTEASES BY TRITERPENES.  
 AU YING Q L; SIMON S R; CHERONIS J C  
 CS SUNY STONY BROOK, N.Y. 11794.  
 SO JOINT MEETING OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR  
 BIOLOGY, AND THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, NEW ORLEANS,  
 LOUISIANA, USA, JUNE 4-7, 1990. FASEB (FED AM SOC EXP BIOL) J. (1990) 4  
 (7), A2282.  
 CODEN: FAJOEC. ISSN: 0892-6638.  
 DT Conference  
 FS BR; OLD  
 LA English  
 CC General Biology - Symposia, Transactions and Proceedings of Conferences,  
 Congresses, Review Annuals 00520  
 Cytology and Cytochemistry - Animal 02506  
 Biochemical Studies - General 10060  
 Biochemical Studies - Lipids 10066  
 Enzymes - Physiological Studies \*10808  
 Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies \*15004  
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and  
 Reticuloendothelial System \*15008  
 Pharmacology - Drug Metabolism; Metabolic Stimulators \*22003  
 IT Miscellaneous Descriptors  
 ABSTRACT NEUTROPHIL **ELASTASE** URSOLIC ACID OLEANIC ACID  
 HEDERAGENIN ALPHA AMYRIN BETA AMYRIN AMIDOLYTIC ACID 18-BETA  
 GLYCYRRHETINIC ACID METABOLIC-DRUG  
 RN 77-52-1 (URSOLIC ACID)  
 465-99-6 (HEDERAGENIN)  
 471-53-4 (GLYCYRRHETINIC ACID)  
 559-70-6 (BETA AMYRIN)  
 638-95-9 (ALPHA AMYRIN)  
 9004-06-2 (**ELASTASE**)  
 37259-58-8D (SERINE PROTEASES)

=> fil embase

FILE 'EMBASE' ENTERED AT 15:38:54 ON 10 FEB 1999

COPYRIGHT (C) 1999 Elsevier Science B.V. All rights reserved.

FILE COVERS 1974 TO 4 Feb 1999 (19990204/ED)

This file contains CAS Registry Numbers for easy and accurate  
 substance identification.

=> d his 165-

(FILE 'BIOSIS' ENTERED AT 15:34:00 ON 10 FEB 1999)

FILE 'EMBASE' ENTERED AT 15:34:23 ON 10 FEB 1999

L65 471 S L19  
 L66 77 S BOSWEL?  
 L67 518 S L65,L66  
 L68 36 S SALAI OR OLIBANUM OR FRANKINCENS? OR BURSERACEAE  
 L69 542 S L67,L68  
 L70 0 S L69 AND (LUNG EMPHYSEMA OR RESPIRATORY DISTRESS OR SHOCK LUNG  
 L71 5 S L69 AND (CHRONIC BRONCHITIS OR GLOMERULONEPHRITIS+NT OR RHEUM

L72 86 S L69 AND (C6.610. OR METASTASIS INHIBITION+NT OR ANTINEOPLASTI  
 L73 0 S L69 AND (PLASMIN OR ANTIPLASMIN)/CT  
 L74 2 S L69 AND (LEUKOCYTE ELASTASE)/CT  
 L75 7 S L71,L74  
 L76 10 S L72 AND L66  
 L77 6 S L72 AND L68  
 L78 5 S L72 AND L5  
 L79 22 S L75-L78

FILE 'EMBASE' ENTERED AT 15:38:54 ON 10 FEB 1999

=> d all tot 179

L79 ANSWER 1 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.

AN 1998370161 EMBASE

TI [COX 2 inhibitor as drug of many talents?].

COX-2-HEMMER ALS ALLESKONNER?.

AU Wagner U.

SO Pharmazeutische Zeitung, (29 Oct 1998) 143/44 (39-40).

ISSN: 0031-7136 CODEN: PZSED5

CY Germany

DT Journal; Note

FS 002 Physiology

005 General Pathology and Pathological Anatomy

008 Neurology and Neurosurgery

015 Chest Diseases, Thoracic Surgery and Tuberculosis

016 Cancer

026 Immunology, Serology and Transplantation

030 Pharmacology

037 Drug Literature Index

048 GastroenterologyPharmacology

LA German

SL German

CT Medical Descriptors:

\*enzyme inhibition

\*prostaglandin synthesis

\*antiinflammatory activity

alzheimer disease: DT, drug therapy

**colon carcinoma: DT, drug therapy**

angiogenesis

ulcerative colitis: DT, drug therapy

asthma: DT, drug therapy

human

nonhuman

note

Drug Descriptors:

\*cyclooxygenase 2 inhibitor: CM, drug comparison

\*cyclooxygenase 2 inhibitor: DT, drug therapy

\*cyclooxygenase 2 inhibitor: PD, pharmacology

\*cyclooxygenase 2: EC, endogenous compound

\*celecoxib: CM, drug comparison

\*celecoxib: DT, drug therapy

\*celecoxib: PD, pharmacology

\*boswellic acid: AN, drug analysis

\*boswellic acid: DV, drug development

\*boswellic acid: DT, drug therapy

\*boswellic acid: PD, pharmacology

unclassified drug

RN (boswellic acid) 631-69-6

CO Searle monsanto (United States)

L79 ANSWER 2 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.

AN 1998358459 EMBASE

TI **Boswellic** acid acetate induces differentiation and apoptosis in leukemia cell lines.

AU Jing Y.; Nakajo S.; Xia L.; Nakaya K.; Fang Q.; Waxman S.; Han R.

CS Y. Jing, Mount Sinai Medical Center, 1 Gustave L. Levy Place, New York, NY 10029, United States. jing@msvax.mssm.edu.

SO Leukemia Research, (1999) 23/1 (43-50).

Refs: 36

ISSN: 0145-2126 CODEN: LEREDD

PUI S 0145-2126(98)00096-4

CY United Kingdom

DT Journal; Article

FS 016 Cancer

025 Hematology

LA English

SL English

AB **Boswellic** acid acetate (BC-4), a compound isolated from the herb *Boswellia carterii* Birdw., can induce differentiation and apoptosis of leukemia cells. Based on cell morphology and NBT reduction, BC-4 induced monocytic differentiation of myeloid leukemia HL-60, U937 and ML-1 cells at a dose under 12.5 .mu.g/ml (24.2 .mu.M). BC-4 was a potent inducer, with 90% of the cells showing morphologic changes and 80-90% of the cells showing NBT reduction. Specific and non-specific esterase were also increased by BC-4. Based on benzidine staining assay, BC-4 failed to induce erythroid leukemia DS-19 and K562 cells differentiation. In contrast to its selective differentiation effect, BC-4 strongly inhibited growth of all cell lines tested. The growth inhibition effect was dose- and time-dependent. In HL-60 cells, 20 .mu.g/ml (38.8 .mu.M) of BC-4 decreased viable cell number by 60% at 24 h, whereas at 3 days there was virtually no viable cells. Morphologic and DNA fragmentation analysis proved that BC-4 induced cell apoptosis. The dual apoptotic and differentiation effects of BC-4 suggest that it may be a powerful agent in the treatment of leukemia. Copyright (C) 1999 Elsevier Science Ltd.

CT Medical Descriptors:

\*apoptosis

cell differentiation

leukemia cell line

growth inhibition

cell strain hl 60

cell count

human

human cell

article

priority journal

Drug Descriptors:

\***boswellic** acid

acetic acid

nonspecific esterase: EC, endogenous compound

DNA fragment: EC, endogenous compound

cell DNA: EC, endogenous compound

RN (**boswellic** acid) 631-69-6; (acetic acid) 127-08-2,  
127-09-3, 64-19-7, 71-50-1

L79 ANSWER 3 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.

AN 1998170995 EMBASE

TI Inhibitory activity of **boswellic** acids from *Boswellia*

- serrata against human leukemia HL-60 cells in culture.
- AU Shao Y.; Ho C.-T.; Chin C.-K.; Badmaev V.; Ma W.; Huang M.-T.  
CS Prof. C.-T. Ho, Department of Food Science, Cook College, State University  
of New Jersey, New Brunswick, NJ 08903, United States.  
ho@aesop.rutgers.edu  
SO Planta Medica, (1998) 64/4 (328-331).  
Refs: 26  
ISSN: 0032-0943 CODEN: PLMEAA  
CY Germany  
DT Journal; Article  
FS 029 Clinical Biochemistry  
030 Pharmacology  
037 Drug Literature Index  
LA English  
SL English  
AB Four major triterpene acids including .beta.-**boswellic** acid (1),  
3-O-acetyl-.beta.-**boswellic** acid (2), 11-keto-.beta.-  
**boswellic** acid (3), and 3-O-acetyl-11-keto-.beta.-  
**boswellic** acid (4) were isolated from the gum resin of  
**Boswellia serrata** and examined for their in vitro antitumor  
activity. They inhibited the synthesis of DNA, RNA and protein in human  
leukemia HL-60 cells in a dose dependent manner with IC50 values ranging  
from 0.6 to 7.1 .mu.M. Among them, compound 4 induced the most pronounced  
inhibitory effects on DNA, RNA and protein synthesis with IC50 values of  
0.6, 0.5, and 4.1 .mu.M, respectively. The effect of 4 on DNA synthesis  
was found to be irreversible. Compound 4 significantly inhibited the  
cellular growth of HL-60 cells, but did not affect cell viability.
- CT Medical Descriptors:  
\*antineoplastic activity  
\*leukemia  
cell strain hl 60  
cell growth  
protein synthesis  
dna synthesis  
cell viability  
human  
human cell  
article  
Drug Descriptors:  
triterpene
- L79 ANSWER 4 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 1998119303 EMBASE  
TI [Is H15 (Extract of **Boswellia serrata**, 'incense') an efficient  
supplementation to established drug therapy in RA? - Results of a double  
blinded pilot trial].  
IST H15 (HARZEXTRAKT VON **BOSWELLIA SERRATA**, 'WEIHRAUCH') EINE  
SINNvolle ERGÄNZUNG ZUR ETABLIERTEN MEDIKAMENTÖSEN THERAPIE DER  
CHRONISCHEN POLYARTHRITIS? - ERGEBNISSE EINER DOPPELBLINDEN PILOTSTUDIE.  
AU Sander O.; Herborn G.; Rau R.  
CS Dr. O. Sander, Evangelisches Fachkran. Ratingen, Rheumatologische Klinik,  
Rosenstrasse 2, D-40882 Ratingen, Germany  
SO Zeitschrift für Rheumatologie, (1998) 57/1 (11-16).  
Refs: 19  
ISSN: 0340-1855 CODEN: ZRHMBQ  
CY Germany  
DT Journal; Article  
FS 031 Arthritis and Rheumatism  
037 Drug Literature Index

LA German

SL English; German

AB Background: Leukotrienes and prostaglandines are important mediators of inflammation. While prostaglandine synthesis can be influenced by NSAIDs therapeutical approaches to the 5-lipoxygenase pathway are rare. Resinous extracts of *Boswellia serrata* (H15, indish incense), known from traditional ayurvedic medicine, decrease leukotriene synthesis in vitro. Case reports suggest a clinical role for that drug. Methods: Outpatients with active RA have been enrolled into a multicenter controlled trial. Patients received 9 tablets of active drug (3600 mg) or placebo daily in addition to their previous therapy. Doses of NSAIDs could be adjusted on demand. Efficacy parameters, Ritchies Index for swelling and pain, ESR, CRP, pain on VAS and NSAID dose were documented at baseline and 6 and 12 weeks after initiation. Mean values and medians were calculated to compare the groups for significant or clinically relevant change from baseline or difference between both groups at any time point of observation. Results: A total of 78 patients were recruited in 4 centers, the data have been published in abstractform. Only 37 patients (verum 18, placebo 19), enrolled in Ratingen were available for detailed efficacy and safety analysis. All evaluations in these patients were performed by one investigator (G.H.). There was no subjective, clinical or laboratory parameter showing a significant or clinically relevant change from baseline or difference between both groups at any time point of observation. The mean NSAID dose reduction reached levels of 5.8% (H15) and 3.1% (placebo). One patient in each group showed a good response in all parameters but 4 patients in each group worsened. The others showed no alteration of their disease. Conclusion: Treatment with H15 showed no measurable efficacy. Controlled studies including a greater patient population are necessary to confirm or reject our results.

CT Medical Descriptors:

\*rheumatoid arthritis: DT, drug therapy

\*supplementation

\*traditional medicine

drug efficacy

tablet

erythrocyte sedimentation rate

drug safety

prostaglandin synthesis

human

major clinical study

clinical trial

randomized controlled trial

double blind procedure

multicenter study

controlled study

aged

adult

oral drug administration

article

Drug Descriptors:

\*boswellic acid: CT, clinical trial

\*boswellic acid: DT, drug therapy

\*ayurvedic drug: CT, clinical trial

\*ayurvedic drug: DT, drug therapy

\*plant extract: CT, clinical trial

\*plant extract: DT, drug therapy

nonsteroid antiinflammatory agent: DT, drug therapy

arachidonate 5 lipoxygenase: EC, endogenous compound

leukotriene: EC, endogenous compound

prostaglandin: EC, endogenous compound  
placebo  
c reactive protein  
RN (boswellic acid) 631-69-6; (arachidonate 5  
lipoxxygenase) 80619-02-9; (c reactive protein) 9007-41-4

L79 ANSWER 5 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 97298895 EMBASE  
TI [Pharmacological aspects of incense (**Olibanum**) and  
**boswellic acids**].  
PHARMAKOLOGISCHE ASPEKTE VON WEIHRAUCH UND **BOSWELLIASAUREN**.  
AU Safayhi H.; Ammon H.P.T.  
CS Dr. H. Safayhi, Lehrstuhl Pharmakologie, Pharmazeutisches Institut,  
Universitat Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany,  
Federal Republic of  
SO Pharmazeutische Zeitung, (1997) 142/39 (11-20).  
Refs: 40  
ISSN: 0031-7136 CODEN: PZSED5  
CY Germany, Federal Republic of  
DT Journal  
FS 016 Cancer  
026 Immunology, Serology and Transplantation  
030 Pharmacology  
031 Arthritis and Rheumatism  
048 Gastroenterology  
037 Drug Literature Index

LA German  
SL German  
CT EMTAGS: therapy (0160); **malignant neoplastic disease** (0306);  
mammary (0738); human (0888); nonhuman (0777); review (0001)  
Medical Descriptors:  
\*drug mechanism  
rheumatic disease: DT, drug therapy  
**cancer: DT, drug therapy**  
ulcerative colitis: DT, drug therapy  
brain edema: DT, drug therapy  
human  
nonhuman  
review  
Drug Descriptors:  
**\*boswellic acid: PD, pharmacology**  
**\*boswellic acid: DT, drug therapy**  
**olibanum extract: PD, pharmacology**  
**olibanum extract: DT, drug therapy**  
\*plant extract: PD, pharmacology  
\*plant extract: DT, drug therapy  
\*lipoxxygenase inhibitor: PD, pharmacology  
\*lipoxxygenase inhibitor: DT, drug therapy  
\*proteinase inhibitor: PD, pharmacology  
\*proteinase inhibitor: DT, drug therapy  
\*dna topoisomerase inhibitor: PD, pharmacology  
\*dna topoisomerase inhibitor: DT, drug therapy  
unclassified drug  
RN (boswellic acid) 631-69-6; (proteinase inhibitor)  
37205-61-1

L79 ANSWER 6 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 97144655 EMBASE  
TI Inhibition by **boswellic acids** of human leukocyte elastase.

AU Safayhi H.; Rall B.; Sailer E.-R.; Ammon H.P.T.  
CS Dr. H. Safayhi, Institute of Pharmaceutical Sciences, University of  
Tuebingen, Auf der Morgenstelle 8, D-72076 Tuebingen, Germany, Federal  
Republic of  
SO Journal of Pharmacology and Experimental Therapeutics, (1997) 281/1  
(460-463).  
Refs: 24  
ISSN: 0022-3565 CODEN: JPETAB  
CY United States  
DT Journal  
FS 030 Pharmacology  
037 Drug Literature Index  
LA English  
SL English  
AB **Frankincense** extracts and **boswellic** acids,  
biologically active pentacyclic triterpenes of **frankincense**,  
block leukotriene biosynthesis and exert potent anti-inflammatory effects.  
Screening for additional effects of **boswellic** acids on further  
proinflammatory pathways, we observed that acetyl- 11-keto-.beta.-  
**boswellic** acid, an established direct, nonredox and noncompetitive  
5-lipoxygenase inhibitor, decreased the activity of human leukocyte  
elastase (HLE) in vitro with an IC50 value of about 15 .mu.M. Among the  
pentacyclic triterpenes tested in concentrations up to 20 .mu.M, we also  
observed substantial inhibition by .beta.-**boswellic** acid, amyirin  
and ursolic acid, but not by 18.beta.-glycyrrhetic acid. The data show  
that the dual inhibition of 5- lipoxygenase and HLE is unique to  
**boswellic** acids: other pentacyclic triterpenes with HLE inhibitory  
activities (e.g., ursolic acid and amyirin) do not inhibit 5-lipoxygenase,  
and leukotriene biosynthesis inhibitors from different chemical classes  
(e.g., NDGA, MK-886 and ZM-230,467) do not impair HLE activity. Because  
leukotriene formation and HLE release are increased simultaneously by  
neutrophil stimulation in a variety of inflammation- and  
hypersensitivity-based human diseases, the reported blockade of two  
proinflammatory enzymes by **boswellic** acids might be the  
rationale for the putative antiphlogistic activity of acetyl-11-keto-  
.beta.-**boswellic** acid and derivatives.  
CT EMTAGS: mammal (0738); human (0888); controlled study (0197); article  
(0060); priority journal (0007); enzyme (0990); therapy (0160)  
Medical Descriptors:  
\*enzyme inhibition  
drug structure  
inhibition kinetics  
antiinflammatory activity  
concentration response  
enzyme activity  
human  
controlled study  
article  
priority journal  
Drug Descriptors:  
\*leukocyte elastase  
\*boswellic acid: CM, drug comparison  
\*boswellic acid: DV, drug development  
\*boswellic acid: DO, drug dose  
\*boswellic acid: PD, pharmacology  
\*triterpene derivative: CM, drug comparison  
\*triterpene derivative: DV, drug development  
\*triterpene derivative: DO, drug dose  
\*triterpene derivative: PD, pharmacology

acetyl 11 oxo beta boswellic acid: CM, drug comparison  
 acetyl 11 oxo beta boswellic acid: DV, drug development  
 acetyl 11 oxo beta boswellic acid: DO, drug dose  
 acetyl 11 oxo beta boswellic acid: PD, pharmacology  
 arachidonate 5 lipoxygenase: EC, endogenous compound  
 lipoxygenase inhibitor: CM, drug comparison  
 lipoxygenase inhibitor: DV, drug development  
 lipoxygenase inhibitor: DO, drug dose  
 lipoxygenase inhibitor: PD, pharmacology  
 ursolic acid: CM, drug comparison  
 ursolic acid: DV, drug development  
 ursolic acid: DO, drug dose  
 ursolic acid: PD, pharmacology  
 glycyrrhetic acid derivative: CM, drug comparison  
 glycyrrhetic acid derivative: DV, drug development  
 glycyrrhetic acid derivative: DO, drug dose  
 glycyrrhetic acid derivative: PD, pharmacology  
 glycyrrhetic acid: CM, drug comparison  
 glycyrrhetic acid: DV, drug development  
 glycyrrhetic acid: DO, drug dose  
 glycyrrhetic acid: PD, pharmacology  
 nordihydroguaiaretic acid: CM, drug comparison  
 nordihydroguaiaretic acid: DO, drug dose  
 nordihydroguaiaretic acid: PD, pharmacology  
 3 [3 tert butylthio 1 (4 chlorobenzyl) 5 isopropyl 2 indolyl] 2,2 dimethylpropionic acid: CM, drug comparison  
 3 [3 tert butylthio 1 (4 chlorobenzyl) 5 isopropyl 2 indolyl] 2,2 dimethylpropionic acid: DO, drug dose  
 3 [3 tert butylthio 1 (4 chlorobenzyl) 5 isopropyl 2 indolyl] 2,2 dimethylpropionic acid: PD, pharmacology  
 1 ethyl 6 [[3 fluoro 5 (3,4,5,6 tetrahydro 4 methoxy 2h pyran 4 yl)]phenoxyethyl] 2 quinolone: CM, drug comparison  
 1 ethyl 6 [[3 fluoro 5 (3,4,5,6 tetrahydro 4 methoxy 2h pyran 4 yl)]phenoxyethyl] 2 quinolone: DO, drug dose  
 1 ethyl 6 [[3 fluoro 5 (3,4,5,6 tetrahydro 4 methoxy 2h pyran 4 yl)]phenoxyethyl] 2 quinolone: PD, pharmacology  
 hydrocortisone: CM, drug comparison  
 hydrocortisone: DO, drug dose  
 hydrocortisone: PD, pharmacology  
 testosterone: CM, drug comparison  
 testosterone: DO, drug dose  
 testosterone: PD, pharmacology  
 chymotrypsin  
 6 [[3 fluoro 5 (3,4,5,6 tetrahydro 4 methoxy 2h pyran 4 yl)]phenoxyethyl] 1 methyl 2 quinolone  
 unclassified drug  
 (leukocyte elastase) 109968-22-1; (boswellic acid) 631-69-6; (arachidonate 5 lipoxygenase) 80619-02-9; (ursolic acid) 77-52-1; (glycyrrhetic acid) 471-53-4; (nordihydroguaiaretic acid) 500-38-9; (3 [3 tert butylthio 1 (4 chlorobenzyl) 5 isopropyl 2 indolyl] 2,2 dimethylpropionic acid) 118414-82-7; (1 ethyl 6 [[3 fluoro 5 (3,4,5,6 tetrahydro 4 methoxy 2h pyran 4 yl)]phenoxyethyl] 2 quinolone) 155944-23-3; (hydrocortisone) 50-23-7; (testosterone) 58-22-0; (chymotrypsin) 9004-07-3, 9014-64-6; (6 [[3 fluoro 5 (3,4,5,6 tetrahydro 4 methoxy 2h pyran 4 yl)]phenoxyethyl] 1 methyl 2 quinolone) 140841-32-3  
 (1) Mk 886; (2) Zm 230487; Ici d2138; L 663536  
 (1) Merck frosst (Canada); (2) Ici (United Kingdom); Sigma (Germany, Federal Republic of); Calbiochem (Germany, Federal Republic of);

RN

CN  
CO



Boehringer mannheim (Germany, Federal Republic of)

- L79 ANSWER 7 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 96374165 EMBASE  
TI [Plant research: Opportunity for new therapies].  
PLFANZENFORSCHUNG: CHANCE FUR NEUE THERAPIEN.  
AU Czajka S.  
SO Pharmazeutische Zeitung, (1996) 141/49 (43-47).  
ISSN: 0031-7136 CODEN: PZSED5  
CY Germany, Federal Republic of  
DT Journal  
FS 030 Pharmacology  
037 Drug Literature Index  
LA German  
SL German  
CT EMTAGS: **malignant neoplastic disease** (0306); chemical procedures  
(0107); methodology (0130); mammal (0738); human (0888); nonhuman (0777);  
short survey (0002); higher plant (0697); plant (0699)  
Medical Descriptors:  
\*phytochemistry  
angiogenesis  
research  
**cancer**  
drug screening  
drug synthesis  
quality control  
plant growth  
human  
nonhuman  
short survey  
Drug Descriptors:  
\*plant extract  
\*herbaceous agent  
vinca alkaloid  
taxol  
camptothecin  
**boswellic acid**  
viscum album  
hypericum perforatum extract  
RN (taxol) 33069-62-4; (camptothecin) 7689-03-4; (**boswellic acid**)  
**631-69-6**; (viscum album) 8031-76-3
- L79 ANSWER 8 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 96111463 EMBASE  
TI Alcoholic extract of **salai-guggal ex-Boswellia**  
**serrata**, a new natural source NSAID.  
AU Singh G.B.; Singh S.; Bani S.  
CS Regional Research Laboratory, Canal Road, Jammu Tawi 180001, India  
SO Drugs of Today, (1996) 32/2 (109-112).  
ISSN: 0025-7656 CODEN: MDACAP  
CY Spain  
DT Journal  
FS 030 Pharmacology  
031 Arthritis and Rheumatism  
037 Drug Literature Index  
LA English  
CT EMTAGS: therapy (0160); mammal (0738); human (0888); nonhuman (0777); oral  
drug administration (0181); review (0001)  
Medical Descriptors:

\*immune response  
\*rheumatoid arthritis: DT, drug therapy  
\*osteoarthritis: DT, drug therapy  
drug safety  
human  
nonhuman  
oral drug administration  
review  
\*antiinflammatory activity  
Drug Descriptors:  
\*nonsteroid antiinflammatory agent: TO, drug toxicity  
\*nonsteroid antiinflammatory agent: PD, pharmacology  
\*nonsteroid antiinflammatory agent: DT, drug therapy  
\*nonsteroid antiinflammatory agent: DO, drug dose  
\*nonsteroid antiinflammatory agent: DV, drug development  
\*plant extract: TO, drug toxicity  
\*plant extract: PD, pharmacology  
\*plant extract: DT, drug therapy  
\*plant extract: DO, drug dose  
\*plant extract: DV, drug development  
boswellia serrata extract: TO, drug toxicity  
boswellia serrata extract: PD, pharmacology  
boswellia serrata extract: DT, drug therapy  
boswellia serrata extract: DO, drug dose  
boswellia serrata extract: DV, drug development  
beta boswellic acid: AN, drug analysis  
beta boswellic acid: DV, drug development  
unclassified drug

L79 ANSWER 9 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.

AN 95295990 EMBASE

TI [Boswellia acid].

**BOSWELLIAZUUR.**

AU Woerdenbag H.J.

SO Pharmaceutisch Weekblad, (1995) 130/40 (1054).

ISSN: 0031-6911 CODEN: PHWEAW

CY Netherlands

DT Journal

FS 031 Arthritis and Rheumatism

037 Drug Literature Index

LA Dutch

CT EMTAGS: mammal (0738); human (0888); nonhuman (0777); mouse (0727); rat (0733); animal experiment (0112); oral drug administration (0181); intraperitoneal drug administration (0178); note (0063); higher plant (0697); plant (0699)

Medical Descriptors:

\*rheumatoid arthritis

biosynthesis

phytochemistry

structure activity relation

human

nonhuman

mouse

rat

animal experiment

oral drug administration

intraperitoneal drug administration

note

Drug Descriptors:

- \*medicinal plant  
\*triterpene  
\*boswellic acid  
RN 631-69-6
- L79 ANSWER 10 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 95178376 EMBASE  
TI **Boswellic acids.**  
SO Drugs of the Future, (1995) 20/4 (408).  
ISSN: 0377-8282 CODEN: DRFUD4  
CY Spain  
DT Journal  
FS 030 Pharmacology  
031 Arthritis and Rheumatism  
037 Drug Literature Index  
LA English  
CT EMTAGS: therapy (0160); mammal (0738); human (0888); oral drug administration (0181); short survey (0002)  
Medical Descriptors:  
\*rheumatoid arthritis: DT, drug therapy  
human  
oral drug administration  
short survey  
Drug Descriptors:  
\*antiinflammatory agent: DT, drug therapy  
\*boswellic acid: DT, drug therapy  
\*antirheumatic agent: DT, drug therapy  
RN 631-69-6  
CO Jammu tawi
- L79 ANSWER 11 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 95035097 EMBASE  
TI Cytotoxic constituents of Bursera permollis.  
AU Wickramaratne D.B.M.; Mar W.; Chai H.; Castillo J.J.; Farnsworth N.R.; Soejarto D.D.; Cordell G.A.; Pezzuto J.M.; Kinghorn A.D.  
CS Program for Collaborative Research, Dept. of Med. Chem./Pharmacognosy, College of Pharmacy, Chicago, IL 60612, United States  
SO Planta Medica, (1995) 61/1 (80-81).  
ISSN: 0032-0943 CODEN: PLMEAA  
CY Germany, Federal Republic of  
DT Journal  
FS 016 Cancer  
030 Pharmacology  
037 Drug Literature Index  
LA English  
SL English  
AB Four cytotoxic lignans were isolated from the stem bark of Bursera permollis (**Burseraceae**), namely, deoxypodophyllotoxin (1), .beta.-peltatin methyl ether (2), picro-.beta.-peltatin methyl ether (3), and dehydro-.beta.-peltatin methyl ether (4). Also isolated was the inactive lignan, nemerosin (5). Compounds 1 and 2 were potently cytotoxic when evaluated against a panel of human cancer cell lines.  
CT EMTAGS: plant (0699); mammal (0738); human (0888); controlled study (0197); human tissue, cells or cell components (0111); article (0060)  
Medical Descriptors:  
\*cytotoxicity  
tumor cell  
phytochemistry  
plant

drug isolation  
drug identification  
human  
controlled study  
human cell  
article  
Drug Descriptors:  
\*lignan  
\*deoxypodophyllotoxin  
nemerosin  
beta peltatin methyl ether  
picro beta peltatin methyl ether  
dehydro beta peltatin methyl ether  
unclassified drug  
RN 19186-35-7

L79 ANSWER 12 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 94229574 EMBASE  
TI Recent progress in the study of anticancer drugs originating from plants  
and traditional medicines in China.  
AU Han R.  
CS Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing  
100050, China  
SO CHIN. MED. SCI. J., (1994) 9/1 (61-69).  
ISSN: 1001-9294 CODEN: CMSJEP  
CY China  
DT Journal  
FS 016 Cancer  
030 Pharmacology  
037 Drug Literature Index  
LA English  
SL English  
AB Drugs of plant origin have received much attention due to their enormous  
potential for the prevention and treatment of cancer. Recent progress in  
the study of anticancer drugs originating from plants and traditional  
medicines in China is reviewed in this paper, with particular emphasis on  
taxol, daidzein, acetyl boswellic acid, curcumin and ginsenosid  
Rh2.  
CT EMTAGS: **malignant neoplastic disease** (0306); mammal (0738);  
human (0888); nonhuman (0777); review (0001); higher plant (0697); plant  
(0699)  
Medical Descriptors:  
\***cancer**  
drug information  
traditional medicine  
**antineoplastic activity**  
phytochemistry  
drug isolation  
drug structure  
human  
nonhuman  
review  
Drug Descriptors:  
\*antineoplastic agent: PD, pharmacology  
\*taxol: PD, pharmacology  
\*plant extract: PD, pharmacology  
\*chinese herb: PD, pharmacology  
curcumin: PD, pharmacology  
daidzein: PD, pharmacology

camptothecin: PD, pharmacology  
ginseng: PD, pharmacology  
harringtonine: PD, pharmacology  
irisquinone: PD, pharmacology  
oridonin: PD, pharmacology  
acetylboswellic acid: PD, pharmacology  
**boswellic acid derivative**  
homoharringtonine: PD, pharmacology  
unclassified drug  
RN 33069-62-4; 458-37-7; 486-66-8; 7689-03-4; 26833-85-2; 28957-04-2;  
26833-87-4

L79 ANSWER 13 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 94045965 EMBASE  
TI Highlight on the studies of anticancer drugs derived from plants in China.  
AU Han R.  
CS Institute of Materia Medica, Chinese Academy of Medical Sciences, 1 Xian  
Nong Tan Street, Beijing 100050, China  
SO STEM CELLS, (1994) 12/1 (53-63).  
ISSN: 1066-5099 CODEN: STCEEJ  
CY United States  
DT Journal  
FS 016 Cancer  
030 Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LA English  
SL English  
AB Recent progress on the study of anticancer drugs originating from plants  
in China is reviewed in this paper. Guided by the experience of  
traditional Chinese medicine, several new drugs have been found. Indirubin  
from *Indigofera tinctoria* is useful for the treatment of chronic  
myelocytic leukemia. Irisquinone from *Iris latea pallasii* and 10-hydroxy  
camptothecin from *Camptotheca accuminata* have exhibited definite activity  
on rodent tumors. Recent studies indicate that ginsenoside Rh2 is an  
inducer of cell differentiation in melanoma B-16 cells in vitro.  
Pharmacological studies have demonstrated that curcumin from *Curcuma longa*  
is an antimutagen as well as an antipromotor for cancer. Daidzein and  
acetyl **boswellic acid** have been shown to be effective inducers  
of cell differentiation in HL-60 cells. Guided by the chemotaxonomic  
principle of plants, harringtonine and homoharringtonine isolated from  
*Cephalotaxus hainanensis* have exhibited significant antileukemia activity  
and are widely used in clinics in China. Taxol from *Taxus chinensis* has  
been shown to be an important new anticancer drug with unique chemical  
structure and mechanism of action. The continuous search for new  
anticancer drugs from plants will be a fruitful frontier in cancer  
treatment and chemoprevention.  
CT EMTAGS: **malignant neoplastic disease** (0306); therapy (0160);  
higher plant (0697); plant (0699); pharmacokinetics (0194); mammal (0738);  
human (0888); nonhuman (0777); human experiment (0104); conference paper  
(0061); adverse drug reaction (0198); iatrogenic disease (0300)  
Medical Descriptors:  
**\*chronic myeloid leukemia: DT, drug therapy**  
**\*melanoma**  
**\*bladder cancer: DT, drug therapy**  
**\*acute granulocytic leukemia**  
medicinal plant  
cell strain hl 60  
**antineoplastic activity**

drug efficacy  
 gastrointestinal toxicity: SI, side effect  
 blood toxicity: SI, side effect  
 drug structure  
 uterine cervix carcinoma  
 lymphosarcoma  
 liver cell carcinoma  
 drug distribution  
 lung cancer: DT, drug therapy  
 human  
 nonhuman  
 clinical trial  
 phase 1 clinical trial  
 phase 2 clinical trial  
 conference paper  
 Drug Descriptors:  
 \*indirubin: AE, adverse drug reaction  
 \*indirubin: CT, clinical trial  
 \*indirubin: DT, drug therapy  
 \*indirubin: PD, pharmacology  
 \*camptothecin derivative: DV, drug development  
 \*camptothecin derivative: DT, drug therapy  
 \*camptothecin derivative: PK, pharmacokinetics  
 \*camptothecin derivative: PD, pharmacology  
 \*ginsenoside: PD, pharmacology  
 \*harringtonine: PD, pharmacology  
 \*homoharringtonine: PD, pharmacology  
 \*taxol: PD, pharmacology  
 antineoplastic agent: AE, adverse drug reaction  
 antineoplastic agent: CT, clinical trial  
 antineoplastic agent: DT, drug therapy  
 antineoplastic agent: PD, pharmacology  
 herbal medicine: AE, adverse drug reaction  
 herbal medicine: CT, clinical trial  
 herbal medicine: DT, drug therapy  
 herbal medicine: PD, pharmacology  
 curcumin: PD, pharmacology  
 daidzein: PD, pharmacology  
 boswellic acid: PD, pharmacology  
 topotecan: DV, drug development  
 topotecan: DT, drug therapy

RN 479-41-4; 74749-74-9; 26833-85-2; 26833-87-4; 33069-62-4; 458-37-7;  
 486-66-8; 631-69-6; 119413-54-6; 123948-87-8  
 CN Skf 104864

L79 ANSWER 14 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
 AN 92274384 EMBASE  
 TI [The Indian incense - New aspects of an old resin].  
 DER INDISCHE WEIHRAUCH - NEUE ASPEKTE EINES ALTEN HARZES.  
 AU Martinetz D.  
 CS Weissdornstrasse 98, 7062 Leipzig, Germany, Federal Republic of  
 SO Z. PHYTOTHER., (1992) 13/4 (121-125).  
 ISSN: 0722-348X CODEN: ZPHYDG  
 CY Germany, Federal Republic of  
 DT Journal  
 FS 029 Clinical Biochemistry  
 030 Pharmacology  
 031 Arthritis and Rheumatism  
 037 Drug Literature Index

LA German  
SL German; English  
CT EMTAGS: mammal (0738); human (0888); nonhuman (0777); review (0001);  
apparatus, equipment and supplies (0510)  
Medical Descriptors:  
\*analgesia  
\*sedation  
**\*rheumatoid arthritis**  
phytochemistry  
antiinflammatory activity  
analgesic activity  
traditional medicine  
human  
nonhuman  
review  
Drug Descriptors:  
\*resin: PD, pharmacology  
\*resin: AN, drug analysis  
\*resin: DV, drug development  
analgesic agent: PD, pharmacology  
analgesic agent: AN, drug analysis  
analgesic agent: DV, drug development  
sedative agent: PD, pharmacology  
sedative agent: AN, drug analysis  
sedative agent: DV, drug development  
antirheumatic agent: PD, pharmacology  
antirheumatic agent: AN, drug analysis  
antirheumatic agent: DV, drug development  
antiinflammatory agent: PD, pharmacology  
antiinflammatory agent: AN, drug analysis  
antiinflammatory agent: DV, drug development  
\*plant extract: PD, pharmacology  
\*plant extract: AN, drug analysis  
\*plant extract: DV, drug development  
incense: PD, pharmacology  
incense: AN, drug analysis  
incense: DV, drug development  
olibanum: PD, pharmacology  
olibanum: AN, drug analysis  
olibanum: DV, drug development  
boswellic acid derivative: PD, pharmacology  
boswellic acid derivative: AN, drug analysis  
boswellic acid derivative: DV, drug development  
boswellia serrata extract: PD, pharmacology  
boswellia serrata extract: AN, drug analysis  
boswellia serrata extract: DV, drug development  
unclassified drug

L79 ANSWER 15 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 91226984 EMBASE  
TI Inhibition of human leucocyte elastase by ursolic acid. Evidence for a  
binding site for pentacyclic triterpenes.  
AU Ying Q.-L.; Rinehart A.R.; Simon S.R.; Cheronis J.C.  
CS Department of Pathology, State University of New York at Stony Brook,  
Stony Brook, NY 11794, United States  
SO BIOCHEM. J., (1991) 277/2 (521-526).  
ISSN: 0264-6021 CODEN: BIJOAK  
CY United Kingdom  
DT Journal

FS 029 Clinical Biochemistry  
LA English  
AB Several pentacyclic triterpenoid metabolites of plant origin are inhibitors of hydrolysis of both synthetic peptide substrates and elastin by human leucocyte elastase (HLE). Ursolic acid, the most potent of these compounds, has an inhibition constant of 4-6  $\mu\text{M}$  for hydrolysis of peptide substrates in phosphate-buffered saline. With tripeptide and tetrapeptide substrates, the inhibition is purely competitive, whereas with a shorter dipeptide substrate the inhibition is noncompetitive, suggesting that ursolic acid interacts with subsite S3 of the extended substrate-binding domain in HLE, but not with subsites S1 and S2. The carboxy group at position 28 in the pentacyclic-ring system of the triterpenes contributes to binding to HLE, since replacement of this group with a hydroxy group, as in uvaol, the alcohol analogue of ursolic acid, reduces the potency of inhibition. The inhibitory potency of ursolic acid is also reduced by addition of 1 M NaCl, further supporting a postulated electrostatic interaction between the negative charge on the triterpene and a positively charged residue on the enzyme, which we assign to the side chain of Arg-217, located in the vicinity of subsites S4 and S6 in HLE. These observations are consistent with a binding site for ursolic acid which extends from S3 towards S4 and S5 on the enzyme. Other triterpenes, including oleanolic acid, erythrodiol, hederagenin and 18 $\beta$ -glycyrrhetic acid, can also interact with this binding site. On the basis of these results we conclude that the extended substrate-binding domain of HLE can accommodate a variety of hydrophobic ligands, including not only such molecules as fatty acids [Ashe and Zimmerman (1977) Biochem. Biophys. Res. Commun. 75, 194-199, Cook and Ternai (1988) Biol. Chem. Hoppe-Seyler 369, 629-637], but also polycyclic molecules such as the pentacyclic triterpenoids.

CT EMTAGS: mammal (0738); human (0888); human tissue, cells or cell components (0111); priority journal (0007); article (0060); enzyme (0990)  
Medical Descriptors:  
\*competitive inhibition  
binding site  
human  
human cell  
priority journal  
article  
Drug Descriptors:  
\*leukocyte elastase: EC, endogenous compound  
\*ursolic acid  
triterpene

RN 77-52-1

L79 ANSWER 16 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 91179960 EMBASE  
TI Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells.  
AU Scanlon K.J.; Wang W.; Han H.  
CS Department of Medical Oncology, Montana Building, City of Hope National Medical Center, Duarte, CA 91010, United States  
SO CANCER TREAT. REV., (1990) 17/SUPPL. A (27-35).  
ISSN: 0305-7372 CODEN: CTREDJ  
CY United Kingdom  
DT Journal  
FS 006 Internal Medicine  
016 Cancer  
022 Human Genetics  
029 Clinical Biochemistry



030 Pharmacology  
037 Drug Literature Index  
LA English  
AB Most cancer chemotherapeutic agents are designed to damage DNA directly or indirectly. One mechanism of cellular resistance to these agents is enhanced DNA repair. Human ovarian carcinoma cells resistant to cisplatin (A2780DDP) respond to cisplatin treatment with a 3-6 fold increase in gene expression for oncogenes, DNA repair enzymes and enzymes necessary for the synthesis of thymidine. Cyclosporin A has been shown to reverse drug resistance, but its mechanism of action is unclear. In this study, weekly exposures of A2780DDP cells to cyclosporin A resulted in the evolution of a revertant cell line A2780DDP/CSA that was sensitive to cisplatin again and suppressed the induction of genes necessary for the repair of drug-induced DNA damage.

CT EMTAGS: therapy (0160); heredity (0137); mammal (0738); human (0888); female (0042); controlled study (0197); human tissue, cells or cell components (0111); priority journal (0007); conference paper (0061)  
Medical Descriptors:  
\*cancer chemotherapy  
\*gene repression  
**\*ovary cancer: DT, drug therapy**  
oncogene c fos  
dna repair  
drug resistance  
**tumor cell: DT, drug therapy**  
gene expression regulation  
dna synthesis  
tumor cell line  
cross resistance  
human  
female  
controlled study  
human cell  
priority journal  
conference paper  
Drug Descriptors:  
\*cyclosporin a: DT, drug therapy  
\*cisplatin: DT, drug therapy  
thymidine phosphate: EC, endogenous compound  
dactinomycin: DT, drug therapy  
camptothecin: DT, drug therapy  
fluorouracil: DT, drug therapy  
methotrexate: DT, drug therapy  
carboplatin: DT, drug therapy  
etoposide: DT, drug therapy  
tetraplatin: DT, drug therapy  
**boswellic acid: DT, drug therapy**  
zidovudine: DT, drug therapy  
cytarabine: DT, drug therapy  
cytidine triphosphate: DT, drug therapy  
fluoropyrimidine: DT, drug therapy

RN 59865-13-3; 63798-73-2; 15663-27-1; 26035-31-4; 96081-74-2; 365-07-1;  
50-76-0; 7689-03-4; 51-21-8; 59-05-2; 41575-94-4; 33419-42-0; 30516-87-1;  
69-74-9; 147-94-4; 65-47-4; 675-21-8

CN (1) Vp16  
CO (1) Bristol; Upjohn; Sigma; New england nuclear (United States); Sandoz

L79 ANSWER 17 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 88002934 EMBASE

- TI Automated leucocyte adherence inhibition testing in patients with colorectal cancer.
- AU McLeod D.K.; Isbister W.H.
- CS Department of Surgery, Wellington Clinical School of Medicine, Wellington, New Zealand
- SO IMMUNOL. CELL BIOL., (1987) 65/5 (377-385).
- CODEN: ICBIEZ
- CY Australia
- DT Journal
- FS 016 Cancer  
026 Immunology, Serology and Transplantation
- LA English
- AB This paper details our initial experiences with a semi-automated leucocyte adherence inhibition (**SALAI**) assay in patients with colorectal disease. Two assay systems were used. Leucocytes from blood donors and patients with different colorectal diagnoses were tested for sensitization to colorectal tumour extracts, and leucocytes from healthy blood donors were assayed with serum from blood donors or patients to determine whether the serum itself contained factors which would react with the non-sensitized leucocytes in the test system. The sensitivity of the **SALAI** assay using patients' leucocytes was 64% and the specificity was 68%. Discriminant analysis did not affect the sensitivity of the assay for colorectal cancer (64%), although the specificity was increased for all patients except those with malignant disease other than colorectal cancer. The sensitivity of the **SALAI** assay using patients' serum was 50% but the specificity was 74%. Discriminant analysis increased the sensitivity of this assay to 80% but specificity was reduced to 61%. Thus, the **SALAI** assay with patients' serum, although potentially more advantageous than the assay using patients' leucocytes in the clinical setting, was less specific. Furthermore, samples from patients with early colorectal cancers were less reactive making the serum assay unsuitable for screening asymptomatic patients. The **SALAI** assay using patients' leucocytes, however, has a higher sensitivity than most reported variations of the assay but a slightly lower specificity. It is suggested that the **SALAI** assay is preferable to other methods for leucocyte adherence inhibition (LAI) testing.
- CT EMTAGS: blood and hemopoietic system (0927); large intestine (0940); **malignant neoplastic disease** (0306); immunological factors (0136); automation, computers and data processing (0530); immunological procedures (0102); diagnosis (0140); human tissue, cells or cell components (0111); cell, tissue or organ culture (0103); human (0888)
- Medical Descriptors:  
\*leukocyte adhesiveness  
\***colorectal cancer**  
\*cancer antigen  
\*cellular immunity  
automation  
sensitization  
\*cell adhesion
- L79 ANSWER 18 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.
- AN 87210939 EMBASE
- TI The membrane glycoprotein of Friend spleen focus-forming virus: Evidence that the cell surface component is required for pathogenesis and that it binds to a receptor.
- AU Li J.-P.; Bestwick R.K.; Spiro C.; Kabat D.
- CS Department of Biochemistry, School of Medicine, The Oregon Health Sciences University, Portland, OR 97201, United States
- SO J. VIROL., (1987) 61/9 (2782-2792).

ISSN: 0022-538X CODEN: JOVIAM

CY United States

FS 016 Cancer

047 Virology

LA English

AB The leukemogenic membrane glycoprotein of Friend spleen focus-forming virus (SFFV) has an apparent M(r) of 55,000 (gp55), is encoded by a recombinant env gene, and occurs on cell surfaces and in intracellular organelles. There is evidence that the amino-terminal region of gp55 forms a dualtropic-specific domain that is connected to the remainder of the glycoprotein by a proline-rich linker (C. Machida, R. Bestwick, B. Boswell, and D. Kabat, Virology 144:158-172, 1985). Using the colinear form of a cloned polycythemic strain of SFFV proviral DNA, were constructed seven in-phase env mutants by insertion of linkers and by a deletion. The mutagenized SFFVs were transfected into fibroblasts and were rescued by superinfection with a helper murine leukemia virus. Four of the mutants cause erythroblastosis. These include one with a 6-base-pair (bp) insert in the ecotropic-related sequence near the 3' end of the gene, two with a 12- or 18-bp insert in the region that encodes the proline-rich linker, and one with a 6-bp insert in the dualtropic-specific region. The other mutants (RI, Sm1, and Sm2) are nonpathogenic and contain lesions in dualtropic-specific sequences that are highly conserved among strains of SFFV. A pathogenic revertant (RI-rev) was isolated from one mouse that developed erythroblastosis 3 weeks after infection with RI. RI-rev contains a second-site env mutation that affects the same domain as the primary mutation does and that increases the size of the encoded glycoprotein. All pathogenic SFFVs encode glycoproteins that are expressed on cell surfaces, whereas the nonpathogenic glycoproteins are exclusively intracellular. The pathogenic SFFVs also specifically cause a weak interference to superinfection by dualtropic MuLVs. These results are compatible with the multidomain model for the structure of gp55 and suggest that processing of gp55 to plasma membranes is required for pathogenesis. The amino-terminal region of gp55 binds to dualtropic murine leukemia virus receptors, and this interaction is preserved in the SFFV mutants that cause erythroblastosis.

CT EMTAGS: cell, tissue or organ culture (0103); blood and hemopoietic system (0927); chemical procedures (0107); nonhuman (0777); etiology (0135); **malignant neoplastic disease** (0306); mouse (0727); heredity (0137); virus (0761)

Medical Descriptors:

\*virus glycoprotein

\*cell surface

\*virus pathogenesis

virus mutation

cell culture

deoxyribonucleic acid transfection

virus receptor

erythroblastosis

electrophoresis

\*friend leukemia virus

L79 ANSWER 19 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.

AN 87133484 EMBASE

TI A comparison of the macrophage migration inhibition (MMI) assay and the semi-automated leucocyte adherence inhibition (SALAI) assay.

AU Isbister W.H.; McLeod D.K.

CS University Department of Surgery, Wellington Clinical School of Medicine, Wellington, New Zealand

SO AUST. J. EXP. BIOL. MED. SCI., (1986) 64/6 (501-503).

CODEN: AJEBAK  
CY Australia  
FS 026 Immunology, Serology and Transplantation  
LA English  
CT EMTAGS: blood and hemopoietic system (0927); large intestine (0940); methodology (0130); immunological procedures (0102); **malignant neoplastic disease** (0306); diagnosis (0140); major clinical study (0150); human (0888)  
Medical Descriptors:  
\*macrophage migration inhibition  
\*leukocyte adherence inhibition  
**colorectal cancer**

L79 ANSWER 20 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 87012185 EMBASE  
TI Zakariya Al-Razi's treatise on botanical, animal and mineral origin drugs used for cancer.  
AU Ahmad J.; Farooqi A.H.; Siddiqi T.O.  
CS Department of Pharmacognosy, Institute of History of Medicine and Medical Research, New Delhi-110062, India  
SO ACTA PHARMACOL. TOXICOL., (1986) 59/SUPPL. 7 (277-278).  
CODEN: APTOA6  
CY Denmark  
LA English  
CC 016.01.02.00.00.  
016.01.11.03.00.  
030.24.00.00.00.  
030.26.00.00.00.  
037.15.00.00.00. Drug Literature Index/ANTINEOPLASTIC DRUGS AND CARCINOGENICS  
CT EMTAGS: priority journal (0007); therapy (0160); **malignant neoplastic disease** (0306); short survey (0002); human (0888); ethnic or racial aspects (0050)  
Medical Descriptors:  
\*pharmacotherapy  
\*botanics  
\*oncology  
\*plant drug  
\*cancer chemotherapy  
\*cuscuta epithymum  
\*solanum nigrum  
\*lactuca sativa  
\*spongia officinalis  
\*lead carbonate  
**\*boswellia glabra**  
\*aloe barbadensis  
\*armenian bole  
\*juglans regia  
\*testudo elegans  
\*cervus duvaduceli  
\*aristolochia longa  
\*peganum harmala  
\*cuscuta reflexa  
\*brassica oleracea  
\*cichory  
\*rosa damascena  
\*althea officinalis  
\*ferula galbaniflua  
\*ammoniac plant

L79 ANSWER 21 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 78124389 EMBASE  
TI Cytotoxic agents from *Bursera morelensis* (**Burseraceae**):  
Deoxypodophyllotoxin and a new lignan, 5'-Desmethoxydeoxypodophyllotoxin.  
AU Jolad S.D.; Wiedhopf R.M.; Cole J.R.  
CS Div. Pharmaceut. Chem., Coll. Pharm., Univ. Arizona, Tucson, Ariz. 85721,  
United States  
SO J.PHARM.SCI., (1977) 66/6 (892-893).  
CODEN: JPMSAE  
CY United States  
LA English  
AB The isolation and identification of deoxypodophyllotoxin and a new lignan,  
5'-desmethoxydeoxypodophyllotoxin, from the dried exudate of *Bursera*  
*morelensis* (**Burseraceae**) are reported. Deoxypodophyllotoxin  
showed high activity in the KB and PS test systems; the new lignan,  
although highly active against the KB test system, demonstrated only  
marginal activity against the PS test system. A structure is suggested for  
the new lignan, which was named morelensin.  
CC 030.24.05.00.00.  
037.15.04.00.00. Drug Literature Index/ANTINEOPLASTIC DRUGS AND  
CARCINOGENICS/Herbaceous substances  
037.26.02.00.00. /TOXIC SUBSTANCES AND PROTECTIVE AGENTS/Plant, animal and  
microbial venoms and toxins  
037.46.00.00.00. /DRUGS AFFECTING CELLS, ORGANELLES, INCLUSIONS  
CT EMTAGS: theoretical study (0110); plant (0699); chemical drug analysis  
(0193)  
Medical Descriptors:  
\*drug isolation  
\*plant  
\*mass spectrometry  
\*drug analysis  
\*drug identification  
\*nuclear magnetic resonance spectrometry  
\*drug screening  
\*infrared spectrometry  
\*leukemia  
\*leukemia p 388  
\*deoxypodophyllotoxin  
\*morelensin  
\*cytotoxicity  
\*lymphatic leukemia  
\*squamous cell carcinoma

L79 ANSWER 22 OF 22 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AN 78124387 EMBASE  
TI Cytotoxic agents from *Bursera klugii* (**Burseraceae**) I. isolation  
of sapelins A and B..  
AU Jolad S.D.; Wiedhopf R.M.; Cole J.R.  
CS Div. Pharmaceut. Chem. Coll. Pharm., Univ. Arizona, Tucson, Ariz. 85721,  
United States  
SO J.PHARM.SCI., (1977) 66/6 (889-890).  
CODEN: JPMSAE  
CY United States  
LA English  
CC 030.24.00.00.00.  
037.15.04.00.00. Drug Literature Index/ANTINEOPLASTIC DRUGS AND  
CARCINOGENICS/Herbaceous substances  
037.46.00.00.00. /DRUGS AFFECTING CELLS, ORGANELLES, INCLUSIONS

CT EMTAGS: theoretical study (0110); plant (0699); chemical drug analysis (0193); mouse (0727)  
Medical Descriptors:  
\*drug isolation  
\*plant  
\*drug analysis  
\*drug identification  
\*mass spectrometry  
\*drug screening  
\*leukemia  
\*leukemia p 388  
\*plant extract  
\*sapelin  
\*lymphatic leukemia  
\*squamous cell carcinoma

=> fil medline

FILE 'MEDLINE' ENTERED AT 15:42:17 ON 10 FEB 1999

FILE LAST UPDATED: 9 FEB 1999 (19990209/UP). FILE COVERS 1966 TO DATE.

MEDLINE has been reloaded to reflect the annual MeSH changes made by the National Library of Medicine for 1999. Enter HELP RLOAD for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

=> d his 180-

(FILE 'EMBASE' ENTERED AT 15:38:54 ON 10 FEB 1999)

FILE 'MEDLINE' ENTERED AT 15:39:54 ON 10 FEB 1999

L80 11 S L5  
L81 63 S BOSWEL?  
L82 63 S L80,L81  
L83 1 S L80 AND C4./CT  
L84 1 S L80 AND (LEUKOCYTE ELASTASE OR PLASMIN)/CT,CN  
L85 0 S L80 AND (PULMONARY EMPHYSEMA+NT OR RESPIRATORY DISTRESS SYNDR  
L86 0 S L80 AND (CYSTIC FIBROSIS OR BRONCHITIS+NT OR BRONCHIOLITIS+NT  
L87 2 S L80 AND (ARTHRITIS+NT)/CT  
L88 4 S L83,L84,L87

FILE 'MEDLINE' ENTERED AT 15:42:17 ON 10 FEB 1999

=> d all tot

L88 ANSWER 1 OF 4 MEDLINE  
AN 1998282873 MEDLINE  
DN 98282873  
TI Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture.  
AU Shao Y; Ho C T; Chin C K; Badmaev V; Ma W; Huang M T  
CS Department of Plant Science, Cook College, Rutgers, State University of New Jersey, New Brunswick, USA.  
SO PLANTA MEDICA, (1998 May) 64 (4) 328-31.  
Journal code: P9F. ISSN: 0032-0943.  
CY GERMANY: Germany, Federal Republic of  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English

EM 199809  
EW 19980901  
AB Four major triterpene acids including beta-boswellic acid (1), 3-O-acetyl-beta-boswellic acid (2), 11-keto-beta-boswellic acid (3), and 3-O-acetyl-11-keto-beta-boswellic acid (4) were isolated from the gum resin of *Boswellia serrata* and examined for their in vitro antitumor activity. They inhibited the synthesis of DNA, RNA and protein in human leukemia HL-60 cells in a dose dependent manner with IC50 values ranging from 0.6 to 7.1 microM. Among them, compound 4 induced the most pronounced inhibitory effects on DNA, RNA and protein synthesis with IC50 values of 0.6, 0.5, and 4.1 microM, respectively. The effect of 4 on DNA synthesis was found to be irreversible. Compound 4 significantly inhibited the cellular growth of HL-60 cells, but did not affect cell viability.

CT Check Tags: Human  
Antineoplastic Agents, Phytogenic: IP, isolation & purification  
\*Antineoplastic Agents, Phytogenic: PD, pharmacology  
Cell Division: DE, drug effects  
DNA, Neoplasm: BI, biosynthesis  
HL-60 Cells  
Leukemia: GE, genetics  
Leukemia: ME, metabolism  
\*Leukemia: PA, pathology  
Neoplasm Proteins: BI, biosynthesis  
\*Plants, Medicinal: CH, chemistry  
RNA, Neoplasm: BI, biosynthesis  
Triterpenes: IP, isolation & purification  
\*Triterpenes: PD, pharmacology

RN 631-69-6 (boswellic acid)  
CN 0 (Antineoplastic Agents, Phytogenic); 0 (DNA, Neoplasm); 0 (Neoplasm Proteins); 0 (RNA, Neoplasm); 0 (Triterpenes)

L88 ANSWER 2 OF 4 MEDLINE  
AN 97256690 MEDLINE  
DN 97256690  
TI Inhibition by boswellic acids of human leukocyte elastase.  
AU Safayhi H; Rall B; Sailer E R; Ammon H P  
CS Department of Pharmacology, Institute of Pharmaceutical Sciences, University of Tuebingen, Germany.  
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1997 Apr) 281 (1) 460-3.  
Journal code: JP3. ISSN: 0022-3565.

CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199707  
EW 19970702  
AB Frankincense extracts and boswellic acids, biologically active pentacyclic triterpenes of frankincense, block leukotriene biosynthesis and exert potent anti-inflammatory effects. Screening for additional effects of boswellic acids on further proinflammatory pathways, we observed that acetyl-11-keto-beta-boswellic acid, an established direct, nonredox and noncompetitive 5-lipoxygenase inhibitor, decreased the activity of human leukocyte elastase (HLE) in vitro with an IC50 value of about 15 microM. Among the pentacyclic triterpenes tested in concentrations up to 20 microM, we also observed substantial inhibition by beta-boswellic acid, amyryn and ursolic acid, but not by 18beta-glycyrrhetinic acid. The data show that the dual inhibition of 5-lipoxygenase and HLE is unique to boswellic acids: other pentacyclic triterpenes with HLE inhibitory

activities (e.g., ursolic acid and amyrin) do not inhibit 5-lipoxygenase, and leukotriene biosynthesis inhibitors from different chemical classes (e.g., NDGA, MK-886 and ZM-230,487) do not impair HLE activity. Because leukotriene formation and HLE release are increased simultaneously by neutrophil stimulation in a variety of inflammation- and hypersensitivity-based human diseases, the reported blockade of two proinflammatory enzymes by boswellic acids might be the rationale for the putative antiphlogistic activity of acetyl-11-keto-beta-boswellic acid and derivatives.

CT Check Tags: Human

\*Anti-Inflammatory Agents, Non-Steroidal: PD, pharmacology

Arachidonate 5-Lipoxygenase: AI, antagonists & inhibitors

\*Leukocyte Elastase: AI, antagonists & inhibitors

Structure-Activity Relationship

\*Triterpenes: PD, pharmacology

RN 631-69-6 (boswellic acid)

CN EC 1.13.11.34 (Arachidonate 5-Lipoxygenase); EC 3.4.21.37 (Leukocyte Elastase); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Triterpenes)

L88 ANSWER 3 OF 4 MEDLINE

AN 90035645 MEDLINE

DN 90035645

TI Anti-arthritic activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis.

AU Sharma M L; Bani S; Singh G B

CS Discipline of Pharmacology, Regional Research Laboratory (CSIR), Jammu Tawi, India..

SO INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, (1989) 11 (6) 647-52.

Journal code: GRI. ISSN: 0192-0561.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199002

AB The effect of boswellic acids on bovine serum albumin (BSA)-induced arthritis in rabbits was studied. Oral administration of boswellic acids (25, 50 and 100 mg/kg/day) significantly reduced the population of leucocytes in a BSA-injected knee and changed the electrophoretic pattern of the synovial fluid proteins. The local injection of boswellic acids (5, 10 and 20 mg) into the knee 15 min prior to BSA challenge also significantly reduced the infiltration of leucocytes into the knee joint, reduced the infiltration of leucocytes into the pleural cavity and inhibited the migration of PMN in vitro. The leucocyte-inhibitory activity of boswellic acids was not due to its cytotoxic effect. The boswellic acids did not show any detergent or surfactant properties.

CT Check Tags: Animal

Anti-Inflammatory Agents, Non-Steroidal: AE, adverse effects

\*Anti-Inflammatory Agents, Non-Steroidal: TU, therapeutic use

Arthritis

\*Arthritis, Adjuvant: DT, drug therapy

Arthritis, Adjuvant: PP, physiopathology

Carrageenan

Cattle

Cell Movement: DE, drug effects

Hemolysis: DE, drug effects

Irritants

Neutrophils: DE, drug effects

Pleurisy: CI, chemically induced



Pleurisy: DT, drug therapy  
Rabbits  
Rats  
Serum Albumin, Bovine  
Triterpenes: AE, adverse effects  
\*Triterpenes: TU, therapeutic use  
RN 631-69-6 (boswellic acid); 9000-07-1 (Carrageenan)  
CN 0 (Irritants); 0 (Serum Albumin, Bovine); 0 (Triterpenes)

L88 ANSWER 4 OF 4 MEDLINE  
AN 88114536 MEDLINE  
DN 88114536  
TI Effect of a new non-steroidal anti-inflammatory agent on lysosomal stability in adjuvant induced arthritis.  
AU Kesava Reddy G; Dhar S C  
CS Department of Biochemistry, Central Leather Research Institute, Madras, India..  
SO ITALIAN JOURNAL OF BIOCHEMISTRY, (1987 Jul-Aug) 36 (4) 205-17.  
Journal code: GYW. ISSN: 0021-2938.  
CY Italy  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 198805  
AB The effect of new non-steroidal anti-inflammatory agents on lysosomal stability was studied by determining the activity of beta-glucuronidase, a typical lysosomal enzyme, in various sub-cellular fractions and its release from the lysosome-rich fraction. Adjuvant arthritic animals showed a significant increase in the beta-glucuronidase activity in sub-cellular fractions. The increased rate of the release of beta-glucuronidase from lysosome-rich fraction clearly suggested that arthritic syndrome caused decreased stability of the lysosomes. Administration of boswellic acids or salai-guggal to arthritic animals was found to increase the lysosomal stability by inhibiting the rate of release from lysosome-rich fraction and reducing beta-glucuronidase activity in various sub-cellular fractions. Of the two anti-inflammatory agents tested, salai-guggal was found to afford more therapeutic value than boswellic acids.  
CT Check Tags: Animal; Male; Support, Non-U.S. Gov't  
\*Anti-Inflammatory Agents, Non-Steroidal: PD, pharmacology  
\*Arthritis: EN, enzymology  
\*Arthritis, Adjuvant: EN, enzymology  
\*Lysosomes: DE, drug effects  
Osmotic Fragility: DE, drug effects  
Rats  
Triterpenes: PD, pharmacology  
RN 631-69-6 (boswellic acid)  
CN 0 (Sallaki); 0 (Triterpenes)

=> fil cancer

FILE 'CANCERLIT' ENTERED AT 15:43:06 ON 10 FEB 1999

FILE COVERS 1963 TO 27 Jan 1999 (19990127/ED)

Cancerlit has been reloaded with 1998 MeSH headings. See NEWS FILE and HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

The problem with incorrect information in the Document Type (DT) field has been corrected.

=> d his 189-

(FILE 'MEDLINE' ENTERED AT 15:42:17 ON 10 FEB 1999)

FILE 'CANCERLIT' ENTERED AT 15:42:27 ON 10 FEB 1999

L89 10 S L82

L90 4 S L89 NOT MEDLINE/OS

FILE 'CANCERLIT' ENTERED AT 15:43:06 ON 10 FEB 1999

=> d all tot

L90 ANSWER 1 OF 4 CANCERLIT

AN 1998639465 CANCERLIT

DN 98639465

TI Antitumor activity of beta-**boswellic** acid and its related triterpene acids from the gum resin exudate of the tree **Boswellia serrata** (Meeting abstract).

AU Huang M-T; Shao Y; Ma W; Badmaev V; Chin C-K; Ho C-T

CS Lab. for Cancer Res., Dept. Chem. Biol., Coll. Pharm., Rutgers Univ., Piscataway, NJ 08855.

SO Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A2465. ISSN: 0197-016X.

DT (MEETING ABSTRACT)

FS ICDB

LA English

EM 199802

AB The gum resin exudate from the stem of the tree **Boswellia serrata** has been used as a traditional medicine in India and China for the treatment of inflammation, arthritic pain, wounds, and other diseases. We found that **Boswellin** (an alcohol extract of the gum resin exudate of **Boswellia serrata** containing about 60% **boswellic** acids) strongly inhibited the growth of HL-60 cells in culture and the synthesis of DNA, RNA, and protein in HL-60 cells. In additional studies, we have isolated and purified 4 major triterpene acids: (1) beta-**boswellic** acid, (2) 3-O-acetyl-beta-**boswellic** acid, (3) 11-keto-beta-**boswellic** acid, and (4) 3-O-acetyl-11-keto-beta-**boswellic** acid from **Boswellin** by repeatedly extracted with KOH solution and ethyl acetate and separated by a silica gel column chromatography. All 4 triterpene acids markedly inhibited the synthesis of DNA, RNA and protein in HL-60 cells in a dose-dependent manner with IC50 values ranging from 0.6-7.1 uM. Among them 3-O-acetyl-11-keto-beta-**boswellic** acid was the most potent inhibitor, and its inhibitory effect on the synthesis of DNA was irreversible.

CT Check Tags: Human

DNA, Neoplasm: BI, biosynthesis

DNA, Neoplasm: DE, drug effects

HL-60 Cells

\*Plant Extracts: PD, pharmacology

Plants, Medicinal: CH, chemistry

Protein Synthesis Inhibitors: PD, pharmacology

RNA, Neoplasm: BI, biosynthesis

RNA, Neoplasm: DE, drug effects

Trees

\*Triterpenes: PD, pharmacology

RN 631-69-6 (boswellic acid)  
CN 0 (DNA, Neoplasm); 0 (Plant Extracts); 0 (Protein Synthesis Inhibitors); 0 (RNA, Neoplasm); 0 (Triterpenes)

L90 ANSWER 2 OF 4 CANCERLIT  
AN 1998639464 CANCERLIT  
DN 98639464  
TI Inhibitory effect of an extract of the gum resin exudate of **Boswellia serrata** on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin tumor promotion in mice (Meeting abstract).  
AU Huang M-T; Badmaev V; Xie J-G; Lou Y-R; Lu Y P; Ho C-T  
CS Lab. for Cancer Res., Coll. of Pharmacy, Rutgers Univ., Piscataway, NJ 08855.  
SO Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A2464. ISSN: 0197-016X.  
DT (MEETING ABSTRACT)  
FS ICDB  
LA English  
EM 199802  
AB The gum resin exudate from the stem of the tree **Boswellia serrata** has been used as a traditional medicine in India and China for the treatment of inflammation, arthritic pain, wounds, and other diseases. We found that **Boswellin** (an alcohol extract of the gum resin exudate of **Boswellia serrata** containing about 60% **boswellic acids**) strongly inhibited TPA-induced inflammation and tumor promotion in mouse epidermis. Topical application of 1.2 - 3.6 mg of **Boswellin** with 5 nmol of TPA to the backs of CD-1 mice once a day for 2-3 days strongly inhibited TPA-induced increases in the number of epidermal cell layers, epidermal thickness and inflammatory cell infiltration. Topical application of 1.2 or 3.6 mg of **Boswellin** with 5 nmol TPA twice weekly for 16 weeks to the backs of mice previously initiated with 200 nmol of 7,12-dimethylbenz[a]anthracene inhibited the number of TPA-induced skin tumors per mouse by 87 or 99%, respectively, and the percent of mice with skin tumors was inhibited by 59 or 92%, respectively. The 1.2 or 3.6 mg **Boswellin** treatment resulted in 4 weeks or 8 weeks latency of tumor formation, respectively. These results suggest that beta-**boswellic acids** are potent inhibitors of skin tumor promotion.

CT Check Tags: Animal  
\*Anticarcinogenic Agents: PD, pharmacology  
Mice  
\*Plant Extracts: PD, pharmacology  
Plants, Medicinal: CH, chemistry  
Skin Neoplasms: CI, chemically induced  
\*Skin Neoplasms: PC, prevention & control  
\*Tetradecanoylphorbol Acetate: TO, toxicity  
Trees  
\*Triterpenes: PD, pharmacology

RN 631-69-6 (boswellic acid); 16561-29-8 (Tetradecanoylphorbol Acetate)  
CN 0 (Anticarcinogenic Agents); 0 (Plant Extracts); 0 (Triterpenes)

L90 ANSWER 3 OF 4 CANCERLIT  
AN 1998638458 CANCERLIT  
DN 98638458  
TI Analysis of pentacyclic triterpene-mediated antiproliferative effects on malignant melanoma cells (Meeting abstract).  
AU Bogenrieder T; Glaessl A; Bosserhoff A-K; Sailer E-R; Landthaler M; Ammon H P T; Stolz W

CS University of Regensburg, Regensburg, Germany 93042.  
SO Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A1458.  
ISSN: 0197-016X.  
DT (MEETING ABSTRACT)  
FS ICDB  
LA English  
EM 199802  
AB Recently, the pentacyclic triterpene betulinic acid (BA) has been shown to be a selective inhibitor of human melanoma that functions by the induction of apoptosis (Nature Medicine; 1:1046). Isolated from the gum resin of *Boswellia serrata*, acetyl-11-keto-beta-boswellic acid (AKBA) is another pentacyclic triterpene derivative which induces apoptosis in HL-60 leukemia cells (Hoernlein RF et al, personal communication). We therefore evaluated the antiproliferative effects of both BA and AKBA against the human metastatic malignant melanoma cell line SK-MEL 28 at concentrations in the range of 3-30 uM. Cells were plated in triplicate wells and growth assays were performed on two separate occasions. Cell number was determined on day 4 using a hemocytometer. Percent inhibition is in comparison to untreated controls. AKBA at concentrations between 3 and 30 uM caused a dose-dependent growth inhibition. Maximal effect was observed at 30 uM with 93% growth inhibition. In contrast, melanoma cells were only moderately growth inhibited (25%) by BA at various concentrations, even at 30 uM. These data indicate that AKBA may be an even more effective drug in melanoma growth inhibition than BA.

CT Check Tags: Human  
\*Antineoplastic Agents, Phytogetic: TU, therapeutic use  
\*Lipoxygenase Inhibitors: TU, therapeutic use  
\*Melanoma, Experimental: DT, drug therapy  
Melanoma, Experimental: PA, pathology  
\*Triterpenes: TU, therapeutic use

RN 472-15-1 (betulinic acid)  
CN 0 (acetyl-11-ketoboswellic acid); 0 (Antineoplastic Agents, Phytogetic); 0 (Lipoxygenase Inhibitors); 0 (Triterpenes)

L90 ANSWER 4 OF 4 CANCERLIT  
AN 1998638291 CANCERLIT  
DN 98638291  
TI Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL60 and CCRF-CEM cells and inhibits topoisomerase I (Meeting abstract).  
AU Hoernlein R F; Orlikowsky T; Zehrer C; Niethammer D; Sailer E R; Dannecker G E; Ammon H P T  
CS Inst. of Pharmaceutical Sciences, Auf der Morgenstelle 8, 72076 Tuebingen, Germany.  
SO Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A1291.  
ISSN: 0197-016X.  
DT (MEETING ABSTRACT)  
FS ICDB  
LA English  
EM 199806  
AB Acetyl-11-keto-beta-boswellic acid (AKBA) is a naturally occurring pentacyclic triterpene isolated from *Boswellia serrata* Roxb. (Burseraceae) which inhibits mammalian 5-lipoxygenases (IC50 1.5 uM in intact rat PMNL). As some 5-lipoxygenase (5-LO) inhibitors were reported to induce apoptosis, we investigated the effect of AKBA on leukemic cell growth. Proliferation of HL60 and CCRF-CEM cells in the presence of AKBA and the structural analogue alpha-amyrin was tested. Cell counts and 3H-thymidine incorporation were significantly reduced in a dose-dependent manner in the presence of AKBA (IC50 30 uM) compared to

controls. An additive effect with the crosslinking of the CD95-receptor, which is known to induce apoptosis under certain conditions, was also observed. AKBA-treated cells showed morphological changes like membrane blebbing and subsequent flow cytometric analysis of propidium-iodide stained cells demonstrated signs of apoptosis. Sub-G1-peaks could be observed after 4 hours. However, since 5-LO mRNA can not be detected in undifferentiated HL60 nor CCRF cells, a mechanism different from 5-LO inhibition must account for AKBA's effect. As inhibitors of topoisomerases (topo) are known to be inducers of apoptosis, we investigated the effect of AKBA on topo I from calf thymus in vitro. In a DNA-relaxation assay with phiX174RF DNA, AKBA inhibited topo I with IC50=20 uM. This suggests that induction of apoptosis in HL60 and CCRF-CEM by AKBA might be due to inhibition of topo I in these cells.

CT Check Tags: Human

\*Apoptosis: DE, drug effects

Cell Division: DE, drug effects

\*DNA Topoisomerase: AI, antagonists & inhibitors

\*Enzyme Inhibitors: PD, pharmacology

Flow Cytometry

G1 Phase

\*Triterpenes: PD, pharmacology

Tumor Cells, Cultured

CN 0 (acetyl-11-ketoboswellic acid); EC 5.99.1.2 (DNA Topoisomerase); 0 (Enzyme Inhibitors); 0 (Triterpenes)

=> fil wpids

FILE 'WPIDS' ENTERED AT 15:48:58 ON 10 FEB 1999

COPYRIGHT (C) 1999 DERWENT INFORMATION LTD

FILE LAST UPDATED: 03 FEB 1999

<19990203/UP>

>>>UPDATE WEEKS:

MOST RECENT DERWENT WEEK 199905 <199905/DW>

DERWENT WEEK FOR CHEMICAL CODING: 199905

DERWENT WEEK FOR POLYMER INDEXING: 199905

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> D COST AND SET NOTICE DO NOT REFLECT SUBSCRIBER DISCOUNTS -  
SEE HELP COST FOR DETAILS <<<

>>> INDEXING UPDATE CODES JUMP FORWARD TO 9901 - SEE NEWS <<<

=> d his 191-

(FILE 'CANCERLIT' ENTERED AT 15:43:06 ON 10 FEB 1999)

FILE 'WPIDS' ENTERED AT 15:43:20 ON 10 FEB 1999

L91 21 S BOSWEL?  
L92 187 S OLIBANUM OR DAMARA OR D ORIENTALIS OR FRANKINCENS? OR BURSER  
L93 202 S L91,L92  
L94 1 S L93 AND (ELASTASE OR PLASMIN OR FIBRINOLYSIN OR THROMBOLYSIN)  
L95 26 S L93 AND (B14-C09? OR C14-C09? OR B12-D03 OR C12-D03 OR B14-H0  
L96 2 S L93 AND (B14-K01? OR C14-K01? OR B12-K? OR C12-K?)/MC  
L97 12 SEA L93 AND (P421 OR P423 OR P631 OR P633 OR P820)/M0,M1,M2,M3,  
M4,M5,M6  
L98 30 S L94-L97

FILE 'WPIDS' ENTERED AT 15:48:58 ON 10 FEB 1999

=> d all tot 198

L98 ANSWER 1 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
 AN 99-045269 [04] WPIDS  
 DNC C99-014178  
 TI Composition for treating bone and joint inflammatory conditions -  
 comprises systemically absorbable cartilage and aminosaccharide.  
 DC B04 D16  
 IN WEISMAN, B  
 PA (WEIS-I) WEISMAN B  
 CYC 82  
 PI WO 9852583 A1 981126 (9904)\* EN 39 pp A61K035-32  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
 OA PT SD SE SZ UG ZW  
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE  
 GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG  
 MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG  
 US UZ VN YU ZW  
 ADT WO 9852583 A1 WO 98-US10758 980522  
 PRAI US 97-862513 970523  
 IC ICM A61K035-32  
 AB WO 9852583 A UPAB: 990127  
 Composition for treating conditions characterised by bone or joint  
 inflammation, in mammals comprises (A) systemically absorbable cartilage  
 (SAC); (B) an aminosaccharide (AS); and optionally (C) (i) a  
 mucopolysaccharide (MPS); (ii) proteolytic enzymes (PE) and (i); (iii) (a)  
 an extract of a herb of the genus Withenia, (b) an extract of the bark of  
 a herb of the genus Salix, or (c) a root of the herb of the genus Panax,  
 and (i) and (ii); (iv) **boswellic** acid or its derivatives and  
 (i), (ii) and (iiia) or (iiic); or (v) chondroitin and (i), (ii), (iv) and  
 (iiia) or (iiic).  
 USE - The composition can be used to treat conditions characterised  
 by bone and joint inflammation such as arthritis, rheumatism, rheumatoid  
 arthritis, bursitis, tendonitis and gout.  
 ADVANTAGE - The composition overcomes the disadvantages of known  
 treatments i.e not sufficiently alleviating pain and discomfort and  
 restoring the use of inflamed joints or causing side effects.  
 Dwg.0/0  
 FS CPI  
 FA AB  
 MC CPI: B04-A10; B04-A10F; B04-A10H; B04-B04E; B04-C02E2; B04-C02F; B04-L05C;  
 B14-C02; B14-C06; **B14-C09**; **B14-C09B**; D05-A02

L98 ANSWER 2 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
 AN 98-506473 [43] WPIDS  
 DNC C98-152852  
 TI Medical or cosmetic composition for treating sports injuries, etc. -  
 comprises essential oil, spice and/or herb.  
 DC B04 D21  
 IN FLETCHER, J C; RILEY, M J H  
 PA (RILE-N) RILEY FLETCHER FOUND  
 CYC 81  
 PI WO 9840086 A2 980917 (9843)\* EN 89 pp A61K035-00  
 RW: AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA  
 PT SD SE SZ UG ZW  
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE  
 GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG  
 MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG  
 US UZ VN YU ZW  
 AU 9864082 A 980929 (9906) A61K035-00

ADT WO 9840086 A2 WO 98-GB708 980310; AU 9864082 A AU 98-64082 980310

FDT AU 9864082 A Based on WO 9840086

PRAI GB 97-4904 970310

IC ICM A61K035-00

AB WO 9840086 A UPAB: 981028

Medical or cosmetic composition comprises at least 1 essential oil in combination with at least 1 spice and/or at least 1 herb.

The essential oil is preferably selected from bergamot, chamomile, german, chamomile maroc, chamomile roman, cinnamon zeylanicum, clove buds, eucalyptus globulus, **frankincense**, fennel, hyssop, juniper, lemon grass, mountain savoury, niaouli, red thyme, rosemary, rose geranium, tagestes and ylang ylang. The Chinese herbs are selected from Acaia Catechu, Acanthopanax granilistylus, Caesalpinia Sappan and Epimedium Spinoso. The spices are selected from asapoetidia, coconut, coriander, fenugreek and horseradish. The composition also contains Aloe vera extract, a honey product and at least 1 vitamin, mineral, amino acid, enzyme, flavouring and/or Bach flower remedy.

USE - The medical composition is used for treating disease or physical disability or sports injuries, or for build up and maintenance of the immune system or for protection against disease or pollution. The cosmetic formulation is used for skin care and/or weight management. The cosmetic composition is topically applied

Dwg.0/0

FS CPI

FA AB

MC CPI: B04-A08; B04-A09; B04-A10; B04-B01A; B04-B01C; B14-N17; D08-B09A

L98 ANSWER 3 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 98-087561 [09] WPIDS

DNN N98-069470 DNC C98-029681

TI Analgesic for e.g. rheumatism.

DC B04 P33

IN WANG, Y

PA (WANG-I) WANG Y

CYC 1

PI CN 1138997 A 970101 (9809)\*

A61K035-78

ADT CN 1138997 A CN 95-117857 951221

PRAI CN 95-117857 951221

IC ICM A61K035-78

ICS A61J003-02; A61K009-16

AB CN 1138997 A UPAB: 980302

Analgesic composition comprises e.g. angelica, safflower, Saposhnikovia divaricata, **frankincense** and myrrh is prepared by drying, crushing, sieving, mixing, bottling, disinfecting and packing. The analgesic is then mixed with Shaoxing wine to give an ointment and applied on a dressing to the affected part. The analgesic is used for treating rheumatism, arthritis, sprains and arthrodynia without side effects.

FS CPI GMPI

FA AB

MC CPI: B04-A08C2; B04-A10; B12-M02B; B14-C01; B14-C06; B14-C09

L98 ANSWER 4 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 98-043010 [05] WPIDS

DNC C98-014595

TI Chinese medicine for curing colitis.

DC B04

IN WANG, F

PA (WANG-I) WANG F

CYC 1

PI CN 1137399 A 961211 (9805)\* A61K035-78  
ADT CN 1137399 A CN 96-101163 960217  
PRAI CN 96-101163 960217  
IC ICM A61K035-78  
AB CN 1137399 A UPAB: 980202  
Chinese medicine contains astragalus root, rhubarb, Chinese gall, **frankincense**, myrrh, hyacinth bletilla, red halloysite, borax, realgar, borneol, cow-bezoar and toad venom. The preparation can destroy enteric pathogenic bacteria, improve local microcirculation, and can clear and activate channels and collaterals, remove necrotic tissue and promote granulation. The medicine has an effective rate of 100 % and a cure rate of above 90 %.  
Dwg.0/0  
FS CPI  
FA AB  
MC CPI: B04-A10; B04-B04M; B10-E02; B14-A01; B14-H01

L98 ANSWER 5 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
AN 98-043007 [05] WPIDS  
DNC C98-014592  
TI Spur pain-relieving plaster.  
DC B04  
IN YANG, L; YANG, M; YANG, S  
PA (YANG-I) YANG S  
CYC 1

PI CN 1137396 A 961211 (9805)\* A61K035-78  
ADT CN 1137396 A CN 96-100012 960228  
PRAI CN 96-100012 960228  
IC ICM A61K035-78  
ICS A61K009-06  
AB CN 1137396 A UPAB: 980202  
Guci Xiaotong Gao plaster for curing hyperosteoecy is made from 21 Chinese medicinal materials e.g. turtle shell, tortoise plastron, raw aconite main tuber, **frankincense** and myrrh which are prepared by boiling. The plaster clears and activates the channels and collaterals, promotes blood circulation by removing blood stasis, removes dampness and relieves swelling and pain. The plaster can also be used to treat arthritis. The plaster is easy to use, low in cost, and its curative rate is 98.7%.  
Dwg.0/0  
FS CPI  
FA AB  
MC CPI: B04-A10; B04-B04M; B12-M02D; B14-C09

L98 ANSWER 6 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
AN 98-019095 [03] WPIDS  
DNN N98-014543 DNC C98-007175  
TI Repellent analgesic ointment for cancer or tumour.  
DC B04 P33  
IN TANG, S  
PA (TANG-I) TANG S  
CYC 1

PI CN 1133725 A 961023 (9803)\* A61K035-78  
ADT CN 1133725 A CN 95-119266 951203  
PRAI CN 95-119266 951203  
IC ICM A61K035-78  
ICS A61J003-04; A61K009-06  
AB CN 1133725 A UPAB: 980119  
An exterior-use plaster is prepared from 26 Chinese medicinal materials



e.g. realgar, rhubarb, sodium sulphate, **frankincense**, myrrh, as well as dimethyl sulphoxide.

USE - The plaster has a total effective rate of 68.6% for shrinking liver tumour and an analgesic rate of more than 96% for liver cancer.

FS CPI GMPI  
FA AB  
MC CPI: B04-A10; B10-A10; B14-C01; **B14-H01**

L98 ANSWER 7 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 98-000279 [01] WPIDS

DNN N98-000146 DNC C98-000190

TI Yingfengaidi medicine production.

DC B04 P33

IN LU, Y

PA (LUYY-I) LU Y

CYC 1

PI CN 1131037 A 960918 (9801)\* A61K035-78

ADT CN 1131037 A CN 95-119652 951112

PRAI CN 95-119652 951112

IC ICM A61K035-78

ICS A61J003-00; A61K009-06; A61K009-16; A61K009-70

AB CN 1131037 A UPAB: 980107

A new anti-carcinogen is suitable for external application to cure exposure carcinosis. It is prepared from 21 Chinese medicinal materials such as datura flower, yellow azalea flower, **frankincense**, myrrh, sal ammoniac, arsenic, mercury, realgar, kansui root, euphorbia/knoxia root, genkwa flower, rhubarb, centipede, mylabris, nux vomica seed, indigo and trichosanthes root. The process involves pulverising, deep-frying and decocting makes the medicinal materials into a powder, ointment and adhesive plaster.

FS CPI GMPI  
FA AB  
MC CPI: B04-A10; B05-A03A; B12-M02D; **B14-H01**

L98 ANSWER 8 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 97-536990 [50] WPIDS

DNC C97-171882

TI Medicinal ointment for resolving blood stasis.

DC B04

IN LIU, D

PA (LIUD-I) LIU D

CYC 1

PI CN 1128660 A 960814 (9750)\* A61K035-78

ADT CN 1128660 A CN 94-112488 940829

PRAI CN 93-115003 931123

IC ICM A61K035-78

ICS A61K009-06; A61K009-70

AB CN 1128660 A UPAB: 971217

Medicinal ointment for resolving blood stasis comprises sichuan aconite root, wild aconite root, betel nut, dried rhizome of rehmannia, root of Dahurian agelica, **frankincense**, myrrh, pangolin, musk, red lead and sesame oil as raw materials. The sesame oil is dehydrated by heating, then the aforementioned components with the exception of red lead are put in the sesame oil successively and fried until they are black and charred. The residues are removed from the decoction and filtered and settled. The filtrate is heated and the red lead is put in to stir and fry until it is black. Then the finished product is bottled after cooling.

USE - The ointment clears and activates the channels and collaterals, promoting the circulation of blood and removing blood stasis, as well as

removing the necrotic tissue to promote regeneration.

FS CPI  
FA AB  
MC CPI: B04-A08; B04-A09D; B04-B01C; B05-A03B; B14-F02; **B14-H01**

L98 ANSWER 9 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 97-490773 [46] WPIDS

DNC C97-156602

TI Traditional Chinese herb medicinal pellets for restoring life.

DC B04

IN LUO, Y

PA (LUOY-I) LUO Y

CYC 1

PI CN 1122713 A 960522 (9746)\* A61K035-78

ADT CN 1122713 A CN 95-113008 950929

PRAI CN 95-113008 950929

IC ICM A61K035-78

AB CN 1122713 A UPAB: 971119

Chinese herb medicinal pellets are used for treatment of injury, hyperostosis and rheumatic arthritis and comprises 28 Chinese medicines, e.g. root of achyranthes bidentata, root of Chinese angelica, peach kernel, tuber of sparganium, **frankincense**, myrrh.

USE - The pellets can be used both for oral administration and external application.

FS CPI  
FA AB  
MC CPI: B04-A10; **B14-C09B**; B14-N01

L98 ANSWER 10 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 97-490760 [46] WPIDS

DNC C97-156589

TI Medicinal powder for curing mastosis, tumour etc..

DC B04

IN FU, Z

PA (FUZZ-I) FU Z

CYC 1

PI CN 1122700 A 960522 (9746)\* A61K035-78

ADT CN 1122700 A CN 94-111970 941108

PRAI CN 94-111970 941108

IC ICM A61K035-78

AB CN 1122700 A UPAB: 971119

Medicinal powder comprises garcinia, realgar, **frankincense**, myrrh, artemisia rupestris, rosin, vomiting nut and alum and is prepared by preprocessing, smashing, sifting, mixing and packaging.

USE - The process is useful for the treatment of mastosis including acute mastitis, mammary tuberculosis sore and tumour with a total effective rate of up to 97%.

FS CPI  
FA AB  
MC CPI: B04-A10; **B14-H01**

L98 ANSWER 11 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 97-449598 [42] WPIDS

DNC C97-143534

TI Traditional Chinese medicinal paste for treating lympho-tuberculosis.

DC B04

IN YANG, J

PA (YANG-I) YANG J

CYC 1

PI CN 1117397 A 960228 (9742)\* A61K035-78  
ADT CN 1117397 A CN 95-104677 950422  
PRAI CN 95-104677 950422  
IC ICM A61K035-78  
AB CN 1117397 A UPAB: 971021  
The ointment for external use contains ground beetle, **frankincense**, myrrh, croton seed, apricot kernel, verdigris, rosin, castor oil and sesame oil. The apricot kernel and croton seed are fried in boiling castor oil and sesame oil, and then the other ingredients which have been ground into a fine powder are added. The paste can be used for the treatment of lympho-tuberculosis and lymphoma with definite curative effects.

FS CPI  
FA AB  
MC CPI: B04-A10G; B14-A01B1; **B14-H01**

L98 ANSWER 12 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
AN 97-449591 [42] WPIDS  
DNC C97-143527

TI Analgesic containing **frankincense**, myrrh, etc..

DC B04  
IN YANG, R  
PA (YANG-I) YANG R  
CYC 1

PI CN 1117390 A 960228 (9742)\* A61K035-78

ADT CN 1117390 A CN 94-111139 940825

PRAI CN 94-111139 940825

IC ICM A61K035-78

AB CN 1117390 A UPAB: 971021

The analgesic consists of **frankincense**, myrrh, seed of strychnos, root of aconitum and twenty other traditional Chinese medicinal ingredients. The analgesic can be used for the treatment of arthritis, ischias, arthralgia and tibia disease, and the curative rate reaches 90%.

FS CPI  
FA AB  
MC CPI: B04-A08C2; B04-A10; B14-C01; **B14-C09**; B14-N01

L98 ANSWER 13 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
AN 97-416183 [39] WPIDS  
DNC C97-133354

TI Anti-cancer Chinese drug-Xiaoliujing capsule.

DC B04  
IN ZHOU, W  
PA (ZHOU-I) ZHOU W  
CYC 1

PI CN 1113790 A 951227 (9739)\* A61K035-78

ADT CN 1113790 A CN 94-110281 940527

PRAI CN 94-110281 940527

IC ICM A61K035-78

AB CN 1113790 A UPAB: 970926

Anticancer Chinese drug-Xiaoliujing capsule comprises root of American ginseng, leech, corydalis tuber, notoginseng, Chinese angelica root, prepared rhizome of Curcuma aromatica, root of Chinese Stellaria, herb of Blushred Rabdosia, **frankincense**, myrrh, toad venom, pilose deer horn, flavescent sophora root, coptis root, batryticated silkworm and Chinese caterpillar fungus. The ingredients are pulverized, uniformly mixed, screened by sieve number zero three times, and then aseptically placed in capsule number zero. The capsules are easy to take and can be stored for a long time.

FS CPI

FA AB  
MC CPI: B04-A08C2; B04-A10F; B04-B04C1; B04-B04L; B04-B04M; B04-F09;  
B14-H01

L98 ANSWER 14 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
AN 97-364532 [34] WPIDS  
DNC C97-116949  
TI Traditional Chinese anti-tumour medicine regulating and recovering soup.  
DC B04  
IN YAN, D  
PA (YAND-I) YAN D  
CYC 1  
PI CN 1109337 A 951004 (9734)\* A61K035-78  
ADT CN 1109337 A CN 94-102959 940328  
PRAI CN 94-102959 940328  
IC ICM A61K035-78  
AB CN 1109337 A UPAB: 970820  
Traditional Chinese anti-neoplastic medicine is prepared in weight ratio 1.5-4.4% of pangolin scales, turtle shell, bark of official magnolia, rhizome of Chinese gold thread, ochre, ginkgo, subprostrate sophora, ligusticum rhizoma, akebi, agalloch eaglewood, green tangerine peel, **frankincense** and myrrh; 2.9-5.9% of each of trichosanthes fruit and poria; 4.4-7.4% of Chinese violet, 7.4-10.3% of each of self heal, marine algae, hairy vein agrimony, root of Chinese pulsatilla and tuber of multiflower knotweed. In clinical observation of 31 cases, the total effective rate is 90%, curative rate is 12%. It features less side effect, simple process, convenience and less environmental pollution.

FS CPI  
FA AB  
MC CPI: B04-A08C2; B04-A09; B04-A10; B04-B04M; B14-H01

L98 ANSWER 15 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
AN 97-320458 [30] WPIDS  
DNC C97-103630  
TI Dysphagia ointment.  
DC B04  
IN WANG, S  
PA (WANG-I) WANG S  
CYC 1  
PI CN 1105575 A 950726 (9730)\* A61K035-78  
ADT CN 1105575 A CN 94-101039 940303  
PRAI CN 94-101039 940303  
IC ICM A61K035-78  
ICS A61K009-06  
AB CN 1105575 A UPAB: 970723  
Chinese adhesive plaster-'Yege Gao' is prepared by frying gum-resin from Ferula asafoetida, ginseng, astragalus root, nutgrass flatsedge rhizome, **frankincense** and myrrh in vegetable oil to extract the effective components, filtering to remove the residue, decotering the vegetable oil using a slow fire to concentrate it into paste material, cooling the paste and adding the Chinese medicines sea dragon, sea horse and eagle wood which have been ground into fine powder, pouring into cold water and at 50-80 deg.C applying to a backing material. The plasters can be applied to acupoints of Chihai, Shihmen, Kuanyuan and right and left Tsusanli for treating carcinoma of oesophagus and cardiac cancer.

FS CPI  
FA AB  
MC CPI: B04-A10; B12-M02D; B14-H01

L98 ANSWER 16 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 97-290001 [27] WPIDS

DNC C97-093437

TI Tongqiaohuasheng pills used against malignant tumours.

DC B04

IN GUAN, X

PA (GUAN-I) GUAN X

CYC 1

PI CN 1103591 A 950614 (9727)\* A61K035-78

ADT CN 1103591 A CN 93-120458 931208

PRAI CN 93-120458 931208

IC ICM A61K035-78

AB CN 1103591 A UPAB: 970702

The Tongqiaohuasheng pill is a medicine used against malignant tumours, especially those of the digestive system. The medicine comprises e.g. dragon's blood, toad-cake, **frankincense**, *Agkistrodon acutus*, gecko and musk.

ADVANTAGE - The pill has an effective rate greater than 81.5%, as seen in experiments with 38 patients.

FS CPI

FA AB

MC CPI: B04-A08C2; B04-A10; **B14-H01**

L98 ANSWER 17 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 97-236614 [22] WPIDS

DNC C97-076022

TI Plaster for treatment of carcinosis pain.

DC B04

IN DU, Y

PA (DUYY-I) DU Y

CYC 1

PI CN 1099295 A 950301 (9722)\* A61K035-78

ADT CN 1099295 A CN 94-105479 940524

PRAI CN 94-105479 940524

IC ICM A61K035-78

ICS A61K009-06

AB CN 1099295 A UPAB: 970530

Plaster comprises **frankincense**, myrrh, *Radix aconiti brachypodi*, *Radix aconiti kusnezoffii*, *arisaema*, *Rhizoma pinelliae*, bornel and natural bezoar of ox and musk.

USE - The plaster can restore normal menstruation and invigorate blood circulation, remove evil heat, soften hard lumps and stop pain. the effective rate reaches 96% without toxic side effects.

FS CPI

FA AB

MC CPI: B04-A10; B12-M02D; B14-C01; B14-F02; **B14-H01**; B14-N14

L98 ANSWER 18 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 97-203799 [19] WPIDS

DNC C97-065403

TI Medicine for curing hyperplasia of mammary glands.

DC B04

IN LU, X

PA (LUXX-I) LU X

CYC 1

PI CN 1096950 A 950104 (9719)\* A61K035-78

ADT CN 1096950 A CN 93-107661 930629

PRAI CN 93-107661 930629

IC ICM A61K035-78

AB CN 1096950 A UPAB: 970512

An external application drug comprises musk, pearl, amber, **frankincense** and myrrh. It is pasty.

USE - The drug invigorates blood circulation, removes swelling, resolves lymph nodes and stops pain. It can directly enter a focus region from the skin surface via osmosis. The total curative rate for hyperplasia of the breast is 97.2%.

ADVANTAGE - The drug is convenient, economic, non-toxic and quick acting.

FS CPI

FA AB

MC CPI: B04-A10; B04-B04G; B04-B04M; B14-C01; B14-C03; **B14-H01**

L98 ANSWER 19 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 97-161430 [15] WPIDS

DNC C97-051708

TI Apoptosis inhibitor as immunomodulatory agent for treating e.g. hepatitis - contains e.g. berberine, palmatine and/or capillarisin.

DC B02 B03 B04

PA (TSUR) TSUMURA & CO

CYC 1

PI JP 09030983 A 970204 (9715)\* 13 pp A61K035-78

ADT JP 09030983 A JP 95-182999 950719

PRAI JP 95-182999 950719

IC ICM A61K035-78

ICS A61K031-01; A61K031-32; A61K031-435; A61K035-84

ICA C07D311-16; C07D455-03

AB JP09030983 A UPAB: 970410

Apoptosis inhibitor comprises berberine, palmatine, capillarisin, 7-methyl-capillarisin, 6,7-dimethyl-esculetin, arcapillin, capillin, capillene and/or capirallin.

Also claimed are apoptosis inhibitors contg. (i) crude drug selected from *Coptis japonica* Makino, *Phellodendron amurense* Rupr. SOBOKU, KOUTAIKYU, OHHI, BOKUSOKU, *C.Zedoaria* Roscoe, BARANSHI, KISOU, KANPAKU, *Ephedra sinica* Stapf, *Pachyma Hoelen* Rumpf., **Frankincense**, ZENGO, *R.sachalinensis* Nakai and/or *Liquidam-baris-fructus*, *A.capillaris* Thumb. and (ii) at least one Chinese herbal medicine selected from OHRENGEDOKUTO, SANOUSYASHINTO, KEISHIBUKURYOUGAN, KEISHIKASYAKUDAIOUTO, DAIJOKITO, INCHINKOUTO, ROKUMIGAN, MOKUBOUITO, MASHININGAN, IREITO, TOKIKENCHUTO, SENKYUCHACHOTO, KARYUKOTSUBOREITO, GOSYUTO, BOUHUUTSUUSYOUSAN, TOUKAKUJYOKUITO, CHIDABOKUIPPPO, DAILOBOTANPITO, SAIBOKUTO, MOOOUTO, MOOUBUSHISAISHINTO and INCHINGOREISAN.

Crude drug or Chinese herbal medicine is used directly or extracted with water, ethanol, acetone or ether, pref. with water. Extn. with water is carried out by adding hot water (8-20 fold) to crude drug or Chinese herbal medicine and by filtration. The apoptosis inhibitor is formulated into oral agent, e.g. suspension, emulsion, syrup or elixirs or parenteral agent, e.g. injection or drip infusion.

USE - Apoptosis inhibitor is an immunomodulator or hepatitis treating agent, and is for treatment of viral hepatitis, hepatic cirrhosis, lowered immunofunction caused by stress. It is also used to prevent death of normal cells which are likely to be damaged by anticancer agent.

In an example, the inhibitory activities against apoptosis induced by TGF beta on highly differentiated hepatic carcinoma strain McA-RH8994 of rat were examined using crude aq. drug extracts and commercially available Chinese herbal medicine prepn. Every crude drug or Chinese herbal medicine inhibited the increase of DNA fragment ratio induced by TGF beta 1, whereas the control increased DNA fragment rate to 69.3% from 32.4% after the addn. of TGF beta 1.

Dwg.0/0  
 FS CPI  
 FA AB; DCN  
 MC CPI: B06-E05; B14-G02D; B14-N12

L98 ANSWER 20 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
 AN 97-155429 [15] WPIDS  
 DNC C97-049939  
 TI Medical or veterinary use of pure **boswellic** acid - to reduce leukocyte **elastase** or **plasmin** activity e.g. in pulmonary emphysema, cystic fibrosis, chronic bronchitis, rheumatoid arthritis and tumours.  
 DC B05 C03  
 IN AMMON, H P T; SAFAYHI, H  
 PA (AMMO-I) AMMON H P T  
 CYC 20  
 PI DE 19531067 A1 970227 (9715)\* 12 pp A61K031-56  
 WO 9707796 A1 970306 (9716) DE 32 pp A61K031-19  
 RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 W: JP US  
 EP 854709 A1 980729 (9834) DE A61K031-19  
 R: AT BE CH DE DK ES FI FR GB IE LI LU NL PT SE  
 ADT DE 19531067 A1 DE 95-19531067 950823; WO 9707796 A1 WO 96-EP3705 960822;  
 EP 854709 A1 EP 96-929309 960822, WO 96-EP3705 960822  
 FDT EP 854709 A1 Based on WO 9707796  
 PRAI DE 95-19531067 950823  
 IC ICM A61K031-19; A61K031-56  
 ICS A61K035-78  
 AB DE19531067 A UPAB: 970410  
 Use of pure **boswellic** acid (I) or its salts or derivs. or salts of its derivs. or an (I)-contg. plant prepn. for the prophylaxis and/or control of diseases caused by an elevated leukocyte **elastase** or **plasmin** activity or diseases treatable by inhibition of normal leukocyte **elastase** or **plasmin** activity in human or veterinary medicine is new.  
 USE - (I) is esp. useful for treating pulmonary emphysema, acute respiratory distress syndrome, pulmonary shock, cystic fibrosis, chronic bronchitis, glomerulonephritis, and rheumatoid arthritis (which are caused by increased leukocyte **elastase** activity), and tumours and tumour metastasis (which are caused by increased **plasmin** activity) (all claimed).  
 Dwg.0/2  
 FS CPI  
 FA AB; DCN  
 MC CPI: B09-B; B14-C09B; B14-H01B; B14-K01;  
 B09-B; C09-B; B14-C09B; C14-C09B;  
 B14-H01B; C14-H01B; B14-K01;  
 C14-K01; C09-B; C14-C09B; C14-H01B;  
 C14-K01

L98 ANSWER 21 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
 AN 97-119705 [12] WPIDS  
 DNC C97-038804  
 TI Mammary gland hyperplasia medical paste prepn..  
 DC B04  
 IN XU, W  
 PA (XUWW-I) XU W  
 CYC 1  
 PI CN 1080532 A 940112 (9712)\* A61K035-78

ADT CN 1080532 A CN 92-104721 920620

PRAI CN 92-104721 920620

IC ICM A61K035-78

AB CN 1080532 A UPAB: 970320

The present invention relates to a method for preparing the mammary gland hyperplasia plaster. The dried rhizome of rehmannia, Chinese angelica, cape jasmine, root of Dahurian angelica, sea horse, scorpion and centipede are soaked in sesame oil, and heated for decocting, filtered to remove dregs, then the powdered borneol, dragon's blood, **frankincense**, myrrh and yellow lead are added and heating is stopped when they become black in colour. They are stirred uniformly into a plaster. The invention cures mainly the periodic mammary gland mass and lobular hyperplasia, mastadenoma, chronic mastitis, mammary swelling and mastalgia, the cure rate is 89% and total effective rate is 98%.

Dwg.0/0

FS CPI

FA AB

MC CPI: B04-A08C2; B04-A10; B04-B04M; B12-M02D; B14-C03; B14-F02;

**B14-H01B**

L98 ANSWER 22 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 97-118735 [11] WPIDS

DNC C97-038272

TI Compsn. comprises terpene-contg. substance(s) with propolis - used to treat inflammatory disorders of e.g. skin, respiratory system, vascular system, muscles, connective tissue, eyes etc..

DC B04 B05 D21

IN BEVILACQUA, M; ZACCAGNA, C A

PA (BEVI-I) BEVILACQUA M; (LAUS-I) MICHELIN LAUSAROT E

CYC 68

PI WO 9702040 A1 970123 (9711)\* EN 22 pp A61K035-78

RW: AT BE CH DE DK ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE  
SZ UG

W: AL AM AU BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK  
LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TR TT  
UA UG US UZ VN

AU 9663058 A 970205 (9721) A61K035-78

EP 836478 A1 980422 (9820) EN A61K035-78

R: AT DE ES FR GB IT NL SE

ADT WO 9702040 A1 WO 96-EP2824 960627; AU 9663058 A AU 96-63058 960627; EP 836478 A1 EP 96-922041 960627, WO 96-EP2824 960627

FDT AU 9663058 A Based on WO 9702040; EP 836478 A1 Based on WO 9702040

PRAI IT 96-PD38 960220; IT 95-PD133 950703; IT 95-PD134 950703

REP 3.Jnl.Ref ; AU 7715491; JP 1245058; RO 108643

IC ICM A61K035-78

ICI A61K035-78, A61K035:

AB WO 9702040 A UPAB: 970410

Pharmaceutical prod. comprises a combination of one or more terpene-contg. substances with propolis. Also claimed is a pharmaceutical prod. based on terpenes, which comprises a combination with myrrh with at least one other resin.

The prod. contains a combination of natural **olibanum** or derivs. with propolis. The prod. is a tablet, pill, capsule, soln., emulsion, ointment, cream, inhalation prepn., aerosol, suppository or pessary.

USE - Prod. is used for the treatment of predominantly inflammatory disorders of varying aetiology, both post-traumatic or not, as a main or sec. event, acute, chronic or in remission, with or without effusion, even



if resistant to common steroid therapy or to FANS (claimed; no further details) ). The prod. is used in the treatment of inflammatory disorders of the skin, respiratory system, vascular system, muscles, connective tissue and skeleton e.g. rheumatoid arthritis, gonitis, epicondylitis and athrosis), eyes and ears, teeth and mouth, gastro-intestinal tract, liver and biliary tracts and genitourinary tracts. Applicn. lasts for 5-10 days (claimed). The prod. is spread on an absorbent medium and adhered to the region to be treated (claimed).

ADVANTAGE - Release rate of prod. is constant, avoiding discontinuous treatments. Prolonged duration of action is achieved, giving lower admin. frequency and a low total daily dose of drug, with high terpene absorption.

Dwg.0/0

FS CPI

FA AB

MC CPI: B04-A10; B14-C03; B14-N17; D08-B08; D08-B09A

L98 ANSWER 23 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 97-101804 [10] WPIDS

DNC C97-032617

TI New fraction contg. known **boswellic** acids and new 2-alpha,3-alpha-di hydroxy urs-12-en-24-oic acid - useful as synergistic anti-inflammatory, antiarthritic and antiulcerogenic agent.

DC B05

IN DHAR, K L; KAPIL, R S; SETHI, V K; TANEJA, S C

PA (COUL) CSIR COUNCIL SCI IND RES

CYC 11

PI EP 755940 A1 970129 (9710)\* EN 15 pp C07J063-00

R: AT BE CH DE DK FR GB IT LI SE

US 5629351 A 970513 (9725)# 9 pp A61K031-015

ADT EP 755940 A1 EP 95-305242 950727; US 5629351 A US 95-421500 950413

PRAI EP 95-305242 950727; US 95-421500 950413

REP 6.Jnl.Ref

IC ICM A61K031-015; C07J063-00

ICS A61K031-56

AB EP 755940 A UPAB: 970307

Anti-inflammatory and antiulcerogenic fractions comprising a mixt. of 3 alpha -hydroxy urs-12-en-24-oic acid ( beta -**boswellic** acid) (I), 3 alpha -acetoxy-urs-12-en-24-oic acid (II), 3 alpha -hydroxy urs-12-en-11-keto-24-oic acid (III), 3 alpha -acetoxy urs-12-en-11-keto-24-oic acid (IV), 3 alpha -hydroxy urs-9,12-dien-24-oic acid (V) and 2 alpha ,3 alpha -dihydroxy urs-12-en-24-oic acid of formula (VI) are new. (VI), an antiulcerogenic and anti-inflammatory antiarthritic agent, is claimed per se.

The fractions pref. comprise 35-55 wt.% (I), 25-45 wt.% (II), 4-14 wt.% (III), 3-13 wt.% (IV), 1-3 wt.% (V) and 1-3 wt.% (VI).

ADVANTAGE - The fractions avoid the ulceration problems associated with prior art drugs. (I)-(VI) together with unidentified compounds exhibit synergistic and combined antiulcerogenic and anti-inflammatory antiarthritic activities, this being partly due to the presence of the novel acid (VI).

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B09-B; B14-C03; **B14-C09**; B14-E08; B14-S09

L98 ANSWER 24 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 97-052981 [06] WPIDS

DNC C97-017697

TI Ointment for treating spur.  
 DC B04  
 IN HAI, N  
 PA (HAIN-I) HAI N  
 CYC 1  
 PI CN 1077130 A 931013 (9706)\* A61K035-78  
 ADT CN 1077130 A CN 93-103931 930401  
 PRAI CN 93-103931 930401  
 IC ICM A61K035-78  
 ICS A61K009-06  
 AB CN 1077130 A UPAB: 970205  
 The present invention discloses an external ointment for curing osteoproliferation. It contains Dahurian angelica root, dried ginger, caulis piperis futokadsurae, Chinese angelica, **frankincense**, psedo-ginseng, Chinese ephedra, turmeric, chilli, lanoline, vaseline, stearic acid, ilex oil, camphor powder, menthol, Towne-80, triethanol amine, sugar and water.  
 Dwg.0/0  
 FS CPI  
 FA AB  
 MC CPI: B04-A10; B04-B01C2; B04-B01C3; B04-C03D; B04-D01; B10-B03B; B10-C04E; B10-E04A; B10-F02; B12-M02B; **B14-H01B**; B14-N01

L98 ANSWER 25 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
 AN 96-321565 [32] WPIDS  
 DNC C96-102326  
 TI Use of **boswellic** acid or derivs. for treating brain tumours - inhibits peritumoural brain oedema and tumour cell growth, has low toxicity and few side effects.  
 DC B05  
 IN AMMON, H P T; SIMMET, T  
 PA (SIMM-I) SIMMET T  
 CYC 19  
 PI WO 9619212 A1 960627 (9632)\* DE 20 pp A61K031-19  
 RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
 W: JP US  
 DE 4445728 A1 960627 (9632)  
 EP 871437 A1 981021 (9846) DE A61K031-19  
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE  
 JP 10511647 W 981110 (9904) 16 pp A61K031-19  
 ADT WO 9619212 A1 WO 95-EP5073 951221; DE 4445728 A1 DE 94-4445728 941221; EP 871437 A1 EP 95-942720 951221, WO 95-EP5073 951221; JP 10511647 W WO 95-EP5073 951221, JP 96-519521 951221  
 FDT EP 871437 A1 Based on WO 9619212; JP 10511647 W Based on WO 9619212  
 PRAI DE 94-4445728 941221  
 REP WO 9001937  
 IC ICM A61K031-19  
 ICS A61K009-20; A61K031-215; A61K031-56; A61K031-57; A61K035-78; C07J001-00  
 AB WO 9619212 A UPAB: 960819  
 Prepn. for the treatment brain tumours comprises pure **boswellic** acid, its physiologically acceptable salts, derivs., salts of derivs. or a plant prepn. contg. **boswellic** acid.  
 The plant prepn. is an incense extract. The pharmaceuticals can be in the form of tablets, dragees, capsules, solns., polymer-bound prepn. or suppositories and can be applied orally, buccally, rectally, intramuscularly, subcutaneously, intraarticularly, intravenously, intracranially or intrathecally. The **boswellic** acid can be applied with other chemically pure pharmaceuticals and/or plant

pharmaceuticals, esp. with cytostatics and/or glucocorticosteroids.

USE - The **boswellic** acid inhibits peritumoural brain oedema and tumour cell growth and leads to the death of tumour cells (claimed).

ADVANTAGE - **Boswellic** acid is of low toxicity and hence doses are not critical. The side effects are few and the substances are well tolerated by patients.

Dwg.0/0

FS CPI  
FA AB; DCN  
MC CPI: B09-B; **B14-H01**

L98 ANSWER 26 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 96-138985 [14] WPIDS

DNC C96-043605

TI Herbal compsn. for treating degenerative musculoskeletal disease - comprises mixt. of extracts from four Indian medicinal plants, used esp. for rheumatoid- or osteo-arthritis.

DC B04

IN PATWARDHAN, B

PA (PATW-I) PATWARDHAN B

CYC 1

PI US 5494668 A 960227 (9614)\* 14 pp A61K035-78

ADT US 5494668 A US 94-273189 940711

PRAI US 94-273189 940711

IC ICM A61K035-78

AB US 5494668 A UPAB: 960405

Degenerative musculoskeletal disease is treated by admin. of a compsn. contg. extracts of 30-50 wt.% Ashwagandha (*Withania sonnifera*), 30-50 wt.% Sallai guggul (*Boswellia serrata*) gum exudate, a trace to 15 wt.% turmeric (*Curcuma longa*) rhizome and 5-15 wt.% ginger (*Zingiber officinale*) rhizome.

Each plant extract is prepd. by (1) comminuting cleaned material to particle size 0.001-10 mm<sup>3</sup>, (2) steam distilling, with recovery of any volatile fraction, (3) sequential extn. of the distilled residue with first and second polar solvents and with a non-polar solvent (the second and third extn. are for 12-36 hrs.) to recover a fraction from each extn. step, and (4) recombining these 3 fractions and any volatile fraction from step (2).

USE - The compsn. has immunomodulatory activity esp. for treatment of rheumatoid arthritis and osteoarthritis but also immunodeficiency diseases.

Dosage is 4-10 (pref. 6) mg/kg/day, given enterally.

ADVANTAGE - All 4 plants are known in Indian traditional medicine but when combined they show a synergistic immunostimulatory action. The compsn. has no toxic or other adverse side effects and is suitable for long term admin.

Dwg.0/3

FS CPI  
FA AB; GI; DCN  
MC CPI: B04-A08C2; B04-A10; B04-A10F; **B14-C09A; B14-C09B;**  
B14-G01

L98 ANSWER 27 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 96-097835 [10] WPIDS

DNC C96-031667

TI Synergistic compsns. for treatment of rheumatoid- or osteo-arthritis - comprise *Withania Somnifera*, *Curcuma longa*, *Jasad Bhasma*, and other plant extracts.

DC B04

IN KASHINATH, J Y  
 PA (KASH-I) KASHINATH J Y  
 CYC 1  
 PI ZA 9500908 A 951227 (9610)\* 12 pp C07D000-00  
 ADT ZA 9500908 A ZA 95-908 950206  
 PRAI ZA 95-908 950206  
 IC ICM C07D000-00  
 AB ZA 9500908 A UPAB: 960308  
 A synergistic compsn. (I) for the treatment of rheumatoid arthritis comprises a tablet or capsule contg. an intimate mixt. of Withania somnifera (prEf. 75 mg); Curcuma longa (pref. 42 mg); Inula racemosa (pref. 25 mg); Paedaria Foetida (pref. 39 mg); **Boswellia** Serrataa (pref. 46 mg); and Jasad Bhasma (organic zinc extract) (pref. 40 mg).  
 Also claimed is a synergistic compsn. (II) for the treatment of osteoarthritis comprising, pref. in tablet or capsule form, Withania somnifera (pref. 75 mg); Sida cardifolia (pref. 50 mg); Curcuma longa (pref. 42 mg); Allium sativum (pref. 30 mg); Prunus Cerasodius (pref. 3 mg); Jasad Bhasma (pref. 40 mg) and Kukut Bhasma (pref. 40 mg).  
 USE - The compsns. are used for treatment of rheumatic diseases, immunodeficiency diseases and various degenerative musculo-skeletal diseases such as rheumatoid arthritis and oostero-arthritis, using the principles of Ayurveda. Maximum safe dose of (I) is 30.37 g/kg in mice, corresp. to 235.4 g for a 70 kg man. LD50 (mice) is above 30.37 g/kg. Maximum safe dose of (II) is 15.15 g/kg in mice, corresp. to 117.53 g for a 70 kg man. LD50 (mice) is above 151.5 g/kg.  
 ADVANTAGE - The compsns. show no toxicity or side-effects. (Reissue of the entry advised in week 9605 based on complete specification).  
 Dwg.0/0  
 FS CPI  
 FA AB  
 MC CPI: B04-A08; B04-A10; B12-M11; **B14-C09**; B14-S09  
 L98 ANSWER 28 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
 AN 94-293987 [36] WPIDS  
 DNC C94-133984  
 TI Novel therapeutic herbal compsn. to enhance the immune system - to treat AIDS, cancer, depression, Epstein Barr syndrome and as a blood tonic, herbs act synergistically to improve the ratio of CD4/CD8 cells.  
 DC B04  
 IN NEIRON, J M  
 PA (NEIR-I) NEIRON J M; (PHAR-N) PHARMAKON USA INC  
 CYC 43  
 PI WO 9418993 A1 940901 (9436)\* 25 pp A61K035-78  
 RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE  
 W: AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU  
 SD SK UA VN  
 AU 9462523 A 940914 (9502) A61K035-78  
 ADT WO 9418993 A1 WO 94-US2183 940223; AU 9462523 A AU 94-62523 940223  
 FDT AU 9462523 A Based on WO 9418993  
 PRAI US 93-20561 930223  
 REP US 5200186  
 IC ICM A61K035-78  
 ICS A61K009-48  
 AB WO 9418993 A UPAB: 941102  
 A therapeutic herbal compsn. (A) is new. It comprises **Boswellia** carterii stem resin (Bos), Styrax benzoic stem resin (Sty), the bark of Cinnamomum zeylanicum (Cin), Betula alba (Bet) and Impatiens balsamina (Imp), the roots of Curcuma zedoaria (Cur), Nardostachys chinensis (Nar),

Costus spicatus (Cos) and Cyperus rotundus (Cyp), Syzygium aromaticum fruit (Syz) and Allilum sativum bulk (All) in amts. effective to produce a physiological effect.

(A) comprises (Bos) in an amt. from 1.5-75 wt.% (pref. 15.5 wt.%), (Sty) in an amt. 1.5-75 wt.% (pref. 15.5 wt.% (Cin) is present from 0.7-35 wt.% (pref. 6.9 wt.%), (Cur), (Nar) and (Syz) are all present in an amt. 0.6-30 wt.% (pref. 6.0 wt.%), (Bet) in an amt. 1.5-75 wt.% (pref. 5.5 wt.%), (Imp) is present in an amt. 1.5-35 wt.% (pref. 5.5 wt.%) and (Cos), (Cyp) and (All) are present in an amt. 0.4-25 wt.% (pref. 4.3 wt.%).

USE/ADVANTAGE - (A) augments the immune system through the synergistic interaction of the herbal components. It is useful for immune enhancement, prophylaxis and treatment of cancer, AIDS, Epstein Barr syndrome depression and as a blood tonic. A 580 mg. dose of (A) would be admin. several times daily, orally. The combination of herbs produces a synergistic effect on improving the immune system. In AIDS (A) has been shown to reduce gland swelling, restore a feeling of well-being and associated wt. gain, an improvement in skin hypersensitivity tests and an increase in the concn. of circulating helper T-cells (dose was 4 capsules twice daily, 1 hr. before meals). (A) is a low toxicity prod. showing a shelf-life of 2 years with good stability.

Dwg.0/2

FS CPI

FA AB

MC CPI: B04-A10; B14-G01B; **B14-H01B**; B14-J01A1; B14-S09

L98 ANSWER 29 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

AN 93-236374 [30] WPIDS

DNC C93-105294

TI **Boswellia** acid or its derivs. or plant extracts - for prophylaxis and therapy of inflammations caused by increased leukotriene formation, e.g. rheumatism, psoriasis.

DC B05

IN AMMON, H P T; SAFAYHI, H; SINGH, G B

PA (AMMO-I) AMMON H P T

CYC 15

PI EP 552657 A1 930728 (9330)\* DE 10 pp A61K031-215

R: AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

DE 4201903 A1 930729 (9331) 16 pp A61K031-56

ADT EP 552657 A1 EP 93-100398 930113; DE 4201903 A1 DE 92-4201903 920124

PRAI DE 92-4201903 920124

REP 5.Jnl.Ref ; WO 9100937

IC ICM A61K031-215; A61K031-56

ICS A61K035-78

AB EP 552657 A UPAB: 931118

Pure **Boswellia** acid, one of its physiologically acceptable

salts, derivs. or salt of derivs. or a plant prepn. contg.

**boswellia** acid can be used for the prophylaxis and/or therapy of inflammations caused by increased leukotriene formation in human and veterinary medicine.

USE/ADVANTAGE - The **boswellia** acid cpds. are esp. effective against diseases of the joints (rheumatism), epidermal lesions (psoriasis), allergic and chronic asthma, endotoxin shock, inflammations of the intestines (colitis ulcerosa, Morbus Crohn) and chronic hepatitis. The **boswellia** acid cpds. selectively influence inflammations by inhibiting leukotriene synthesis. They can be used to replace steroidal antirheumatic drugs and can be used for prlonged periods without causing side effects, esp. the effects on the metabolic and hormone systems caused by steroidal antirheumatics. The **boswellia** acid prepn. can be taken intraperitoneally, orally, buccally, rectally, intramuscularly,

topically, subcutaneously, intraarticularly or intravenously. IC50 values for 5-lipoxygenase are 5uM for beta-boswellia acid, 11-keto-beta-boswellia acid and alpha-boswellia acid, 7 micro-M for acetyl-boswellia acid and acetyl-alpha-boswellia acid and 2 micro-M for acetyl-11-keto-beta-boswellia acid.

Dwg.0/4

FS CPI  
FA AB; DCN  
MC CPI: B09-B; B12-A01; B12-A07; B12-D02; B12-D09; B12-G01; B12-G02;  
B12-K01; B12-K02

L98 ANSWER 30 OF 30 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
AN 90-099251 [13] WPIDS  
DNC C90-043590  
TI Topoisomerase inhibition and cancer therapy - using boswellic acid cpds..  
DC B03 B05  
IN COOK, C E; FANG, O; LEE, Y; LI, D; WANG, Z; FANG, Q; COOK, C; FANG, Q C; LEE, Y W; WANG, Z G  
PA (RETR-N) RES TRIANGLE INST; (RETR-N) RES TRIANGLE SOC  
CYC 20  
PI WO 9001937 A 900308 (9013)\* EN 54 pp  
RW: AT BE CH DE FR GB IT LU NL SE  
W: AU DK JP KR NO  
AU 8943033 A 900323 (9033)  
CN 1043131 A 900620 (9112)  
EP 431076 A 910612 (9124)  
R: AT BE CH DE FR GB IT LI LU NL SE  
NO 9100696 A 910221 (9125)  
DK 9100313 A 910222 (9128)  
US 5064823 A 911112 (9148) 17 pp  
JP 04500209 W 920116 (9209)  
EP 431076 B1 931013 (9341) EN 35 pp A61K031-705  
R: AT BE CH DE FR GB IT LI LU NL SE  
DE 68909947 E 931118 (9347) A61K031-705  
TW 225990 A 940701 (9430) A61K031-70  
CA 1330944 C 940726 (9432) A61K031-56  
EP 431076 A4 920115 (9520)  
JP 2828295 B2 981125 (9901) 17 pp A61K031-16  
ADT WO 9001937 A WO 89-US3581 890824; EP 431076 A EP 89-910793 890824; US 5064823 A US 90-517176 900501; JP 04500209 W JP 89-510077 890824; EP 431076 B1 EP 89-910793 890824; WO 89-US3581 890824; DE 68909947 E DE 89-609947 890824; EP 89-910793 890824; WO 89-US3581 890824; TW 225990 A TW 90-104733 900609; CA 1330944 C CA 89-608654 890817; EP 431076 A4 EP 89-910793 ; JP 2828295 B2 JP 89-510077 890824; WO 89-US3581 890824  
FDT EP 431076 B1 Based on WO 9001937; DE 68909947 E Based on EP 431076, Based on WO 9001937; JP 2828295 B2 Previous Publ. JP 04500209, Based on WO 9001937  
PRAI US 88-235903 880824  
REP US 4501734; 3.Jnl.Ref  
IC A01N063-00; A61K031-70; C07J063-00  
ICM A61K031-16; A61K031-56; A61K031-70; A61K031-705  
ICS A01N063-00; A61K031-165; A61K031-18; A61K031-19; A61K031-195; A61K031-21; A61K031-215; A61K031-235; C07J063-00  
AB WO 9001937 A UPAB: 930928  
Methods for inhibiting topoisomerase I and II, inducing cell differentiation in cancer cells, and treating small-cell lung cancer, testicular cancer, lymphoma, leukaemia and cancer of the oesophagus,

stomach, colon, breast, CNS, liver and prostate, are claimed, all involving the use of pentacyclic triterpenoid cpds. of formula (I) or their salts.

R1 = COOR4, CONH2, CONHR5 or CON(R5)2; R4 = H, 1-4C alkyl, 2-4C alkenyl, 3-4C alkynyl, 6-8C aryl (opt. substd. by halogen, OMe, OEt, sulphonamide, NH2, mono- or di(1-4C alkyl)amino, mono- or diacetylamino, 1-4C alkyl and/or 2-4C alkenyl) or a mono-, di- or trisaccharide residue; R5 = Me, CH2COOH, CH2CH2COOH, 2-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, 6-8C aryl (opt. substd. as above) or a mono-, di- or trisaccharide residue; one of R2 and R3 is H or R5 and the other is H, OR4, NH2, NHR5, N(R5)2, OCOR5 or NHCOR5, or R2+R3 = O or NOR4; R6 and R7 are as defined for R2 and R3; one of X1 and X2 is H and the other is Me.

Specified cpds. (I) have higher activity than camptothecin against topoisomerase I and higher activity than VP-16-213 against topoisomerase II. They induce differentiation in HL-60 cells at a concn. of 10 mcg/ml, and are active against L1210 leukaemia in mice.

0/6

FS CPI

FA AB; DCN

MC CPI: B09-B; B12-G01B5; B12-G05; **B12-G07**